



E C O S

# Processes & Considerations for Setting State PFAS Standards

By Sarah Grace Hughes, Senior Project Manager, ECOS

Supported by & in conjunction with the ECOS PFAS Caucus

## Executive Summary

In recent years, federal, state, and international authorities have established various health-based regulatory values and evaluation criteria for a number of specific per- and polyfluoroalkyl substances (PFAS) in response to growing concerns with contamination. In April 2024, the U.S. Environmental Protection Agency (EPA) enacted federally enforceable PFAS standards for five PFAS in drinking water. However, at this time, the U.S. has no federally enforceable PFAS standards for other PFAS or for these PFAS in other environmental media, leaving individual states to navigate various avenues for addressing contamination. Some states have established legally enforceable values (e.g., drinking water Maximum Contaminant Levels [MCLs]) for certain PFAS in drinking water, groundwater, surface water, soil, or air. Other states and regulatory agencies have opted for non-enforceable values such as guidance levels, screening numbers, or advisories that may apply to PFAS for which promulgated standards do not exist.

The Environmental Council of the States (ECOS) in 2019 compiled information on state PFAS standards, advisories, and guidance values (hereinafter referred to as “guidelines”<sup>1</sup>). Sharing data and regulatory approaches helps federal, state, and international authorities avoid unnecessary duplication of efforts, as well as understand and communicate about differences in guidelines. This paper<sup>2</sup> outlines ECOS’ findings on state efforts and considerations for future regulatory activities on PFAS.

---

<sup>1</sup> For the purposes of this paper, the term “guidelines” will apply to both regulatory (enforceable) standards and non-regulatory (non-enforceable) values.

<sup>2</sup> The paper was initially published in February 2020. It was updated with new information and state participants in April 2021, March 2022, March 2023, and April 2024, and will continue to be updated annually as appropriate.

## Table of Contents

|  |     |
|--|-----|
| Introduction.....  | 6   |
| Overview of States' PFAS Guidelines .....                                    | 9   |
| States without PFAS Guidelines.....  | 9   |
| States with PFAS Guidelines.....   | 12  |
| Grouping PFAS.....   | 13  |
| Individual PFAS.....   | 14  |
| PFOA & PFOS, Summed.....   | 16  |
| More than 2 PFAS, Summed.....  | 17  |
| Evaluating Differences among States' PFAS Guidelines .....                   | 18  |
| Section I. Legislative Considerations .....                                  | 19  |
| Rulemaking Capacities.....   | 19  |
| Regulating PFAS as Hazardous.....  | 23  |
| Other Regulatory Developments .....  | 26  |
| Intra-State PFAS Collaboration .....   | 27  |
| Impacts of Federal Regulatory & Legislative Uncertainty.....                 | 27  |
| Section II. Risk Assessment .....  | 30  |
| Scientific Considerations, Professional Judgment, & Peer Review.....         | 30  |
| Toxicity Criteria & Methodology.....   | 31  |
| State Trends on the Basis of Guidelines.....                                 | 33  |
| Fish Consumption Advisories & Aquatic Life Criteria.....                     | 36  |
| Section III. Risk Management.....  | 37  |
| Analytical Methods & Limitations .....                                       | 38  |
| Establishing Guidelines.....   | 43  |
| PFAS Resource (Cost) Issues.....   | 43  |
| Conclusions.....   | 47  |
| State Agency Reports on PFAS Guidelines .....                                | 50  |
| Appendix A: State Drinking Water PFAS Guideline Criteria .....               | 51  |
| Appendix B: State Groundwater PFAS Guideline Criteria .....                  | 63  |
| Appendix C: State Surface Water PFAS Guideline Criteria .....                | 77  |
| Appendix D: State Soil PFAS Guideline Criteria.....                          | 85  |
| Appendix E: State Air PFAS Guideline Criteria.....                           | 106 |
| Appendix F: State Fish and Wildlife Consumption PFAS Guideline Criteria..... | 110 |

## List of Acronyms

---

| <b>ACRONYM</b> | <b>FULL PHRASE</b>   |
|----------------|--|
| ACGIH          | American Conference of Governmental Industrial Hygienists                |
| ACWA           | Association of Clean Water Administrators                                |
| AFFF           | Aqueous film-forming foam  |
| APFO           | Ammonium perfluorooctanoate  |
| ARAR           | Applicable or Relevant and Appropriate Requirements                      |
| ASDWA          | Association of State Drinking Water Administrators                       |
| ASTM           | ASTM International (formerly American Society for Testing and Materials) |
| ATSDR          | Agency for Toxic Substances and Disease Registry                         |
| BIL            | Bipartisan Infrastructure Law  |
| BMDL           | Benchmark dose (lower confidence limit)                                  |
| CERCLA         | Comprehensive Environmental Response, Compensation, and Liability Act    |
| CIPFPECA       | Chloroperfluoropolyether carboxylate                                     |
| CSF            | Cancer slope factor  |
| CTL            | Cleanup Target Level   |
| CWA            | Clean Water Act  |
| DOD            | U.S. Department of Defense   |
| ECOS           | Environmental Council of the States                                      |
| EMEG           | Environmental Media Evaluation Guide                                     |
| EPA            | U.S. Environmental Protection Agency                                     |
| ESL            | Effect Screening Level   |
| FDA            | U.S. Food and Drug Administration  |
| FTE            | Full-time employee   |
| FTS            | Fluorotelomer sulfonate  |
| GAC            | Granular activated carbon  |
| HBV            | Health-Based Value   |
| HED            | Human equivalent dose  |
| HFPO-DA        | Hexafluoropropylene oxide dimer acid                                     |
| HRL            | Health Risk Limit  |
| ISO            | International Organization for Standardization                           |
| ITRC           | Interstate Technology and Regulatory Council                             |
| ITSL           | Interim Threshold Screening Level  |

|             |   |
|-------------|---|
| kg          | Kilogram  |
| L           | Liter   |
| LHA         | U.S. EPA Lifetime Health Advisory               |
| LOAEL       | Lowest Observed Adverse Effect Level            |
| MCL         | Maximum Contaminant Level                       |
| MCLG        | Maximum Contaminant Level Goal                  |
| mg          | Milligram                                       |
| MLA         | Multi-linear array (SGS Axys method)            |
| MPART       | Michigan PFAS Action Response Team              |
| MRL         | Minimal risk level                              |
| MRP         | Monitoring and Reporting Program                |
| NDAA        | National Defense Authorization Act              |
| NEtFOSA     | N-ethyl perfluorooctane sulfonamide             |
| NEtFOSAA    | N-Ethyl perfluorooctane sulfonamidoacetic acid  |
| NEtFOSE     | N-Ethyl perfluorooctane sulfonamidoethanol      |
| NGO         | Non-governmental organization                   |
| NOAEL       | No Observed Adverse Effect Level                |
| NPDES       | National Pollutant Discharge Elimination System |
| NPDWR       | National Primary Drinking Water Regulation      |
| NRWQC       | National Recommended Water Quality Criteria     |
| PFAS        | Per- and polyfluoroalkyl substances             |
| PFBA        | Perfluorobutanoic acid                          |
| PFBS        | Perfluorobutanesulfonic acid                    |
| PFDA        | Perfluorodecanoic acid                          |
| PFHpA       | Perfluoroheptanoic acid                         |
| PFHxA       | Perfluorohexanoic acid                          |
| PFHxS       | Perfluorohexane sulfonic acid                   |
| PFIB        | Perfluoroisobutylene                            |
| PFNA        | Perfluorononanoic acid                          |
| PFOA        | Perfluorooctanoic acid                          |
| PFOS        | Perfluorooctane sulfonate                       |
| PFOSA, FOSA | Perfluorooctanesulfonamide                      |
| PFUnDA      | Perfluoroundecanoic acid                        |
| POD         | Point of Departure                              |
| ppb         | Parts per billion                               |
| ppm         | Parts per million                               |

|              |   |
|--------------|---|
| <b>ppt</b>   | <b>Parts per trillion</b>   |
| <b>PWS</b>   | <b>Public water system</b>  |
| <b>QA/QC</b> | <b>Quality Assurance/Quality Control</b>  |
| <b>RCRA</b>  | <b>Resource Conservation and Recovery Act</b>   |
| <b>RfC</b>   | <b>Reference Concentration</b>  |
| <b>RfD</b>   | <b>Reference Dose</b>   |
| <b>RSC</b>   | <b>Relative Source Contribution</b>   |
| <b>RSL</b>   | <b>Regional Screening Level</b>   |
| <b>RCL</b>   | <b>Residual Contaminant Level</b>   |
| <b>SAB</b>   | <b>Science Advisory Board</b>   |
| <b>SDWA</b>  | <b>Safe Drinking Water Act</b>  |
| <b>SOP</b>   | <b>Standard operating procedure</b>   |
| <b>SPE</b>   | <b>Solid phase extraction</b>   |
| <b>SPLP</b>  | <b>Synthetic precipitation leaching procedure</b>                                     |
| <b>TOF</b>   | <b>Total organic fluorine</b>   |
| <b>TOP</b>   | <b>Total oxidizable precursor</b>   |
| <b>TRI</b>   | <b>Toxics Release Inventory</b>   |
| <b>TSCA</b>  | <b>Toxic Substances Control Act</b>   |
| <b>UCMR</b>  | <b>Unregulated Contaminant Monitoring Rule (Number indicates round of monitoring)</b> |
| <b>WAX</b>   | <b>Weak anion exchange</b>  |

## Introduction

PFAS are a group of synthetic chemicals used in a wide array of consumer and industrial products since the 1940s. Several decades later, publicly available studies on certain PFAS risks indicated potential human health concerns related to these chemicals. In 2000, 3M announced a voluntary phase-out of certain legacy PFAS (e.g., perfluorooctanoic acid [PFOA], perfluorooctane sulfonate [PFOS], perfluorohexane sulfonic acid [PFHxS]). In 2006, the EPA initiated the PFOA Stewardship Program, which encouraged eight major chemical manufacturers to eliminate the use of PFOA and similar long-chain<sup>3</sup> PFAS in their products and in the emissions from their facilities.<sup>4</sup> International signatories of the United Nations' Stockholm Convention on Persistent Organic Pollutants treaty voted in 2009 and 2020 to add PFOS and PFOA, respectively, to the list of substances to be eliminated.<sup>5</sup> In 2020, the EPA issued a rule under the Toxic Substances Control Act (TSCA) prohibiting the manufacturing, processing, and/or importing of products containing certain PFAS without prior agency review and approval, and began the process of annually adding certain PFAS to the list of chemicals covered by the Toxics Release Inventory (TRI) beginning in Reporting Year 2021. In 2022, 3M announced that it will, among other actions, discontinue PFAS manufacturing and the use of PFAS across its products by the end of 2025. Despite these actions, U.S. manufacturers can, with approval, still import PFOA, PFOS, PFHxS, and perfluorononanoic acid (PFNA) for use in consumer goods, and some U.S. sites are legally required to keep PFAS-containing firefighting foams on-site for emergencies.<sup>6</sup>

U.S. manufacturers have developed numerous PFAS to replace long-chain PFAS such as PFOA, PFOS, and PFNA. One example is hexafluoropropylene oxide dimer acid (HFPO-DA) and the HFPO-DA ammonium salt, the two chemical substances that are part of the [GenX](#) technology developed as PFOA replacements by Chemours (formerly DuPont). There are more than 14,000<sup>7</sup> PFAS, some of which the EPA has approved for manufacture and use in the U.S. PFAS pose many problems: many do not break down under typical environmental conditions or, in the case of PFAS that are precursors<sup>8</sup>, are converted to terminal PFAS that do not break down, and are very hard to remove and/or destroy with treatment. Therefore, there is a persistent “supply” of PFAS in the environment that maintain their carbon-fluorine chemical structures and potential toxicity, in contrast to many other organic compounds that degrade in the environment over time. Although there have been advances in analytical methods, regulators lack routine analytical methods for PFAS detection and measurement across some environmental media. In addition, limited toxicological data and definitive chemical and physical parameters for the majority of PFAS (including the precursors) are available to define risks to human and ecological receptors. Recently, however, the EPA has added a number of PFAS to the TRI under Section 313 of the Emergency Planning and Community Right-to-Know Act, a requirement of the 2020 National Defense Authorization Act (NDAA). As the EPA has designated PFAS “chemicals of special concern,” the de minimis exemption is no longer available for TRI reporting and therefore the EPA expects a

---

<sup>3</sup> Long-chain PFAS are those with carbon chain lengths of 6 or higher for sulfonic acids like PFOS and PFHxS, and carbon chain lengths of 8 or higher for carboxylic acids like PFOA and perfluorononanoic acid (PFNA). In general, perfluoroalkyl acids (sulfonic acids and carboxylates) of all chain lengths do not break down, and long-chain PFAS have been found to bioaccumulate and pose risks to human health and the environment.

<sup>4</sup> [Fact Sheet](#), 2010/2015 PFOA Stewardship Program, U.S. EPA.

<sup>5</sup> For more information on international PFAS regulations, including the European Union's Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) regulation, see the [European Chemicals Agency website](#).

<sup>6</sup> The U.S. Department of Defense in January 2023 updated [Military Specifications](#) (MIL-SPEC), a requirement under the 2020 National Defense Authorization Act, to no longer require the use of fluorinated chemicals. However, the existing performance standard for firefighting foams remains unchanged. Certain airports must remain in compliance by using approved foams that satisfy MIL-SPEC performance requirements.

<sup>7</sup> This number is cited on U.S. EPA's Master List of PFAS Substances on its [Comptox Chemical Dashboard](#). However, given that there is no consensus on how PFAS is defined, this number may vary depending on what source is cited.

<sup>8</sup> Precursor, as used here, are PFAS, known or unknown, which have the potential to degrade to terminal PFAS that do not break down in the environment.

more complete reporting of relevant data. These efforts should increase regulators' awareness of which PFAS are being manufactured, processed, or otherwise used and at what quantities.

In the last decade, the EPA has taken a number of actions on PFAS in drinking water, as outlined below:

- **May 2016:** The EPA updated its short-term Provisional Health Advisory values for PFOA (400 parts per trillion [ppt]) and PFOS (200 ppt) to a Lifetime Health Advisory (LHA) of 70 ppt for PFOA and PFOS, individually or in combination, in finished drinking water.<sup>9</sup> The EPA stated that this LHA was calculated “to provide Americans, including the most sensitive populations, with a margin of protection from a lifetime of exposure to PFOA and PFOS from drinking water.”<sup>10</sup> The LHA is a non-regulatory and non-legally enforceable value, and is intended to provide guidance to federal, state, and municipal governments for addressing PFOA and PFOS contamination in public water systems and private potable wells.
- **February 2019:** The EPA released its [PFAS Action Plan](#) in which the agency committed to make a “regulatory determination” for PFOA and PFOS under the Safe Drinking Water Act (SDWA). The SDWA requires the EPA to make formal regulatory determinations for at least five contaminants from the most recent drinking water Contaminant Candidate List<sup>11</sup> within five years of the completion of the previous round of regulatory determinations. A positive determination initiates the rulemaking process to establish an enforceable [National Primary Drinking Water Regulation](#) (NPDWR) (i.e., MCL or Treatment Technique).
- **January 2021:** The EPA announced that it had evaluated more than 11,000 public comments and made a final decision to regulate PFOA and PFOS. This decision was reissued by the new Administration on February 22, 2021. The agency also noted that it intends to fast track evaluation of other PFAS for future drinking water regulatory determinations if necessary data and information are available.
- **November 2021:** The EPA requested that its Science Advisory Board (SAB) review draft scientific documents that support the development of NPDWRs for PFOA and PFOS, as well as a draft document that provides a framework for risk assessment of PFAS mixtures. In the draft documents, the EPA [concludes](#) that “recent scientific data and new analyses ... indicate that negative health effects may occur at much lower levels of exposure to PFOA and PFOS than previously understood and that PFOA is a likely carcinogen.” The EPA also has initiated efforts to engage the public on environmental justice considerations for the NPDWR and to obtain input from stakeholders, including small public water systems and state, local, and tribal officials.
- **June 2022:** The EPA [published](#) interim updated LHAs of 0.004 ppt for PFOA and 0.02 ppt for PFOS, which are based on the draft scientific document mentioned above, as well as final LHAs of 10 ppt for GenX chemicals and 2,000 ppt for perfluorobutanesulfonic acid (PFBS). The EPA stated that these interim LHAs for PFOA and PFOS supersede the 2016 LHA of 70 ppt for the total of the two compounds.
- **August 2022:** The EPA SAB finalized its review of the draft [scientific documents](#). In the Agency's October 18, 2021 publication of the [PFAS Strategic Roadmap](#), the EPA stated that it expected to propose MCLs for PFOA and PFOS in the fall of 2022, with a final rule to follow in late 2023.
- **March 2023:** The EPA [announced](#) the proposed NPDWR to establish MCLs for six PFAS, including 4 ppt for PFOA and PFOS as individual contaminants and a 1.0 (unitless) Hazard Index<sup>12</sup> for PFHxS, PFNA, PFBS, and

<sup>9</sup> In December 2019, the EPA issued [interim guidance](#) that recommends a screening level of 40 ppt to assess whether the levels of PFOA and/or PFOS present in groundwater at a federal cleanup site may require further investigation. The EPA will use the LHA of 70 ppt as a preliminary remediation goal for contaminated groundwater. While this may be useful to states, many states have their own guidance for PFAS in groundwater.

<sup>10</sup> The [EPA Drinking Water Health Advisories for PFOA and PFOS](#)

<sup>11</sup> The EPA's [Contaminant Candidate List](#) (CCL) is a list of contaminants that are currently not subject to proposed or promulgated national primary drinking water regulations, but are known or anticipated to occur in public water systems. It was most recently updated in November 2022 (CCL 5) and includes PFAS as a class, per its structural definition included in the hyperlinked document.

<sup>12</sup> The Hazard Index is a tool used to evaluate potential health risks from exposure to chemical mixtures. For the PFAS

HFPO-DA as a PFAS mixture. The updated draft documents that provide the scientific basis for the proposed rule incorporate input from the SAB review of the earlier draft documents. The proposed rule includes health-based, non-enforceable Maximum Contaminant Level Goals (MCLGs; health-based drinking water concentrations) for these six PFAS.

- **April 2024:** The EPA [announced](#) the final NPDWR to establish, as proposed, MCLs for six PFAS, including 4 ppt for PFOA and PFOS as individual contaminants (with MCLGs of 0 ppt as they are carcinogens and no level of exposure is acceptable) and a 1.0 (unitless) Hazard Index for PFHxS, PFNA, PFBS, and HFPO-DA (GenX chemicals) as a PFAS mixture, as well as MCLs of 10 ppt for PFNA, PFHxS, and HFPO-DA as individual contaminants (with MCLGs of 10 ppt).

Other federal agencies have also taken efforts to regulate PFAS. In 2021, the U.S. Department of Health and Human Services' Agency for Toxic Substances and Disease Registry (ATSDR) finalized [minimal risk levels](#) (MRLs) for four PFAS: PFOA, PFOS, PFHxS, and PFNA. MRLs are not regulatory values<sup>13</sup> and are not intended to be used as public water or environmental cleanup standards. MRLs are screening tools to identify contaminants of concern at hazardous waste sites. If an exposure is below an MRL, it is not expected to result in adverse health effects, whereas an exposure exceeding an MRL warrants further investigation to determine if the exposure might harm human health. Additionally, MRLs are presented in terms of dose (a measurement of exposure in units of milligrams/kilogram/day) and not in terms of concentration (the amount of a substance present in a particular media in units of parts per million [ppm], parts per billion [ppb], or ppt), analogous to Reference Doses (RfDs) developed by the EPA. The ATSDR developed Environmental Media Evaluation Guides (EMEGs) specific to children and adults to convert these dosages into drinking water concentrations that represent about how much water a person can drink each day. Differences among the MRLs, EMEGs, RfDs, LHAs, and MCLs have resulted in public confusion and emphasize the need for improved risk communication, especially in the news media, to explain that the ATSDR's MRLs and EMEGs and the EPA's RfDs, LHAs, and MCLs (and Hazard Indexes) are used in different situations and are not/should not be considered "equivalent."

Historically, many states relied on the promulgated standards from federal agencies to regulate chemicals, while other states have had the authority to develop their own standards for contaminants of concern. If no federal standard exists, states may rely on toxicity values from the [EPA Tier 3 Toxicity Value Workgroup document](#), the [Regional Screening Levels](#) list,<sup>14</sup> or similar reference documents. Noting the broad range and complexity of PFAS, the need for cross-media consideration, and the absence of promulgated federal standards, states have taken alternative routes to actively address PFAS across a wide range of programs. At least 29 states<sup>15</sup> have developed draft, proposed, or final health-based regulatory and/or guidance values for several PFAS in drinking water, groundwater, surface water, soil, air, and/or fish and wildlife. These guidelines may significantly differ from the EPA's LHAs or MCLs, and vary from state to state as a result of different legislative and scientific considerations. For example, states may have different mandates (e.g., regulations, policies) that direct them on approaches for the development of human health-based guidelines (e.g., consideration of exposures to sensitive life stages like infants or pregnant women) or require them to use the EPA's toxicity values as the basis for their guidelines. Several states

---

NPDWR, it considers the combined toxicity of PFHxS, PFNA, PFBS, and GenX chemicals by summing fractions that compare the level of each PFAS measured in drinking water to the level determined not to cause health effects.

<sup>13</sup> While the MRLs are not regulatory values themselves, the EPA used them as the basis for its proposed and final MCLs and MCLGs for PFNA and PFHxS.

<sup>14</sup> As of 2023, there are 12 PFAS (PFOA, PFOS, PFBS, PFBA, PFNA, PFODA, PFHxS, PFDoDA, HFPO-DA, PFPrA, PFTetA, PFUDA) on the [Regional Screening Levels list](#). The risk-based values are not cleanup standards but help the EPA determine if further investigations or actions are needed to protect public health and the environment.

<sup>15</sup> Several states in addition to those that completed the ECOS survey are known to have drafted, proposed, or finalized health-based regulatory and/or guidance values for PFAS in various environmental media. They are not included in the facts and figures outlined in this report.



developed drinking water guidelines for PFOA and PFOS that are lower than the EPA's 2016 LHA of 70 ppt due to considerations of more recent scientific information, more sensitive toxicological endpoints, and/or more stringent exposure parameters. When the EPA updated its interim LHAs, which were set at much lower values, most state drinking water guidelines were higher than the interim LHAs. Many states have also developed guidelines for various PFAS in addition to PFOA and PFOS and in environmental media other than drinking water. Other states have adopted the EPA's 2016 LHA for PFOA and PFOS in drinking water and/or groundwater to guide their efforts upon detection of contamination.<sup>16</sup> When the March 2023 iteration of this report was published, none of the states that provided updates to the paper had used the 2022 LHAs for PFOA and PFOS, but several clarified that they are either following the [advice](#) outlined by the EPA to assess the situation and inform the public about confirmed levels above the new health advisories, that they consider the values but have not used them for decision making or to guide an investigation or cleanup, that they address any detections of PFOA and PFOS, or that they are waiting for the EPA MCL. The EPA states that the MCLs for PFOA and PFOS were set at the lowest possible levels for analytical detection at labs across the country; however, this is much lower than many states' current guidelines. The *Impacts of Federal Regulatory & Legislative Uncertainty* section of this report details how states say this may change their previously published considerations and state guidelines.

With a growing body of science to inform standards development, the absence of a federally enforceable standard for many PFAS in environmental media beyond drinking water, and pressures from the public and legislative bodies to take regulatory action, it is important to know which states are setting guidelines, understand how the guidelines are developed, and be able to educate legislators on differences between state, federal, and other guidelines. This is essential so that states can make informed decisions when establishing their own regulations and/or implementing risk communication practices.

## Overview of States' PFAS Guidelines

ECOS surveyed states on their processes, rulemaking requirements, and other considerations for establishing PFAS guidelines (e.g., occurrence of specific PFAS in drinking water sources or other environmental media). ECOS and its working group of state environmental agency officials (the PFAS Caucus) examined responses from 43 states (*Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming*).<sup>17</sup> Below are findings and conclusions from the 40 states that completed the ECOS survey.

### *States without PFAS Guidelines*

14 states (*Alabama, Arizona, Arkansas, Idaho, Kansas, Missouri, Nebraska, North Dakota, Oklahoma, South Carolina, Tennessee, Utah, Virginia, Wyoming*) indicated that they do not have state guidelines.<sup>18</sup>

Reasoning for Not Establishing State PFAS Guidelines:

<sup>16</sup> In reference to states that use the 2016 LHA, the health basis for standards for other contaminants of emerging concern may be as low as those for PFAS, but the actual standards for those other contaminants are often higher because they are based on analytical limitations, while the PFAS standards can be set at the 2016 health-based levels.

<sup>17</sup> Individual state PFAS websites can be found in the "Overview" section on ECOS' [PFAS Risk Communication Hub](#).

<sup>18</sup> These states may use the EPA's 2016 LHA as guidance, remediation goals, action levels, or for regulatory oversight if PFAS contamination is detected. However, they will likely wait for a federal standard before enacting their own state guidelines.

- 14 states (*Arizona, Arkansas, Idaho, Indiana, Iowa, Kansas, Maryland, Missouri, Montana, New Mexico, North Carolina, North Dakota, Oklahoma, Utah*)<sup>19,20,21</sup> have restrictions that prohibit them from setting a drinking water and/or groundwater guideline more stringent (i.e., more protective) than a federal standard in at least one environmental medium. This could dissuade a state from setting a PFAS standard (at any level), or from setting a PFAS standard lower than the EPA's LHA in anticipation that a federal MCL may be enacted at a similar level, forcing the state to amend its guideline(s) in a way that appears to "weaken" it.
- Many states lack the capacity or resources to effectively and individually regulate PFAS. Barriers include a lack of one or more of the following: technical expertise needed for toxicity interpretation and standard development,<sup>22</sup> numerical data and established limits for PFAS in various environmental media, labs certified to test for PFAS in the state, cost-benefit analyses (especially to smaller systems), interdependence of programs, legislative support, legal authority, and funding. One state noted it is required to complete an economic impact analysis of treatment, sampling, and analysis before it would be allowed to consider its own guidelines, especially ones that may be more stringent than a federal standard, and therefore it will instead incorporate federal regulations into its state rules to address PFAS.
- There are still limitations to available toxicity data, approved monitoring or analytical methods, and established federal criteria, all of which may contribute to scientific and regulatory uncertainty. Many states noted the need for more peer-reviewed science to make informed decisions on whether to establish guidance levels for some of the PFAS that have been found in their environmental media. States may also have many sites with known contaminants that need to be addressed and must choose to prioritize those over others impacted by emerging contaminants with less available data.

Without their own state-based guidelines, several of these states are still taking actions to inform the public, and to monitor, investigate, and remediate PFAS. Efforts include statewide sampling of public water systems (PWSs) and surface water and groundwater intakes; conducting inventories of facilities that use or have used or produced PFAS; responding to drinking water and fish contamination; notifying local emergency planning committees, fire departments, airports, and industry of the human health and environmental impacts associated with using legacy aqueous film-forming foams (AFFF); sampling potentially-impacted private wells; and forming interagency task forces to coordinate the messaging for and response to PFAS contamination within the state. For example:

- *Alabama* does not currently have any ambient water quality criteria or drinking water standards for any PFAS, but it does include PFAS monitoring and reporting requirements in National Pollutant Discharge Elimination System (NPDES) permits (new sources and renewals) for certain industry sectors. Based on those results, the state may require facilities to develop and implement a PFAS Minimization Plan to identify and reduce possible PFAS sources in discharge. Alabama also required all of its public drinking water systems that treat

<sup>19</sup> *Indiana, Iowa, Maryland, Montana, New Mexico, and North Carolina* are included in this list because they have such a law governing rule-based standards in at least one environmental medium. However, they have a guideline for at least one PFAS analyte, as indicated below. *Iowa* state law prohibits water quality effluent standards from being more stringent than federal standards, but drinking water standards can be more restrictive if certain state law conditions are met (although historically, the state has not adopted drinking water standards for analytes listed in an EPA health advisory).

<sup>20</sup> *Kansas'* restrictions prohibit setting more stringent standards in air. Regardless, the state indicates it will not move ahead of pending federal regulations.

<sup>21</sup> *North Carolina's* restrictions prohibit setting more stringent standards in drinking water. However, the statute does provide exemptions, such as if there is a serious and unforeseen threat to public health, as they pertain only to federal rules, like a MCL under the SDWA. North Carolina also needs final RfDs from the EPA or other federal agency to establish drinking water guidelines, and is preparing to propose guidelines now that the RfDs and MCLs are finalized.

<sup>22</sup> This also applies to some states that have guidelines. For example, *Indiana* reports that it does not have the resources to hire a toxicologist to set its own standards, so its reported guidelines are the EPA Regional Screening Levels for cleanup numbers. As the EPA updates those values, *Indiana* updates its screening level tables.

source water to test for PFAS in either 2020 or 2022. In situations where PFAS results were higher than expected, Alabama has attempted to identify sources that may be contributing to those PFAS concentrations.

- *Arizona* has been sampling small drinking water systems and providing results publicly through a [map](#), similar to other states. The sampling has allowed Arizona to develop a statewide drinking water PFAS mitigation plan, which leverages state and federal funding to provide support to small water systems and disadvantaged communities that are considering PFAS mitigation.
- *Kansas* has also been sampling wastewater from selected municipal wastewater plants around the state, PWSs tagged by the EPA's fifth round of the Unregulated Contaminant Monitoring Rule (UCMR5), 128 PWSs participating in the state's voluntary PFAS sampling program, and from monitored streams in both urban and rural settings. While the state has seen some elevated concentrations in distinct areas, it notes that PFAS is generally found in low concentrations, particularly in rural areas. Kansas intends to wait for federal regulations rather than formulating its own standards, but plans to initiate fish tissue sampling.
- *Missouri* developed a [PFAS webpage](#) and interactive PFAS map viewer, which is connected to the Safe Drinking Water Information System and reports all public water system PFAS results collected since 2013. The state is collecting occurrence study samples from community and non-community non-transient PWS' with the intent to have PFAS data for all systems by the end of 2025. Missouri is also developing a PFAS dashboard map viewer. By utilizing a variety of data layers, including industry NAICS and SIC codes, Superfund, Federal Facility, and Resource Conservation and Recovery Act (RCRA) sites with PFAS detections, and environmental media sampling, Missouri is identifying potential source locations for exceedances found in public drinking water. The state convened a PFAS workgroup to develop policies and tools related to PFAS. This workgroup established multiple subgroups that met throughout 2023 to research and develop recommendations, and the workgroup will work in 2024 to develop a final report consolidating the information gathered.
- *Tennessee* has taken several efforts to monitor the presence of PFAS across the state. Concurrent with sampling for 29 PFAS under UCMR5, Tennessee has implemented a [statewide sampling strategy](#) to test source (e.g., raw/untreated) water for the same 29 PFAS in all PWSs to better understand the presence and concentration of PFAS in raw public drinking water sources. The state will test approximately 1,295 water intakes (surface water, springs, and water wells) which provide source water for 784 regulated PWSs serving about 88 percent of Tennesseans. Results are updated regularly on a publicly-available [interactive dashboard](#) and are anticipated to be completed by summer 2025. Tennessee is working to create a similar dashboard of results of UCMR5 sampling and hopes that the data of both raw and treated water will help characterize water quality in the state; its study may be used to identify contaminated watersheds or aquifers, characterize groundwater conditions, and provide insight into where additional concentration efforts and/or treatment should focus, as well as determine how well a given treatment plant is operating to filter PFAS from source water. The state's Department of Environmental Conservation regularly updates its [PFAS webpage](#) with rule information, frequently asked sampling-related questions, and other information for the public.
- *Utah* has worked with PWSs to test finished drinking water and water sources for PFAS since 2020, and posts the results annually to an [interactive map](#). Utah also formed a PFAS task force that meets periodically to discuss actions being taken on PFAS around the state.
- *Virginia* has an [interactive map](#) of its water column, sediment, and fish tissue sampling data.
- *Wyoming* is conducting a statewide evaluation of the impact of PFAS to public and private drinking water supplies throughout the state. In June 2018, the Wyoming Department of Environmental Quality published its PFAS Response and Implementation Strategy to identify actions to further evaluate the potential for PFAS compounds to impact the state's water supplies. It includes several key tasks, the first three of which have been completed and the others of which are underway: 1) Inventory and map where PFAS have been used, stored, or disposed of; 2) Prioritize sites for further investigation based on relation to the Department's Aquifer Prioritization Map; 3) Incorporate sites into a GIS-based data management system; 4) Identify and sample private and public wells to assess potential impacts on drinking water supplies from prioritized sites;

5) Investigate options to develop analytical capacity in the Department's laboratory; 6) Develop and implement a public education/outreach plans to keep the public informed of the status of investigations and findings, and of safe and proper use and disposal of products containing PFAS; 7) Continue coordination with local, state, and federal partners to maintain awareness of latest scientific and regulatory developments.

## States with PFAS Guidelines

29 states (*Alaska, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Texas, Vermont, Washington, Wisconsin*) have a guideline for at least one PFAS in at least one environmental medium.<sup>23</sup>

State guidelines for water and soil specified in ECOS' survey have been incorporated into the Interstate Technology and Regulatory Council's (ITRC) [PFAS Water and Soil Regulatory and Guidance Values Table](#).<sup>24</sup> The table defines which environmental medium each standard applies, as well as whether the values are promulgated or advisory. States may have slightly different definitions of each medium. For example, most states consider drinking water standards to be finished water from the PWSs, but a state may also include groundwater used as drinking water from a private residential well or similar source. ECOS compiled responses based on how the state categorized each medium in the survey and how it defines it generally for the public. For more detailed state-specific definitions, see [state PFAS websites](#).

Of the states that responded to ECOS' survey, the following have different types of guidelines:

### Regulatory Standards

- Drinking Water<sup>25</sup>: 11 states (*Maine [interim], Massachusetts, Michigan, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Washington, Wisconsin*)
- Groundwater: 17 states (*Alaska, Colorado, Delaware, Illinois [proposed], Iowa, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, Pennsylvania, Rhode Island [in process], Texas, Vermont, Washington*)
- Surface Water: Six states (*Massachusetts, Michigan, Minnesota [site-specific criteria enacted, standards in process], New York, Washington, Wisconsin*)
- Soil: 12 states (*Alaska, Delaware, Iowa, Massachusetts, New Hampshire [in process], New Jersey, New Mexico, Pennsylvania, Texas, Vermont, Washington, Wisconsin*)
- Air: Two states (*Michigan, New Hampshire*)
- Other: *California* added PFOA and PFOS as developmental toxicants, PFOA and "PFOS and its salts and transformation and degradation precursors" as carcinogens, and PFNA and its salts as male reproductive toxicants to the Proposition 65 list of chemicals known to cause cancer or reproductive toxicity; *Washington* has regulatory standards for PFAS as halogenated organic compounds in state designated hazardous waste, for PFOA and PFOS in children's products, and regulatory requirements for PFAS in Class B firefighting foams, certain consumer products, and certain food packaging

<sup>23</sup> These include promulgated or interim rules and advisories (e.g., action and notification levels, cleanup target levels, initiation levels), and may be determined by the state or may be consistent with EPA's 2016 LHA of 70 ppt.

<sup>24</sup> ITRC is a subsidiary of ECOS.

<sup>25</sup> See States with a Final or Proposed MCL (Drinking Water Only) designation below.

## Advisory Guidelines

- Drinking Water: 14 states (*Alaska, California, Connecticut, Hawaii, Illinois, Indiana, Iowa, Maryland, Minnesota, North Carolina, Ohio, Oregon, Vermont, Wisconsin*)
- Groundwater: 13 states (*California, Colorado, Connecticut, Florida, Hawaii, Illinois, Indiana, Maine, Minnesota, New York, North Carolina [in process], Washington, Wisconsin*)
- Surface Water: 10 states (*Colorado, Florida, Hawaii, Illinois, Minnesota, Montana, New York, North Carolina [in process], Oregon [wastewater], Rhode Island*)
- Soil: 13 states (*California, Connecticut, Florida, Hawaii, Illinois, Indiana, Maine, Minnesota, Montana, New Hampshire, New York, North Carolina, Washington*)
- Air: Four states (*Hawaii [draft], Minnesota, New Jersey, Texas*)
- Fish or Wildlife Consumption Advisories<sup>26</sup>: 18 states (*Connecticut [fish], Delaware [in process], Hawaii [in process], Illinois [fish], Indiana [fish], Maine [fish, beef, milk, free ranging white-tailed deer, and wild turkey], Maryland [fish], Massachusetts [fish], Michigan [fish and deer], Minnesota [fish], Montana [fish, in process], New Hampshire [fish], New Jersey [fish], New York [fish], North Carolina [fish], Texas [fish], Washington [fish], Wisconsin [fish and deer]*)

## States with a Final or Proposed MCL (Drinking Water Only)

- *Delaware* (Proposed for PFOA and PFOS, individually and summed)
- *Massachusetts* (Enacted for six PFAS, individually and summed)
- *Michigan* (Enacted for seven PFAS, individually)
- *New Hampshire* (Enacted for four PFAS, individually)
- *New Jersey* (Enacted for PFOA, PFOS, and PFNA, individually)
- *New York* (Enacted for PFOA and PFOS, individually)
- *Pennsylvania* (Enacted for PFOA and PFOS, individually)
- *Rhode Island* (Enacted for 6 PFAS, individually and summed)
- *Vermont* (Enacted for five PFAS, individually and summed)
- *Wisconsin* (Enacted for PFOA and PFOS, individually and summed)

## Grouping PFAS

Proposed congressional legislation suggested creating a federal MCL for total PFAS, derived by adding the concentration of each PFAS detected in a sample. This total PFAS concentration depends on which analytical methods are used, as different analytical methods detect different suites of PFAS and have different reporting levels. Given that there are more than 14,000 PFAS, most of which have little known information about their toxicities, some regulators and subject-matter experts advise against grouping PFAS as an entire class, while other regulators and experts are considering all of the thousands of PFAS as a class based on common properties such as environmental persistence.<sup>27</sup> Additionally, some state guidelines address PFOA, PFOS, and other specific PFAS individually, while other state guidelines are based on the total concentration of PFOA and PFOS, as the EPA does in its LHA, or on the total concentration of PFOA, PFOS, and several additional specific long-chain PFAS, based on the assumption of similar toxicological and toxicokinetic properties.

<sup>26</sup> Advisories apply to fish only, unless otherwise noted.

<sup>27</sup> There are different opinions on if and how to group PFAS, many of which depend on which definition for PFAS is used. In [Section 2.2](#) of its guidance, ITRC states that there is no universally accepted definition of PFAS, and the definition of PFAS continues to evolve and is different depending on the regulatory body, operational criteria used, and intended scope and application of specific PFAS. While a number of states currently use the definition of “at least one fully fluorinated carbon atom,” ECOS is still working with states to understand if and how they would like to encourage a more unified definition nationwide.

States' approaches for grouping PFAS, and the reasoning provided for grouping PFAS under each method, are as follows:

### *Individual PFAS*

- 23 states
  - *Alaska*: Soil and groundwater cleanup levels for PFOA, PFOS
  - *California*: Non-regulatory notification levels and response levels for PFOA, PFOS, PFBS, and PFHxS in drinking water; Non-regulatory environmental screening levels for PFOA, PFOS in soil, groundwater, aquatic habitat, terrestrial habitat, and leaching to groundwater
  - *Connecticut*: Advisory action levels for PFOA, PFOS, PFNA, PFHxS, PFHxA, PFBS, PFBA, HFPO-DA, 6:2 Cl-PFESA, 8:2 Cl-PFESA in drinking water; Fish tissue consumption advisories for PFOS in some waterbodies
  - *Delaware*: Proposed MCLs for PFOA, PFOS individually and summed; Hazardous substance screening values reflecting the EPA's Regional Screening Levels (RSLs) for PFOA, PFOS, PFHxS, PFHxA, PFNA, PFBS, PFBA, and HFPO-DA in groundwater implemented through its risk-based cleanup program
  - *Florida*: Provisional Soil Cleanup Target Levels for PFOA, PFOS; Provisional Irrigation Water Screening Levels for PFOA, PFOS; Surface Water Screening Levels for fish consumption for PFOA, PFOS<sup>28</sup>
  - *Hawaii*: Environmental Action Levels for PFOA, PFOS, PFNA, PFBS, PFHxS, PFHpS, PFDS, PFBA, PFPeA, PFHxA, PFHpA, PFDA, PFUnDA, PFDODA, PFTrDA, PFTeDA, PFOSA, HFPO-DA, 6:2 FTS, PFPeS, PFPrA, ADONA, 6:2 FTOH, 8:2 FTOH, 6:2 FtTAoS in drinking water, groundwater, surface water, soil; Environmental Action Levels for PFPrA in indoor air for semi-volatile compounds and subslab soil vapor<sup>29</sup>
  - *Illinois*: Drinking water health advisory levels for PFOA, PFOS, PFBS, PFHxS, PFNA, PFHxA; Proposed groundwater standards for PFOA, PFOS, PFBS, PFHxS, PFNA, HFPO-DA; Soil guidance levels for PFOA, PFOS, PFBA, PFHxA, PFNA, PFUnA, PFDODA, PFTA, PFBS, PFHxS, HFPO-DA, HQ-11, PFPrA, TFSI, PFODA; Fish consumption advisory for PFOS; Surface water guidance levels based on the EPA Draft Aquatic Life Criteria for PFOA, PFOS
  - *Indiana*: Guidance Remediation Screening Levels for PFOA, PFOS, PFBS, PFBA, PFHxA, PFHxS, and PFNA<sup>30</sup> in drinking water, groundwater, and soil; Fish consumption advisories for PFOS
  - *Iowa*: Groundwater and soil standards for PFOA, PFOS, PFBS, PFBA, PFNA, PFHxS, HFPO-DA; Public notice minimum reporting requirements for PFOA, PFOS in finished drinking water samples above the EPA health advisory
  - *Maine*: Screening levels used as remedial action guidelines for PFOA, PFOS, PFBA, PFHxS, PFHxA, PFNA, and PFBS in soil and fish,<sup>31</sup> and for PFOS in milk and beef
  - *Maryland*: Drinking water advisory level for PFHxS as a requirement for impacted water utilities to provide alternative water to customers;<sup>32</sup> Site-specific fish consumption advisory for PFOS

<sup>28</sup> *Florida* developed Provisional Groundwater and Soil Cleanup Target Levels (CTLs) in accordance with rules 62-780.150 and 62-780.650, Florida Administrative Code. The Provisional CTLs are considered enforceable as they were generated in accordance with the process established in these rules that allows for the development of CTLs.

<sup>29</sup> *Hawaii* in March 2024 published an update to its Environmental Action levels for PFAS, adding several compounds to bring the total number under state guidance to 25 and providing a new guidance on "Total PFAS Risk" (more in the Analytical Methods section of this report). The Environmental Action Levels apply to drinking water, groundwater, surface water, soil, and air and are described in detail in the state's March [memorandum](#).

<sup>30</sup> *Indiana's* guidelines reflect the EPA Regional Screening Levels, so include these PFAS and their salts.

<sup>31</sup> Updated in November 2023 via *Maine's* Remedial Action Guidelines.

<sup>32</sup> This may include acquisition of an alternative water source, improvements to the construction of the existing source, connection to another water system, or treatment of the source. If treatment is installed, the system is asked to conduct quarterly monitoring if feasible.

- *Massachusetts*: Fish consumption advisory levels for PFOS, PFBS, PFHxS, PFOA, PFNA
- *Michigan*: MCLs for 7 PFAS (PFOA, PFOS, PFNA, PFHxA, PFHxS, PFBS, HFPO-DA); Surface Water Quality Standards for PFOA, PFOS, PFBS, PFNA, PFHxS; Groundwater cleanup criteria for 7 PFAS (PFOA, PFOS, PFNA, PFBS, PFHxA, PFHxS, HFPO-DA); Consumption advisories for PFOS in fish and deer tissue; Initial Threshold Screening Levels (ITSLs) for PFOA, PFOS, 6:2 fluorotelomer sulfonate (FTS)
- *Minnesota*: Promulgated Health Risk Limits (HRLs) for PFOA, PFOS, PFBA, PFBS, PFHxS, PFHxA in groundwater<sup>33</sup>; Health-Based Values (HBVs) for PFOA, PFOS in groundwater; Rule-based Intervention Limits for PFOA, PFOS, PFBA, PFBS to protect surface water and groundwater at solid waste facilities; Soil Reference Values for PFOA, PFOS, PFBS, PFBA, PFHxS, PFHxA; Site-Specific Water Quality Criteria for PFOA, PFOS, PFBS, PFBA, PFHxS, PFHxA in surface water; Fish Consumption Advice for PFOS; Risk-Based Inhalation Values for PFOA, PFOS, PFHxS, PFBA, PFBS, PFHxA in air
- *Montana*: Soil screening levels for PFAS in water, based on the EPA's RSLs
- *New Hampshire*: MCLs and Ambient Groundwater Quality Standards for PFOA, PFOS, PFHxS, PFNA; Soil contact value for PFOA, PFOS, PFHxS, PFNA for evaluating sites<sup>34</sup>; Ambient air limit for APFO; Fish consumption advisories for PFOS in some waterbodies
- *New Jersey*: MCLs and Groundwater Quality Standards for PFOA, PFOS, and PFNA; Interim Specific Groundwater Quality Standards for chloroperfluoropolyether carboxylates (ClPFPECAs) and GenX; Interim Soil Remediation Standards for PFOA, PFOS, PFNA, GenX; Consumption Advisories in waterbodies where fish have been monitored for PFOS, as well as for PFNA or PFUnDA at some sites; inhalation Reference Concentrations (RfCs) for PFOA, PFOS; screening inhalation RfC for HFPO-DA (GenX)<sup>35</sup>
- *New Mexico*: Groundwater and vadose zone standards for PFOA, PFOS, PFHxS; Surface water screening level for PFOA and/or PFOS implemented through Clean Water Act (CWA) Section 401 conditional certification of a National Pollutant Discharge Elimination System (NPDES) permit; Soil and tap water screening levels for PFOA, PFOS and its potassium salt, PFBS and its potassium salt, PFNA, PFHxS
- *New York*: MCLs for PFOA, PFOS; Ambient water quality guidance values for PFOA, PFOS; Groundwater effluent limitations for PFOA, PFOS; Interim soil cleanup objectives for PFOA, PFOS; Fish advisories for PFAS (testing included PFOA, PFOS); Chronic annual guideline concentration values for ambient air quality for 5 individual PFAS (PFOA and its salts) listed in [DAR-1](#)
- *North Carolina*: Non-Regulatory Drinking Water Health Goal for HPFO-DA (GenX); Groundwater and surface water standards [in process] for PFOA, PFOS, HPFO-DA (GenX), PFBS, PFNA, PFHxS, PFBA, PFHxA; Preliminary soil remediation goals for PFBS; Fish consumption advisory for PFOS
- *Ohio*: Advisory Drinking Water Action Levels for PFOA, PFOS, GenX, PFHxS, PFNA, PFBS
- *Oregon*: Initiation levels for PFOA, PFOS, PFNA, PFHpA, PFOSA in municipal wastewater effluent
- *Pennsylvania*: MCLs for PFOA, PFOS; Medium-specific concentrations for PFOA, PFOS, PFBS as groundwater and soil cleanup values
- *Texas*: Health-Based Non-Carcinogenic Toxicity Factors and Cleanup Values for 16 PFAS (including PFOA and PFOS) in soil and groundwater; Fish tissue consumption advisory for PFOS in select waterbodies; Interim short- and long-term Effects Screening Levels (ESLs) for PFOA, PFOS in air permitting; Chronic, non-carcinogenic reference concentrations for nine PFAS in air for remediation

<sup>33</sup> *Minnesota's* Health Risk Limits and Health-Based Values for groundwater are also used as guidance values for drinking water.

<sup>34</sup> Pursuant to state law RSA 485-H:13, the *New Hampshire* Department of Environmental Services is required to initiate rulemaking for Soil Remediation Standards by November 1, 2023 for the four PFAS (PFOA, PFOS, PFHxS, and PFNA) currently regulated in groundwater and drinking water in the state.

<sup>35</sup> *New Jersey* regulates PFAS individually, as written above. However, a state law enacted in 2024 requires assessment of the feasibility of establishing a drinking water standard for PFAS as a class, or for certain PFAS subclasses or mixtures rather than individually.

- *Washington*: Action levels for PFOA, PFOS, PFNA, PFHxS, PFBS in drinking water; Human health groundwater and soil (direct contact and soil leaching) values for PFOA, PFOS, PFNA, PFHxS, PFBS, PFBA, PFHxA, HFPO-DA (GenX); Ecological soil values for PFOA, PFOS, PFBS, PFDA, PFNA, PFHxA, PFHxS, PFDaA; Ecological marine surface water values for PFOA, PFOS, PFNA, PFDA, PFBS; Ecological freshwater surface water values for PFOA, PFOS, PFHxA, PFHxS, PFDA, PFNA, PFBA, PFBS, PFUnA, PFDaA; Fish Consumption Advisory for PFOS; Regulatory standards for PFOA, PFOS in children's products under the Children's Safe Products Act<sup>36</sup>
  - *Wisconsin*: Proposed health guidelines for 18 PFAS in drinking water and groundwater; Residual Contaminant Levels (RCLs) for PFOA, PFOS, PFBS in Soil, based upon the EPA RSLs web calculator; Fish and wildlife consumption advisories for PFOS
- Reasoning:
    - Risk assessors evaluate PFAS analytes individually in the regulatory determination process. Regulations are therefore based on conclusions that human health effects, analytical limitations, and removal of drinking water contaminants vary among PFAS.
    - Regulations vary based on the presence of PFAS in a state, availability of chemical guidelines used for testing, and ability of available labs to test for and measure that analyte. States with more limited contamination potential and evaluations of health effects may be waiting to see whether the EPA develops a technical basis for grouping PFAS before summing or regulating additional analytes.
    - Toxicologists have more data on the perfluoroalkyl acids (carboxylates and sulfonates) that are a result of the terminal degradation process of PFAS precursors, and less on the PFAS precursors and other non-perfluoroalkyl acids in the same family.
    - Toxicological studies demonstrate differences in the potency and bioaccumulation (i.e., physiological half-lives) among individual PFAS.

### *PFOA & PFOS, Summed*

- Nine states
  - *Alaska*: Drinking water action level for PFOA, PFOS
  - *Delaware*: Proposed MCLs for PFOA, PFOS individually and summed
  - *Florida*: Provisional Groundwater Cleanup Target Level for PFOA, PFOS, individually or combined
  - *Maryland*: Drinking water advisory level for PFOA, PFOS as a requirement for impacted water utilities to provide alternative water to customers.<sup>37</sup>
  - *Montana*: Groundwater standard for PFOA, PFOS individually and summed; Screening level for surface water for PFOA, PFOS individually and summed, Remedial Action Guidelines for PFOA, PFOS in sediment at contaminated sites
  - *New Mexico*: Groundwater standard for PFOA, PFOS; Surface water screening level for PFOA and/or PFOS implemented through CWA Section 401 conditional certification of a NPDES permit

<sup>36</sup> *Washington's* human health values for drinking water, groundwater, and soil, as well as the ecological values for surface water and soil, were **derived** based on equations in the state's Model Toxics Control Act (MTCA). The actual values are not in Rule, but the method to derive them is. The values are considered applicable or relevant and appropriate requirements for cleanup sites. The state action levels (drinking water values) are not considered ARARs at state cleanup sites unless Washington conducts a site-specific evaluation to determine that they are. The state action levels themselves (not the method) are in Rule.

<sup>37</sup> This also may include acquisition of a new source, improvements to the construction of existing wells, connection to other water systems, or installation of treatment. If a system installs treatment, they are asked to conduct quarterly monitoring to ensure that it is effective. Certain water systems may be asked to conduct semi-annual monitoring depending on the concentrations of PFOA and PFOS.



- *Ohio*: Advisory Drinking Water Action Levels for PFOA, PFOS individually and summed
- *Pennsylvania*: Medium-specific concentrations for PFOA, PFOS, individually or summed, as groundwater and soil cleanup values
- *Wisconsin*: Drinking water standard for PFOA, PFOS

- Reasoning:

- Regulating PFOA and PFOS aligns with the EPA's LHA. While the EPA has developed draft toxicity factors for a few other PFAS, PFOA and PFOS remain the only analytes with federal health advisories.
- Regulating PFOA and PFOS together can streamline processes given their similar characteristics and known toxicities. PFOA and PFOS are the most thoroughly studied of the long-chain PFAS, with a large quantity of publicly available toxicity information available, and are considered hazardous substances or listed as a similar toxicant under some states' laws.

### *More than 2 PFAS, Summed or Otherwise Grouped*

- 13 states

- *California*: Identification of PFOS and its salts and transformation and degradation precursors as carcinogens, and PFNA and its salts as male reproductive toxicants, under California's Proposition 65 law. Enforcement action can be applied to any compounds within these groups.
- *Colorado*: Policy interpreting narrative groundwater and surface water quality standards for PFAS sums PFAS constituents based on endpoint toxicity (e.g., PFOA, PFOS, PFNA, and any identified parents are added together based on developmental toxicity; PFHxS and any identified parents are added together based on endocrine toxicity; PFBS and any identified parents are added together based on renal toxicity)
- *Connecticut*: Advisory groundwater protection criteria, groundwater pollutant mobility criteria (soil leaching to groundwater), and soil direct exposure criteria for the sum of 5 PFAS (PFOA, PFOS, PFNA, PFHxS, PFHpA)
- *Maine*: Interim drinking water standard for the sum of 6 PFAS (PFOA, PFOS, PFNA, PFHxS, PFHpA, PFDA) for community water systems and non-transient, non-community water systems that are schools or childcare facilities; Screening levels used as groundwater remedial action guidelines for the sum of 6 PFAS (PFOA, PFOS, PFNA, PFHxS, PFHpA, PFDA)
- *Massachusetts*: MCL and groundwater cleanup standard for the sum of 6 PFAS (PFOA, PFOS, PFNA, PFHpA, PFHxS, PFDA); Surface water target values for PFOA, PFDA, PFHpA, PFNA, and for PFOS, PFHxS
- *Minnesota*: MN's [Health Risk Limits Rules for Groundwater](#) require evaluation of exposure to multiple contaminants in groundwater. Hazard ratios are summed across contaminants with guidance values based on the same health endpoints. An [Excel-based calculator](#) has been created to facilitate cumulative assessments. For example, MDH guidance values for PFHxS, PFHxA, PFBS, and PFBA are all based on thyroid effects. The hazard ratios for each of these contaminants would therefore be added together to calculate a multiple contaminant health risk index.
- *New Mexico*: Soil and tap water screening levels implemented through risk assessment guidance that provides for summation of PFOS, PFOA, PFBS, PFNA, PFHxS
- *Oregon*: Health Advisory Levels for PFOA, PFOS, PFNA, and PFHxS in drinking water
- *Vermont*: MCL and promulgated groundwater standard for the sum of 5 PFAS (PFOA, PFOS, PFNA, PFHpA, PFHxS)
- *Rhode Island*: Drinking water standards in groundwater quality regulations and surface water quality action limits for the sum of 6 PFAS (PFOA, PFOS, PFHxS, PFNA, PFHpA, PFDA)

- *Washington*: Regulatory standard for the sum of all PFAS in state-designated hazardous waste when halogenated organic compounds are present; Regulatory standards for the sum of all PFAS in certain consumer products under the Pollution Prevention for Health People and Puget Sound Act, Class B firefighting foams, and certain food packaging.
  - *Wisconsin*: Proposed groundwater enforcement standard and health advisory limit for the sum of PFOA, PFOS, and four of their precursors (FOSA, NEtFOSA, NEtFOSAA, and NEtFOSE). Wisconsin uses a [hazard index approach](#) to establish drinking water advisories for PFAS. Hazard quotients for detected PFAS with standards are added and compared to a value of 1.
- Reasoning: Many of the summed PFAS analytes are similar as indicated below:
    - They are long-chain compounds with similar chemical structures (+/- two carbons in chain length) to PFOA and PFOS.
    - They are often found together in the environment and have characteristically similar bioaccumulative patterns and fate and transport mechanisms.
    - Human exposures to these PFAS often are correlated, making it difficult to differentiate the contributions of the individual PFAS to health effects observed in humans.
    - Their toxicity is assumed to be additive based on a substantial body of publicly available data indicating that they cause similar toxicological effects, have long serum half-lives in humans (long-chain PFAS only), and are associated with similar health effects in humans.<sup>38</sup>
    - They have similar limits for lab detection via EPA Method 537.1 (see the *Analytical Methods* section on page 38), and there is a minimal cost difference between analyzing a few or 18 compounds, so regulating and requiring testing for more analytes does not increase the cost and lessens the potential for the need to resample in the future.
    - PFOA, PFOS, PFNA, PFHxS, PFHpA, and PFBS were the six PFAS included in the EPA's UCMR3. These PFAS have been researched to the extent that they are regulated individually by some states. PFHpA has minimal toxicity data available and PFDA was not included in UCMR3, but some states regulate both of these PFAS with the other long-chain PFAS based on close structural similarity and their inclusion as analytes in the EPA's analytical methods for drinking water.<sup>39</sup>
    - Regulating more analytes can provide information on conceptual site model development and the potential for PFAS fingerprinting (forensics on the fate and transport of chemicals over time).

## Evaluating Differences among States' PFAS Guidelines

One of the most common questions that states are asked to address when communicating risks to the public and co-regulators is why guidelines vary from state to state. Many of the states' derived values typically differ within a factor of two to three, indicating that they are similarly protective; however, this is difficult to communicate with audiences who lack a background in the scientific and regulatory basis for the guidelines. Consequently, communicating the rationale for varying guidelines among state and federal entities remains a challenge.

States report that deviations among PFAS guidelines are driven by several main factors:

---

<sup>38</sup> On the other hand, though similar, these PFAS do still present differences (e.g., different levels at which toxicity occurs, different toxicological effects and modes of action) that a state might acknowledge as a reason *not* to group the chemicals, but rather to regulate them individually.

<sup>39</sup> This list of PFAS is expected to expand in 2023-2025 as PWSs will be required under UCMR5 to monitor for all 29 PFAS that are within the scope of EPA methods 537.1 and 533. The first [UCMR5](#) data set was published in August 2023.

- Differences in professional judgments regarding the choice of the critical study and endpoint, whether animal or human data are used, the method for animal-to-human extrapolation, the uncertainty factors, and exposure parameters such as the Relative Source Contribution. Differences in any one of these choices (described in more detail in the *State Trends for the Basis of Guidelines* section on page 33) will result in different numerical values for the PFAS standard being developed.<sup>40</sup>
- Differences in timing. *When* guidelines are developed and *when* a state looks at the available scientific information affects *what* the guidelines are. While many technically sound guidelines have been developed from older studies, toxicologists and epidemiologists continue to conduct new PFAS research that will provide states with more referential data for deriving values. In this fast-paced field, short timeframes can change what studies relevant to PFAS standard development are available.
- Differences in state legislative or rulemaking requirements. The next section of this paper will explore differences in legislative procedures, but it should also be noted that beyond legislatures, state environmental and health agency programs (e.g., drinking water, surface water, wastewater, remediation, air, and others) have varying priorities or responsibilities in the standard-setting process.
- Differences in state regulatory processes and histories. States have different histories of developing standard methods, enacting regulations, and setting policy, all of which may direct toxicologists to use specific approaches and require protection of certain human life stages/vulnerable populations or other factors. *Minnesota*, for example, is required to evaluate risks to pregnant women, infants, and children in its exposure assumptions. *Washington* chose to regulate PFAS as a class in certain consumer products under the Safer Products for Washington Program, Class B firefighting foams under the Firefighting Agents and Equipment – Toxic Chemical Use law, and certain food packaging under the Packages Containing Metals and Toxics Chemicals law. These factors, coupled with how well a state’s standard-setting methods reflect current and evolving science, can greatly affect how guidelines are calculated and what the resulting values are.

## Section I. Legislative Considerations

### Rulemaking Capacities

ECOS asked states to describe what authorities and processes they had to set PFAS guidelines. Responses indicate that most state guidelines are adopted/enacted through general rulemaking processes outlined in state administrative policies or acts, while some states have bills or statutes specifically targeted to PFAS. Examples of categories of such rulemakings besides those specifically setting PFAS guidelines include:

#### Consumer Products

- The *California* Department of Toxic Substances Control’s Safer Consumer Products Program lists PFAS as Candidate Chemicals and evaluates PFAS in consumer products like carpets, rugs, treated textiles, and leathers in accordance with its Safer Consumer Products Regulations. California state legislature has passed several bills prohibiting PFAS from being used in the manufacturing, distribution, or sale of juvenile products (i.e., a product designed for use by infants and children under 12 years of age), cosmetics, textiles, and food packaging.
- *Colorado* has passed bills banning certain products containing PFAS starting in 2024.
- *Maine* is requiring all manufacturers intentionally adding PFAS to any product to report such actions to its Department of Environmental Protection by 2025; prohibits the sale of carpets or rugs, as well as the sale of fabric treatments, that contain intentionally-added PFAS; and is banning all PFAS in products (unless

<sup>40</sup> An August 2020 [critical review](#) published in the Society of Environmental Toxicology and Chemistry’s online journal discusses some of the toxicity and exposure considerations that lead to similarities and differences among state and federal guidelines.

unavoidable) by 2030. Rulemaking for the implementation of this program was suspended in 2023, pending legislative actions, and will restart in 2024.

- In 2023, *Minnesota* passed Amara's Law, which prohibits intentionally-added PFAS in 11 product categories by January 1, 2025. By 2032, all other intentionally-added PFAS in products will be prohibited, except for uses of PFAS that the Minnesota Pollution Control Agency determines to be "currently unavailable" in rule. Rulemaking is ongoing to establish rules for 1) manufacturers to report information about PFAS intentionally added to products for sale or distribution in Minnesota by January 1, 2026, 2) fees assessed from manufacturers in relation to this reporting, and 3) determine any "currently unavailable uses" of PFAS.
- *New York* signed into law the Toxic Chemicals in Children's Products Law, which establishes an ingredient disclosure program and prohibits certain chemicals in children's products. *New York* also enacted restrictions on the sale, and offering for sale, of apparel with intentionally-added PFAS. These restrictions go into effect starting January 1, 2025.
- The *Vermont* legislature in 2021 passed a regulation banning PFAS from certain commercial products, including personal protective equipment, rugs and carpets, and ski wax.
- *Washington's* Safer Products for Washington Program can conduct rulemaking to reduce PFAS in consumer products. In 2023, Washington restricted PFAS as a class in carpets and rugs, furniture and furnishings intended for indoor use, and aftermarket stain and water resistance treatments, and required reporting of PFAS used in outdoor furniture and furnishings. Washington recently opened rulemaking for PFAS in apparel and gear, firefighting PPE, cleaning products, waxes and polishes, hard surface sealants, and cookware. Rules must be adopted by December 2025.

## Food Packaging

- The *California* Department of Resources Recycling and Recovery adopted several regulations imposing statewide restrictions on PFAS in food packaging, including one that establishes a threshold of 100 ppm total fluorine concentration for "compostable" and "recyclable" food service packaging served at food service facilities that are state-owned, operated on state property, or under contract with the state.<sup>41</sup> Additionally, cookware manufacturers must include a list of intentionally-added PFAS chemicals in packaging.
- *Maine* is prohibiting the use of PFAS in food packaging if safer alternatives are available at comparable cost and function. Rulemaking for the implementation of this program will continue into 2024.
- Manufacturers of food packaging in *Maryland* must establish a certificate of compliance showing that PFAS was not intentionally added.
- *Minnesota* passed a law prohibiting the use of intentionally-added PFAS in food packaging by January 1, 2024.
- *New York* enacted the Hazardous Packaging Act, Title II of Article 37 of the state's Environmental Conservation Law, which applies specifically to food packaging with intentionally-added PFAS.
- The *Rhode Island* legislature in 2022 similarly passed a regulation prohibiting the sale or promotional distribution of any food packaging containing intentionally-added PFAS beginning in 2024.
- In 2021, the *Vermont* legislature passed a regulation banning PFAS in food packaging, and the *Connecticut* legislature passed updates to the state's Toxics in Packaging Law to include a prohibition on intentionally-added PFAS in food packaging, which went into effect on January 1, 2024.
- *Washington* prohibits the use of PFAS in those types of paper-based food packaging where available safer alternatives have been identified; intentionally-added PFAS will be restricted in fast food and takeout packaging as of May 2024.

---

<sup>41</sup> Total fluorine measurements are a reliable proxy for determining the presence of PFAS in food service packaging.

## AFFF

- *Arizona* revised a statute prohibiting the use of AFFF for training or testing purposes unless those activities are conducted using proper containment, treatment, and disposal measures approved by the state.
- *California* legislation amended the state Health and Safety Code to prohibit AFFF beginning January 1, 2022; ban AFFF training classes; restrict unused foam disposal; and track sales of and require notice of PFAS in personal protective equipment.
- *Colorado* has passed bills to prevent further contamination from AFFF.
- In 2021, the *Connecticut* legislature passed a law banning training with Class B firefighting foam containing intentionally-added PFAS effective July 13, 2021, and most other uses effective October 1, 2021. The law also required implementation of an AFFF takeback program for municipal fire services. The AFFF ban allowed a later effective date (October 1, 2023), for airports, and provisions for chemical facilities, oil refineries, and terminals to request a two-year extension for transitioning.
- *Illinois's* Public Act 102-0290, effective January 2022, regulates the use of Class B firefighting foam to minimize PFAS exposure. Under the law, AFFF may not be used by a person, local government, fire department, or state agency for training or testing purposes unless the fire authority has evaluated the testing facility for containment, treatment, and disposal measures to prevent uncontrolled release of the foam to the environment; notified the Illinois Emergency Management Agency of the AFFF discharge or release within 48 hours; and provided training to employees of the possible hazards, protective actions, and a disposal plan.
- *Indiana* state law IC 36-8-10.7 prohibits the use of PFAS-containing firefighting foam for training purposes and requires containment, treatment, and disposal measures when used for testing purposes.
- *Maine's* legislature enacted a law in 2021 prohibiting the discharge of firefighting or fire suppressing foam for testing or training to which PFAS have been intentionally added; requiring the reporting of discharges to the state's Department of Environmental Protection; enacting a notice and recall provision; and prohibiting the manufacture, sale, and distribution of intentionally-added PFAS to firefighting foams. Report on the Implementation of an Act to Restrict the use of PFAS Substances in Firefighting Foam was submitted to the 130<sup>th</sup> Maine legislature on March 2, 2022.
- *Minnesota* has prohibited intentionally-added PFAS in firefighting foam used for testing and training, except under certain conditions, since July 1, 2020. Most other uses of firefighting foam with intentionally-added PFAS have been prohibited since January 1, 2024, with some time-limited exemptions.
- *New Hampshire* in September 2019 adopted regulation [154:8-b](#) which sets certain requirements relative to the sale and use of firefighting foam containing PFAS.
- In 2023, *New Jersey* enacted a law prohibiting the use, sale, and manufacture of AFFF containing intentionally-added PFAS, with a longer timeframe for oil refineries and petroleum terminals than for other AFFF users.
- *New York* enacted restrictions on the sale and use of firefighting equipment containing PFAS. The law also includes a recall provision where manufacturers of restricted Class B firefighting foam must "recall the product, which includes collection, transport, treatment, storage and safe disposal," and that the manufacturers "reimburse the retailer or any other purchaser of the product."
- In March 2022, *Ohio* enacted ORC 3737.52, which prohibits the use of AFFF in training exercises.
- *Rhode Island* recently developed draft legislation to require extra measures for storage of AFFF and limiting the use of these foams for training in environmentally-sensitive areas.
- The *Vermont* legislature in 2021 passed a regulation banning PFAS in AFFF.
- In 2018, *Washington* law prohibited the use of AFFF containing intentionally-added PFAS for training purposes. In 2020, under the state's Firefighting Agents and Equipment – Toxic Chemical Use Law, the manufacture, sale, or distribution of AFFF with intentionally-added PFAS was prohibited in most cases.

## Air Toxics

- *Minnesota* has been directed by the state legislature to promulgate separate but related rules for the reporting and regulation of air toxics. Minnesota must have the reporting rule on notice with intent to adopt by November 2024 and the regulations rules on notice with intent to adopt by May 2025. It is possible that some number of PFAS could be listed as air toxics in both the reporting and regulatory rules, although no specific determinations have been made.
- Since 1997, *New Hampshire's* state air toxics regulation has contained annual and 24-hour inhalation standards for APFO, the ammonium salt of PFOA. Additionally, New Hampshire is required by state statute to write rules and require the installation of best available control technology for PFAS and PFAS precursor air emissions that may have contributed to ambient groundwater or surface water quality standards.
- *New York* currently has five PFAS with chronic ambient air concentration values under its state regulations.

## Water Sampling and Investigation

Many states have or are in the process of enacting laws or taking other steps to require sampling of all statewide PWSs. Additionally, states are sampling and investigating non-drinking water sources, or have specific legislative initiatives for PFAS sampling.

- As of 2024, *California* has incorporated requirements into NPDES permits (new and renewals) for the inclusion of PFAS testing as part of monitoring and reporting programs (MRP), and has added routine PFAS sampling and testing requirements to some existing landfill MRPs.
- *Maine* is conducting statewide soil and groundwater testing for PFAS at or associated with sludge and septage land application sites, testing landfill leachate,<sup>42</sup> and coordinating with other agencies on PFAS impacts to active agricultural operations and pesticide uses.
- *New Jersey* revised its regulations to add PFOA, PFOS, and PFNA to the list of contaminants that must be analyzed in private wells when a residential property is sold and in rental residences served by private wells.
- *North Carolina* is using legislatively-appropriated funding, on a sliding scale based on household income level, to conduct PFAS testing and offer filtration options for residential wells.
- *Virginia's* General Assembly in 2023 established legislation requiring PFAS testing by industrial users of publicly owned treatment works that refurbish, clean, or repair wastewater treatment equipment used in a manufacturing process containing PFAS.

## Land Application of Residuals (Sludge and Septage)

- The 130<sup>th</sup> *Maine* legislature, in Public Law 2021, Chapter 641, banned the land application of sludge and sludge-derived products beginning August 8, 2022.<sup>43</sup> This does not include all sludges (some sludges are specifically exempt in statute) and it does not ban the licensed land application of septage.<sup>44</sup>

While Maine is the only state with a ban on land application, some other states have taken or are considering rulemaking pertaining to PFAS in biosolids. For example, in September 2023, *New York* adopted [Materials](#)

<sup>42</sup> *Maine* released its "[Report on the Testing of Landfill Leachate for \[PFAS\] Contamination](#)" on January 16, 2024.

<sup>43</sup> This action was taken in response to the detection of PFAS-contaminated milk, resulting from PFAS in the biosolids that were applied to dairy farms in the state.

<sup>44</sup> *Maine* has published two [reports](#) that provide more information on biosolids and sludge management. On December 21, 2023, the Maine Department of Environmental Protection and the Maine Water Environment Association released a report completed by Brown and Caldwell called "An Evaluation of Biosolids Management in Maine and Recommendations for the Future." On January 17, 2024, the Department completed its "Analysis of Sludge and State-owned Landfills as Public Utilities."

[Management Program Policy 7](#), which establishes interim PFOA and PFOS criteria for biosolids that are recycled and actions that will be taken by the state's Department of Environmental Conservation based on those results. The interim policy will remain in effect until the EPA issues risk-based standards applicable to biosolids that will be recycled, and the Department completes a rulemaking to incorporate those standards, or more stringent standards if deemed appropriate.

More information about state actions on PFAS in biosolids can be found in ECOS' [PFAS in Biosolids: A Review of State Efforts & Opportunities for Action](#), published in January 2023.

These examples represent only a few of the active state PFAS bills and other regulatory actions prohibiting AFFF for firefighting, regulating food packaging, and requiring PFAS sampling, among other actions. There are also examples of interstate collaboration. In March 2024, the Northeast Waste Management Officials' Association, Inc. (NEWMOA) published its [PFAS Prevention Model Legislation](#), which provides a comprehensive framework to help jurisdictions develop more consistent approaches to addressing PFAS and PFAS-containing products. Drafted by a workgroup of representatives from Connecticut, Massachusetts, New Hampshire, New Jersey, New York, and Vermont, the model legislation is designed to present a flexible set of concepts and options from which state policy makers can consider.

States active in PFAS regulation are typically backed by their legislators, Attorneys General, and other leadership entities that provide funding and direct the environmental agencies to take action on contamination. Such actions include forming task forces for improved coordination (see the *Intra-State PFAS Collaboration* section on page 27), setting guidelines in different media by certain dates (e.g., *Vermont*), or initiating directives or lawsuits against PFAS manufacturers or the DOD (e.g., *Minnesota, New Jersey, New York, New Mexico*).

Enforcement of state regulations is typically a programmatic issue specific to the contaminated medium and is conducted in accordance with rules or policies in effect for each regulatory program (e.g., Superfund and hazardous waste, RCRA, SDWA). Consequently, enforcement efforts for PFAS in drinking water, groundwater, surface water, solid waste, biosolids, and other environmental media are led by the state agency with authority to administer the applicable rules, and would be conducted as directed by program rules, unless specific rules for PFAS have been adopted. A couple of states indicated that they may rely on the state Attorney General for broader authorities or look to primacy agreements with the EPA. Enforcement may occur if a regulatory standard is exceeded, the contamination is considered hazardous, or there is a requirement for assessment and remediation. Some states noted that PFAS enforcement is a challenge without having adequate toxicity data necessary to establish the criteria on which a permit limit or enforcement/remediation action is based.

## Regulating PFAS as Hazardous

25 states (*Alaska, Arkansas, Connecticut, Florida, Hawaii, Indiana, Iowa, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Mexico, New York, North Dakota, Ohio*,<sup>45</sup> *Pennsylvania, Rhode Island, South Carolina*,<sup>46</sup> *Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming*) noted that they have emergency rulemaking powers. Emergency

<sup>45</sup> In *Ohio*, on an agency's request, the Governor may issue a written order suspending the normal rulemaking procedure for a particular rule if an emergency exists. The agency then immediately may adopt the rule without complying with the notice, hearing, and other proposal requirements. An emergency 119 rule takes effect immediately on filing, but expires on the 121<sup>st</sup> day after its effective date unless, in the meantime, the agency has readopted the 119 rule under the normal rulemaking procedure.

<sup>46</sup> *South Carolina* can only use its emergency rulemaking power, issued under authority 1-23-130, where there is imminent peril to public health, safety, or welfare before compliance with the statutory promulgation procedures can be followed or abnormal or unusual conditions, immediate need, or the state's best interest requires immediate promulgation. The regulation is only good for 90 days and cannot be refiled if the legislature is in session, or can be refiled if 90 days expires before the legislation is in session.

rulemaking powers can be invoked to respond to a PFAS contamination event or if a specific PFAS is declared hazardous at the federal level.

Several states also regulate PFAS as hazardous under certain conditions. For example, *Alaska* includes PFOA and PFOS in a list of hazardous substances for which groundwater and soil cleanup levels are set. *Delaware's* Hazardous Substance Cleanup Act lists PFOA, PFOS, PFHxS, PFHxA, PFNA, PFBS, PFBA, and HFPO-DA as hazardous substances with screening values reflecting Regional Screening Levels in groundwater through a risk-based cleanup program. *New Jersey* added PFNA to the NJ Hazardous Substance List in 2018, and added PFOA and PFOS to the list in 2020. *New York* regulates PFOA and PFOS as hazardous substances under 6 NYCRR Part 597. Regulators in *New Mexico* may include PFAS in RCRA corrective action permits and take action in response to a PFAS contamination event of which the quantity, concentration, or other characteristics of the waste threaten human health or the environment. In 2021, the state amended its Hazardous Waste Act to allow for the promulgation of rules more stringent than federal law. In October 2021, the *Washington* Department of Ecology announced that PFAS are hazardous substances under the state's Model Toxics Control Act. Ecology released final Toxic Control Program PFAS guidance in June 2023 that provides cleanup levels and direction on how to address PFAS contamination in the state. *Maine* adopted Public Law 2021, Chapter 117 in June 2021 redefining hazardous substances in the state to be consistent with the definition of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), including a CERCLA "pollutant or contaminant" which allows PFAS contamination to be considered, evaluated, or managed under Maine's uncontrolled site law. *Minnesota* considers PFAS to be hazardous substances under the Minnesota Environmental Response and Liability Act. *Montana* has an equivalent Superfund policy under state law. *Oregon* is working on a draft strategic plan in 2023 that will include rulemaking options for regulating PFAS as hazardous. Lastly, *Rhode Island* regulates six PFAS as hazardous under state law.

While the federal government has in the past considered designating PFOA and PFOS as hazardous substances, as outlined in the EPA's PFAS Action Plan and considered by Congress for the Fiscal Year 2020 National Defense Authorization Act (NDAA), it was not until more recently that the federal government has taken formal steps to move forward with such rulemaking. In August 2022, the EPA [proposed](#) to designate PFOA and PFOS, including their salts and structural isomers, as CERCLA hazardous substances.<sup>47</sup> In April 2023, the EPA issued an Advance Notice of Proposed Rulemaking to seek public input and information on the potential to designate other PFAS as hazardous under CERCLA. On April 19, 2024, the EPA [finalized](#) the rule. The designations require facilities to report on PFOA and PFOS releases that meet or exceed a reportable quantity of one pound or more within a 24-hour period, and provide the EPA with the statutory authority to investigate, monitor, and respond to PFOA and PFOS releases (or threats of releases) into the environment. It also requires responsible parties to conduct or pay for cleanups to address such releases or threats of releases. The EPA published an enforcement discretion and settlement policy [memorandum](#) alongside the final rule to provide direction about how it will focus on holding responsible entities who significantly contributed to the release of PFAS contamination into the environment liable. The EPA published its updated interim [guidance](#) on PFAS destruction and disposal on April 9, 2024; the guidance is open to public comment for 180 days after it is published in the *Federal Register*.

Designating PFAS (PFOA and PFOS, or also including additional analytes) as hazardous substances under CERCLA has some, though likely different, impacts on states. In previous iterations of this report, *North Carolina* noted that the declaration may provide more information to its rulemaking body. Other states noted that empowering them to act using existing regulatory CERCLA mechanisms allows for an expedited cleanup process and prevents draining

---

<sup>47</sup> Note that the designation of PFOA and PFOS as CERCLA hazardous substances is different than the addition of five PFAS to the EPA's Regional Removal Management Levels (and Regional Screening Levels) lists. Regional Removal Management Levels are risk-based values used to define areas, contaminants, and conditions that may warrant immediate intervention under CERCLA (whereas the Regional Screening Levels are used to identify air, tap water, or soil at a site that may warrant further investigation). States can use these levels to make decisions at contaminated sites.



already-strained funds for site investigation and characterization. *Kansas* said this definition is what it needs to regulate PFAS and that it cannot set PFAS standards until EPA does, as the state's definition of a hazardous substance is based on its inclusion as a CERCLA hazardous substance, and that it will provide more opportunity to ensure companies evaluate PFAS impacts. In 2023, and again in 2024 ahead of the finalization of the rule, ECOS asked states to share how the rule, if finalized, would affect them and gathered a number of responses.<sup>48</sup>

- *Alaska and Rhode Island* already list PFOA and PFOS as hazardous substances in state regulations so they reported that a CERCLA listing would not have a direct or notable impact. Similarly, *Florida's* definition of a hazardous substance directly incorporates all of the substances listed in CERCLA, so it will automatically update if and when EPA finalizes their rule for PFOA and PFOS.
- *Arizona* said the designation would allow additional sites to be investigated and remediated under the state's Water Quality Assurance Revolving Fund, the state's equivalent to the Superfund Law.
- *Arkansas* mentioned that the designation would give the state additional authorities to address the wide-ranging impacts of PFOA and PFOS, but will also undoubtedly lead to new sites being added to State or federal (National Priority List) lists of contaminated sites, exacerbating the staffing issues the state already faces and requiring additional funding to meet the new workload required.
- *Delaware*, which lists eight PFAS as hazardous substances under state law, noted that with regard to the potential of regulating other PFAS under CERCLA, listing PFAS as a class would create challenges as analytical methods are not able to detect the majority of PFAS, and the majority of PFAS do not have toxicological data.
- *Indiana* noted it is waiting for the CERCLA designation to be able to regulate PFAS as hazardous in the state and to include PFAS in cleanup considerations.
- *Iowa* said that the CERCLA designation would, at a minimum, affect EPA-Lead Sites and military sites across the state.
- *Kansas* said that one of its greatest concerns will be the appropriate disposal or land application of biosolids from municipal wastewater plants, especially regarding larger mechanical plants with daily sludge production. The CERCLA designation will influence disposal options and conditions for land application.
- *Maine* said the designation would make the process clear and consistent among states, which is needed for all PFAS requirements. The state did note, however, that there is some concern about the scope and liability once PFOA and PFOS are listed, specifically as to what degree regulated parties will be subject to enforcement. The 131<sup>st</sup> Maine Legislature is considering a bill (LD 2066) to amend Maine's uncontrolled site law, in part, to provide a limited exemption from liability for PFAS contamination associated with a licensed land application site.
- *Minnesota* said actions taken at the federal level will not impact the state's current position regarding PFAS as hazardous substances under the Minnesota Environmental Response and Liability Act. Formal recognition as hazardous substances under CERCLA would better align investigation and response actions taken at federal lead sites in Minnesota (e.g., EPA-lead, DOD-lead) to actions initiated by the state under state authorities.
- *Montana* has an equivalent Superfund policy under state law and is currently considering how it will move forward once PFOA and PFOS are designated as hazardous substances under CERCLA.
- *North Dakota* noted that by designating PFOA and PFOS as hazardous substances, they will be added to a list in North Dakota Administrative Code (NDAC) 33.1-24-02 appendix V (Fed Rules 40 CFR 261 appendix VIII-Hazardous Constituents). This is one of the lists that CERCLA draws from when it comes to delineating a site for contamination and potential listing on the National Priorities List (NPL). The hazardous waste program does not regulate hazardous constituents, but to be "nominated" to become a hazardous waste under RCRA, it has to be on the hazardous constituents list first.

<sup>48</sup> ECOS recognizes that this list of state stances is not comprehensive and there are many different opinions from states and other stakeholders about how this rule should be implemented. Some of these states provided formal comments to the EPA.

- *Ohio* will incorporate final federal hazardous substances designations for PFOA and PFOS under CERCLA into its state assessment and cleanup programs accordingly. Additionally, the CERCLA designation could impact its Class I underground injection control non-hazardous wells' ability to accept PFAS waste.
- *Oregon* has many more sites under state cleanup authority than under federal CERCLA authority and a state rulemaking will be required to make some PFAS state hazardous substances, so it may pursue that before or after EPA finalizes its rulemaking.
- *Pennsylvania* said that any CERCLA defined or designated hazardous substance is deemed a "hazardous substance" under the state's Hazardous Sites Cleanup Act, which also provides emergency response authority to address releases of nonhazardous substances if deemed imminent or a substantial threat to public health or the environment. The federal CERCLA hazardous substance designation will enhance the state's authority under this Act to pursue responsible parties and provide a legal path for private citizens to file civil actions.
- *South Carolina* said if finalized, the designation will enhance its ability to require assessment and remediation of PFOA and PFOS at release sites in the state. The state will continue to work with Federal Facilities to meet requirements of federal law and policy as they implement the CERCLA process.
- *Texas* said it has no concerns.
- *Utah* said the designation would allow the state to include PFAS data collection in the Site Assessment work it conducts in support of the CERCLA process, strengthen the state's ability to require it as part of its site characterizations and remedial action plans for cleanup, and provide a foundation to request investigations and/or monitoring at additional sites.
- *Virginia* said the designation would result in landfill operators revisiting their waste acceptance criteria, likely choosing to limit inbound wastes with known elevated concentrations of PFAS (including filter materials, biosolids, and impacted soils), and that there are potential CERCLA liabilities for past discharges from publicly owned treatment works, as well as possible indirect impacts on Brownfield redevelopment projects.

In October 2021, in response to a petition from New Mexico Governor Michelle Lujan Grisham to identify individual PFAS or a class of PFAS as hazardous wastes under RCRA, the EPA [announced](#) that it also plans to initiate rulemaking for two new actions under the Act. These actions include evaluating existing data to propose adding four PFAS as RCRA Hazardous Constituents under Appendix VIII to ensure they are subject to corrective action requirements, and clarifying in agency regulations that PFAS can be cleaned up through the RCRA Corrective Action Program. On February 1, 2024, the EPA [announced](#) its proposed rule to amend its RCRA regulations to add nine PFAS to the list of RCRA hazardous constituents and to modify the definition of hazardous waste as it applies to cleanups at permitted hazardous waste facilities.

## *Other Regulatory Developments*

There are a number of other regulatory actions and considerations that may impact state PFAS guidelines, or PFAS regulation generally, across the U.S. In its December 2023 [PFAS Strategic Roadmap: Second Annual Progress Report](#), the EPA outlined some of the key actions it has taken across different environmental media and under various statutes. Under TSCA, the agency in 2023 expanded work under its [National PFAS Testing Strategy](#); proposed amendments to a [rule](#) that would eliminate exemptions from a full safety review process before PFAS can enter commerce; announced a [framework](#) for evaluating new PFAS and new uses of PFAS; proposed a [rule](#) to prevent manufacturing or processing of about 300 "inactive" PFAS without risk assessment and management; finalized a [rule](#) to require manufacturers and importers of PFAS and PFAS-containing in any year since 2011 to report information on PFAS uses, production volumes, disposal, exposures, and hazards; added certain PFAS to the TRI; and finalized a [rule](#) eliminating an exemption that allowed facilities to avoid reporting PFAS information to the TRI when used in small concentrations, among other actions. In December 2022, the EPA sent state co-regulators a [memorandum](#) that asked states to leverage the CWA's NPDES permitting program to restrict PFAS discharges at point sources and address pollution at known or suspected industrial sites. It included recommendations for what

states can include in the permits, encouraging the use of EPA Method 1633 for effluent monitoring and best management practices for pollution prevention and source reduction, for example. Some states already incorporate PFAS sampling or monitoring into their NPDES permits, or for compliance inspections, and others noted that they are exploring wastewater monitoring options and other efforts that can be added to NPDES permits in the future.

In July 2023, ECOS, the EPA, and the National Association of State Departments of Agriculture jointly developed [Principles for Preventing and Managing PFAS in Biosolids](#). ECOS in May 2024 will also launch a webpage on PFAS use in industry; ECOS compiled information from states, federal agencies, and nongovernmental organizations and put together an interactive table and list of resources for how PFAS is used in a subset of industries that are of interest to states. These cross-media actions represent only a limited number of those taken on PFAS in the past year or two, but states are tracking this information and the impacts it will have on industrial operations, water and wastewater utilities, permitting, and other efforts.

### *Intra-State PFAS Collaboration*

States have varying procedures for designating who regulates PFAS. Many state environmental agencies are coordinating with their health, agriculture, and other state agency counterparts on the state's PFAS response. For example, the *Michigan* PFAS Action Response Team (MPART) was created in 2017 through an executive directive to investigate sources and locations of PFAS and protect drinking water and public health. In 2019, MPART was signed into an executive order as an enduring advisory body of seven state agencies, led by the Michigan Department of Environment, Great Lakes, and Energy. Other states (e.g., *Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Indiana, Iowa, Maine, Massachusetts, Minnesota, Missouri, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South Carolina, Utah, Washington, Wisconsin*) have formed similar task forces and action teams charged with recommending PFAS guidelines and/or conducting other statewide PFAS efforts.

### *Impacts of Federal Regulatory & Legislative Uncertainty*

In the original and subsequent publications of this report, ECOS asked states that have already established guidelines about the expected impact of the pending federal MCL or a similarly enforceable federal PFAS standard on their regulations. States responded that they may be required to modify their guidelines to be “no more stringent than” federal requirements, or they may be required to “strengthen” their guidelines so that they are as protective as federal standards. States recognize that this may impact the number of public water systems that need to address PFAS contamination as a result of adjusted standards. At the time, *North Carolina* noted that a federal MCL could affect its groundwater and drinking water programs, *Maryland* acknowledged that a lowered reference dose may impact its fish tissue monitoring work and result in more sites needing to be revisited, *Kansas* expressed its concerns about how its state labs will accommodate a large influx of samples and associated analytical workloads once it promulgates the necessary federal regulations, and another state noted its concern that a federal MCL may or may not adequately address protection for all populations and impacted communities because MCLs are not strictly risk-based. Numerous states with advisory guidelines expressed their preference for the EPA to have the primary role in setting MCLs, which they argue will facilitate a unified approach to mitigating PFAS contamination in drinking water supplies, as well as federal standards in other media. States recognized, however, the timeline associated with setting a nationwide standard and expressed their intentions to move forward with statewide MCLs or guidance in the interim. When the EPA enacts an enforceable drinking water standard for PFOA and PFOS, some states may need to make challenging management decisions regarding how to adjust their existing guidelines and PFAS response efforts to comply with the federal standard.

In 2023, and again in 2024 ahead of the finalization of the rule, ECOS asked states to share how the NPDWR, would affect their published concentrations or state guidelines, given that the proposed MCL for six PFAS was lower than any state guidelines at the time, and/or how they will work to incorporate the enforceable federal regulations into their state rules and programs. Some responses are below:<sup>49</sup>

- *Alaska* will adopt the final PFAS rule by reference once it is promulgated by the EPA.
- *Arizona* noted that it will consider the federal MCL in potentially setting state PFAS water quality standards.
- *Arkansas* said a MCL would have a tremendous economic impact due to the state's rural water and wastewater infrastructure, and would require the expense of regular sampling and analysis across the state, as well as potential mitigation efforts, which the state does not currently have the capacity to undertake.
- *Connecticut* will adopt the federal MCL once finalized. The state currently uses its action levels as guidance values.
- *Delaware* said the creation of MCLs for any individual PFAS would create Reporting Values for those PFAS under the Hazardous Substance Cleanup Act.
- *Florida* is required by state statute to establish Cleanup Target Levels if EPA has not finalized its MCLs by January 1, 2025. The Department of Environmental Protection would then adopt the MCLs for PFOA and PFOS as the groundwater Cleanup Target Levels, allowing the agency to move forward with requiring cleanup at sites that exceed the levels.
- *Hawaii* will present the draft MCLs in its current PFAS guidance and will adopt final, promulgated MCLs into its regulations.
- *Idaho* said it plans to follow primacy requirements and timelines for adoption once EPA promulgates its final rule, and will include a review and approval by the Board of Environmental Quality and the Idaho Legislature.
- *Indiana* relies on the EPA RSLs for screening levels, and these will presumably incorporate the MCL. Once the MCL is finalized, Illinois' groundwater level will revert to the value of the MCL.
- *Iowa* intends to propose the adoption of any federal PFAS standard required to maintain delegation of a federal program in the state.
- *Maine* is required to revise its regulations to incorporate the federal MCLs once they are promulgated.
- *Michigan* will continue to utilize state MCLs until the EPA has fully-enforceable MCLs and will evaluate the new requirements under the SDWA.
- *Montana* will evaluate implementation and impacts to communities of new guidance, MCLs, and other rulemakings as released by the EPA before determining how to proceed with adoption of (and ensure ability to adopt) standards or guidance in the state. Montana is a largely rural state and most of its communities have limited resources. Therefore, the state noted it will need to carefully consider the impacts to communities of adopting MCLs or surface water quality criteria prior to adopting them. Further, Montana has many small businesses that must be considered as the state considers implementation of new standards.
- At the request of the *New Jersey* Department of Environmental Protection Commissioner, the Health Effects Subcommittee of the New Jersey Drinking Water Quality Institute, an advisory body to the Department, reviewed the scientific basis of the EPA (2021) Interim LHAs for PFOA and PFOS and other relevant information, and they **concluded** that human data are appropriate for use as the RfDs for PFOA and PFOS and the Cancer Slope Factor (CSF) for PFOA. Considerations will need to be given to the differences in the monitoring framework between existing New Jersey state MCLs and the proposed (at the time) federal regulations, as well as how to enable water systems to utilize previously collected data to satisfy the proposed monitoring requirements. New Jersey is encouraging public water systems to continue to proactively implement actions that protect drinking water consumers from PFAS contamination.

<sup>49</sup> ECOS recognizes that this list of state stances is not comprehensive and there are many different opinions from states and other stakeholders about how this rule should be implemented and/or how it will affect states' PFAS guidelines. Some of these states provided formal comments to the EPA.

Recommendations include conducting monitoring at any treatment plant(s) where PFAS were detected or where unregulated PFAS have not been sampled for, reviewing all available data and evaluating if installation of treatment or other actions will be required to meet the federal MCLs, and notifying customers regarding sample results and actions the system is taking.

- North Dakota said it is happy to have a number to reference (and adopt, as the state does not have its own guidelines currently), but is concerned that the MCL is so low that the state will essentially regulate by treatment techniques.
- *Ohio* will initiate rulemaking to incorporate the finalized primary drinking water MCLs and replace the state's current PFAS Advisory Guidelines/Action Levels.
- *Oregon* uses MCLs as de facto groundwater reference levels, so there will be analysis and possible remediation efforts under several state authorities for sites with groundwater monitoring.
- *Pennsylvania* is supportive of a federal MCL to ensure national consistency, especially since many states do not have the resources to set such limits themselves. In the state, the MCL would be treated like any other new rule – the Department of Environmental Protection would review and evaluate the federal rule to determine if any provisions are more stringent than existing state provisions, and would move forward with a state rulemaking as needed.
- *Rhode Island* said it will continue to implement standards that are protective of human health and the environment, and to refine them as necessary based on new federal, or other, guidance arises.
- *Texas* continues to present the final MCLs in its current PFAS guidance and will adopt final, promulgated MCLs into its regulations.
- *Utah* has not taken a stance on the federal MCL but said any federal action to regulate PFAS will affect most of its state programs, allowing for integration of the new standards into state rules and for regulation of PFAS releases. The MCL would also allow the Department of Environmental Quality to require monitoring and evaluation of these substances in its current and future permits.
- *Vermont* intends to review the final PFAS regulation when it becomes available and expects to adopt the federal regulation, but is considering and analyzing impacts of PFAS that may require a state-specific approach.
- *Virginia* is evaluating a number of PFAS found in its public drinking water supplies and may consider regulatory action related to monitoring and limits based on the outcome of EPA's PFAS risk assessment and the MCL.
- *Washington* will use the MCLs for cleanup sites to determine risks from PFAS in groundwater. They are lower than the values the state currently uses so it will result in an increase in PFAS contaminated sites. Washington also noted that it would help the state's Toxics Cleanup Program if the EPA developed toxicity factors, and MCLs, for additional PFAS.

Ahead of the final rule, some states were pursuing other federal regulatory and legislative actions that might make PFAS remediation and regulation more consistent nationwide. In 2019, the bipartisan Congressional PFAS Task Force was established, and has been actively working to educate Members of Congress and their staff about PFAS, craft legislation to address PFAS, and advocate for federal appropriations to clean up PFAS contamination. In October 2020, a coalition of 20 attorneys general sent a letter to Congress outlining states' PFAS-related priorities for the fiscal year 2021 NDAA. In addition to again encouraging Congress to designate PFAS as hazardous substances under CERCLA, these states argued for DOD to meet or exceed the PFOA and/or PFOS standards established in the state in which the military installation is located when those standards are more stringent than federal standards or health advisory levels. These provisions were not included in the final NDAA bill.<sup>50</sup> However,

<sup>50</sup> The [fiscal year 2021 NDAA](#) did, however, include many PFAS provisions geared towards remediating PFAS contamination and searching for suitable AFFF alternatives. It also ordered the formation of an interagency federal working group to coordinate on research and development.

several state governors, including those from *Michigan, Ohio, and Arizona*, have written letters under Section 332 of the fiscal year 2020 NDAA requesting that the DOD amend and/or enter into cooperative agreements with the state environmental agencies to address PFAS contamination resulting from military installation activities. The states cite that natural gradients have caused AFFF-contaminated drinking water, surface water, or groundwater to flow to nearby communities and, as such, argue that the DOD should coordinate with the state to mitigate further migration of PFAS contamination off base, oversee the implementation of state standards, and pay for treatment technologies, among other actions. Additionally, several states in late 2022 sent a joint letter to the Federal Aviation Administration urging the agency to secure federal funding to support airports' efforts to investigate the extent of PFAS contamination and put in place appropriate controls to address the risks posed by PFAS at and around commercial service airports.

## Section II. Risk Assessment

State environmental and public health agencies use quantitative risk assessment to develop health-based criteria for PFAS guidelines. The processes for evaluating exposure and developing these criteria are described across several guidance documents produced by the EPA.<sup>51</sup>

At its core, risk assessment is used to develop the human health basis for guidance values or standards by considering the following:

$$\textit{Toxicity} \times \textit{Exposure} = \textit{Risk}$$

Risk is a function of the toxicity of a chemical and a person's exposure to that chemical. The higher one's exposure, the greater the risk; similarly, the more toxic a chemical is, the more risk there is at the same level of exposure. Both variables are fundamental to the resulting calculation of risk.

As described in more detail below, differences among state PFAS guidelines may arise from differences in toxicity factors, which include RfDs for non-cancer effects and CSFs for carcinogenic effects. These toxicity factors are developed based on animal toxicology and/or human epidemiology studies. Choices in the scientific study and toxicity endpoint used, as well as choices made in developing an RfD or CSF from the selected study and endpoint, will result in differences in the numerical values of these toxicity factors. Additionally, a cancer risk level (e.g.,  $10^{-5}$ ,  $10^{-6}$ ) must be selected when using a CSF to develop a health-based criterion, and states may differ as to the cancer risk level used for guidance development.

Different guidelines may also result from variations in exposure factors, which include parameters relating to daily water ingestion, body weight of an individual, duration of exposure, and fraction of total exposure from the medium of concern (e.g., drinking water). As with toxicity factors, state agencies use evidence-based methods to characterize exposure factors.

### *Scientific Considerations, Professional Judgment, & Peer Review*

In general, states prefer to use peer-reviewed, publicly available toxicity studies that meet risk assessment criteria (e.g., study duration, route of exposure) as the basis for their guidelines. In some cases, states will consider non-peer reviewed reports (e.g., contract lab reports). Regulators review studies to ensure that they were properly conducted

<sup>51</sup> Examples of these EPA guidance documents include the [Risk Assessment Guidelines](#), [Water Quality Standards Handbook](#), and [Exposure Factors Handbook](#) (2011).

and reported, and consider a study's results coupled with its relevance, degree of rigor, and importance to the question at hand. Some states routinely develop their own guidelines for chemicals of interest to their state; however, if the EPA completes this process first, states can review the agency's conclusions and decide whether to use them, saving states the effort of doing this on their own. When EPA values are not available to use, some states refer to ATSDR's MRLs (as they would RfDs) or use health-protective values from other agencies like the American Conference of Governmental Industrial Hygienists (ACGIH).

## Toxicity Criteria & Methodology

Regulatory agencies may rely on a chemical-by-chemical approach or grouping approaches for developing PFAS toxicity criteria (e.g., RfDs for non-carcinogens and CSFs for carcinogens). Most states conducting their own evaluations do not rely solely on EPA or ATSDR risk assessments, for which the only published documents are those supporting the EPA's former (2016) and interim (2022) LHAs for PFOA and PFOS, RfDs for PFHxA, PFBA, PFBS, and GenX chemicals and its final MCLs and/or hazard indexes for PFOA, PFOS, PFHxS, PFNA, PFBS, and GenX chemicals, and the ATSDR's MRLs for non-cancer effects of PFOA, PFOS, PFHxS, and PFNA. Performing the scientific analysis needed to effectively regulate PFAS is time consuming, and regulators lack toxicological data needed to develop criteria for some PFAS detected in environmental media.

To develop health-based guidelines, agencies conduct risk assessments, which usually follow this sequence of events:

1. Review available studies (e.g., toxicological, epidemiological) to identify critical endpoints that are sensitive and relevant to humans.

Scientists generally prefer human epidemiological information as the basis for guidelines when the data are appropriate. Previously, the EPA and most states have concluded that currently available human studies are not appropriate to use as the primary basis for PFAS guidelines. As such, most current federal and state PFAS guidelines are based on laboratory animal study data that are then translated. For PFOA and PFOS, the EPA and some states have identified developmental effects (e.g., decreased pup body weight, thyroid effects [PFOS]; accelerated puberty; delayed ossification, delayed mammary gland development, neurobehavioral and skeletal effects [PFOA]; hepatic [liver] toxicity, immune system suppression [PFOA, PFOS]) as critical endpoints. Critical endpoints can vary from state-to-state based on scientific judgment.

*California* was the first state to use human epidemiological data (kidney cancer) to develop a draft drinking water guideline level for PFOA. While it treats PFOS as a carcinogen based on animal data, the California non-cancer health protective concentrations are also based on human data (liver toxicity for PFOA, increased total cholesterol for PFOS). In January 2024, *Minnesota* became the first state to finalize health-based drinking water guidance using epidemiological data for PFOA and PFOS. Minnesota used epidemiological data as the basis for both its cancer (kidney) and non-cancer (immune effects) PFOA guidance, as well as its non-cancer (low birth weight) PFOS guidance; due to lack of sufficient epidemiological data, its PFOS cancer guidance was based on animal data. Minnesota is in the process of promulgating these values into state rule. At a federal level, recently, the EPA MCLGs for PFOA and PFOS are based on draft health risk assessments that include Reference Doses for PFOA and PFOS, and a likely carcinogen descriptor and CSF for PFOA based on human data, and a likely carcinogen descriptor and CSF for PFOS based on animal data.<sup>52</sup> These draft [documents](#) were updated from the previous 2021 versions to reflect input from the agency's SAB, and the draft 2021 toxicity factors for PFOA

<sup>52</sup> [Human Health Toxicity Assessment for Perfluorooctanoic Acid \(PFOA\) and Related Salts](#); EPA 815R24006; U.S. EPA, April 2024, and [Human Health Toxicity Assessment for Perfluorooctane Sulfonic Acid \(PFOS\) and Related Salts](#); EPA 815R24007; U.S. EPA, April 2024.

and PFOS were revised in response to the SAB's comments. Internationally, the [European Food Safety Authority](#) was the first entity to use epidemiological data to derive an “acceptable” dose level in 2018 and 2020.

2. Determine a point of departure (POD), the spot on the dose-response curve from the animal or human study at which toxicologists begin to apply uncertainty factors (UFs) to obtain a dose that should not be associated with adverse effects. PODs can be a No Observed Adverse Effect Level (NOAEL), Lowest Observed Adverse Effect Level (LOAEL), or Benchmark Dose (lower confidence limit; BMDL). BMDL is used as the POD when developing a CSF, and is the preferred POD, when available, for use in developing an RfD for non-cancer effects as it is less dependent on dose selection and sample size.

Toxicologists typically adjust the POD to account for the much slower excretion rate of PFAS in humans than animals (i.e., calculating human equivalent doses [HEDs] that will result in an equivalent internal dose [serum level] at the POD in animal studies). This dosimetric adjustment can be performed using estimated human clearance values, or the ratio of estimated serum half-lives in humans and animals.<sup>53</sup>

3. For non-cancer effects, apply UFs to the HED to determine the RfD, an estimate of the daily oral dose at which humans are expected to be without risk from repeated<sup>54</sup> exposure to a chemical, including PFAS. An RfD is expressed as mass of chemical per day on a body weight basis ( $\text{mg}_{\text{chemical}}/\text{kg}_{\text{body weight}}/\text{day}$ ).

Toxicologists apply UFs of 3 (i.e., the square root of 10, which rounds to 3 if a single such factor is applied; if two such factors are applied, the value equals 10), or 10 to reflect uncertainties associated with the data used. Uncertainties include variability in human sensitivity (intraspecies), extrapolation from animals to humans (interspecies), shorter duration of exposure than the intended timeframe for the RfD in the study used, use of a LOAEL as the POD, and information gaps (i.e., potentially more sensitive effects that have not been studied) in the toxicological database. The UFs are applied selectively for each chemical as appropriate for the toxicity data being used as the basis for the RfD.

Toxicologists multiply the UFs together to obtain the total UF, and then divide the selected (NOAEL, LOAEL, or BMDL) POD (or as adjusted, the HED) by the total UF. A dosimetric adjustment is then performed to determine the RfD (as shown in the equation below).<sup>55</sup>

<sup>53</sup> The dosimetric adjustment is used to determine the human serum PFAS level expected from a given external (oral) dose, and is how toxicologists account for PFAS bioaccumulation in risk assessment. It can be applied to the POD to develop the HED as described, or applied to the ratio of the POD and Total UFs as shown in the RfD equation below. Both methods are mathematically equivalent and the order of operations does not affect the final result.

<sup>54</sup> The length of exposure to which the toxicity factor is intended to apply can vary depending on the chemical and regulatory agency. For example, in its toxicity values for [PFBS](#) and [GenX](#), the EPA characterizes exposure over a lifetime (chronic RfD) or less (subchronic RfD). For the EPA's 2016 LHA for [PFOA and PFOS](#), the RfDs were derived from developmental toxicity studies, where a single exposure at a critical time in development could cause an adverse effect. Thus, EPA recommended that the lifetime LHA be applied to both short-term (e.g., during pregnancy and lactation) and lifetime exposure scenarios. For the EPA's 2022 interim LHA for [PFOA and PFOS](#), the RfDs are based on an effect that occurs from short term exposure in children. The ATSDR uses the term MRL instead of RfD to describe the daily dose of a chemical that is not expected to pose a risk to human health. Its PFAS [MRLs](#) are derived for intermediate (14-364 days) exposure. To establish the Health Based Water Concentrations for PFHxS, PFNA, GenX chemicals, and PFBS, the EPA derived reference doses from an ATSDR Intermediate-Duration Oral MRL (PFHxS and PFNA) and from an EPA 2021 human health toxicity assessment with reference doses based on liver (GenX chemicals) and thyroid effects (PFBS) of mice. Additional details for the calculations and toxicity factors for the six PFAS included in the final NPDWR are available in the supporting final toxicity assessment [documents](#).

<sup>55</sup> As stated in footnote 53, the dosimetric adjustment can alternatively be made on the POD to determine a HED, to which the UFs are applied, yielding the same result for the calculated RfD.



$$\frac{POD}{Total\ UFs} \times dosimetric\ adjustment\ factor = RfD$$

When tumor data are available that can be used to develop a quantitative estimate of cancer risk, the BMDL is used to derive a cancer slope factor (as shown in the equation below).

$$CSF = \frac{benchmark\ response}{BMDL}$$

For example, if the BMDL estimates a lower bound on the dose associated with an increased cancer incidence of five percent, the CSF is 0.05 divided by the BMDL. The CSF can be used to estimate an upper bound on risk for a given level of exposure, or it can be used to derive a health-based guidance level. When a health-based guideline based on cancer risk is developed, a lifetime cancer risk level (e.g., one in one million [ $10^{-6}$ ]; one in 100,000 [ $10^{-5}$ ]) must be selected and used along with the CSF.

4. Combine the RfD or CSF and cancer risk level with selected exposure parameters to establish a concentration (i.e., standard or guidance value) for PFAS in a specific medium (e.g., drinking water) that is intended to be protective of human health. Exposure assumptions vary among states and can result in different guidelines despite similar RfDs.

Some states select exposure parameters for subgroups such as pregnant women or children if they are more sensitive for the toxicological effect of concern. Exposure parameters for health-based guidelines include the exposure rate (e.g., amount of drinking water, fish, or soil assumed to be ingested each day) and representative body weights for the target population. Several states use a model that predicts exposure to the developing fetus and breastfed infant from maternal drinking water exposure. For drinking water guidelines (and groundwater guidelines based on drinking water exposure parameters) based on non-cancer effects, states consider the Relative Source Contribution (RSC), which is the percentage of the RfD allocated or allowed to come from drinking water. For example, the EPA's LHAs (2016, and 2022 interim for PFOA and PFOS and final for GenX and PFBS) and final MCLs allow drinking water to contribute only 20 percent of the RfD and other sources can contribute 80 percent, so the RSC is 20 percent. In the absence of adequate data to determine exposure from non-drinking water sources, default assumptions, typically a lower-bound estimate of 20 percent and an upper-bound estimate of 80 percent, may be used as the RSC. Furthermore, scientists are still learning about PFAS sources and extents/impacts of exposure levels; as such, states' assumptions about the RSC may change in the future and affect PFAS guidelines.

As mentioned above, both PFOA and PFOS are described as likely human carcinogens in the EPA's MCL rule. Toxicity factors and exposure assumptions are not used in setting the EPA MCLGs for known or likely human carcinogens, per the EPA's policy to set the MCLGs for likely human carcinogens at zero (an aspirational goal).

### *State Trends on the Basis of Guidelines*

ECOS examined states' calculations and factors applied to oral routes of exposure to PFAS that contributed to their standard setting processes.

Appendices A-F of this report include tables of state toxicological information and exposure assumptions for setting guidelines in drinking water, groundwater, surface water, soil, air, and fish and wildlife. Some of the trends in the data are summarized below:

**Critical Studies and Endpoints:** This is a critical first step in the process, as it indicates the most sensitive health effect identified for which toxicologists are protecting (e.g., fetal/infant growth delays, thyroid dysfunction, infertility, alterations in liver function, and/or impaired immune function). Ten states indicated that they use the EPA's preferred critical studies (e.g., Lau et al. [2006] for the PFOA LHA and Luebker et al. [2005] for the PFOS LHA) and pharmacokinetic model for developing a toxicity factor (i.e., EPA modeled average animal serum levels at the POD). States also use a variety of critical studies and endpoints based on which PFAS they are evaluating. As discussed in the *Human-to-Animal Extrapolation Methods* section on page 35, state approaches may differ from the EPA methodology in that the POD is based on serum PFAS levels measured at the end of the animal study rather than serum levels predicted using the EPA pharmacokinetic model.

**Points of Departure:** The choice of POD depends on the dose response data for the critical endpoint being used as the basis for risk assessment. As previously mentioned, BMDL is the preferred POD when available as it is less dependent on the dose selection and sample size than the NOAEL or LOAEL. If a BMDL cannot be derived, the NOAEL is preferred. If there is no NOAEL in the study (i.e., effects occur at all doses), the LOAEL is used. Twelve states and the EPA use the LOAEL and NOAEL PODs for PFOA and PFOS in drinking water. Other states indicated that they use a combination of PODs depending on which PFAS they are examining, with LOAEL the most commonly used for PFOA and NOAEL the most commonly used for PFOS. Six states reported using a BMDL for various PFAS in drinking water.

**Uncertainty Factors:** States use a variety of combinations for UFs that differ based on the study used. Some states reported applying a total UF of 300 for PFOA (with a UF of 3 for interspecies; 10 for intraspecies; and other UFs for extrapolation from LOAEL to NOAEL, database limitations, duration of exposure [i.e., subchronic to chronic extrapolation], and/or sensitive developmental endpoints), and a total UF of 30 (with a UF of 3 for interspecies and 10 for intraspecies) for PFOS. Some states have applied higher UFs depending on their interpretations of the relevant scientific data. UFs selected for other PFAS vary.

#### **Exposure Parameters:**

- **Populations at Risk:** States including *Michigan, Minnesota, New Hampshire, Pennsylvania, and Washington* use Minnesota's model (Goeden et al. [2019]) to predict neonatal and infant exposure to PFAS from transplacental transfer, breastmilk transfer, and consumption of formula prepared with contaminated water. This model applies the 95<sup>th</sup> percentile drinking water ingestion rates for pregnant women and formula-fed infants, and the upper-percentile breastmilk intake rate for breast-fed infants. The Minnesota model was updated in 2023 to improve its performance and incorporate new chemical-specific parameters that reflect the most current available research. *Minnesota* has applied the revised model to the development of revised 2024 guidance values for PFOA and PFOS. Other states account for populations that may be at increased risk by considering their higher intake rates, with infants and lactating women consuming more than typical adults when adjusted for body weight. Examples include, but are not limited to, a 0-1 year old body weight-adjusted drinking water intake rate of 0.175 L/kg/day (*Vermont*), a 10 kg body weight adjusted drinking water intake rate of 0.1 L/kg/day (*Wisconsin*), or a lifetime average drinking water intake rate of 0.053 L/kg/day that accounts for increased water consumption relative to body weight at young ages (*California*), as compared to the default adult upper percentile water consumption rate (0.029 L/kg/day) (*New Jersey*). The EPA's LHA assumed the drinking water ingestion rate of the 90th percentile of lactating women to be 0.053 L/kg/day. Several states look at fish consumption rates as well when developing surface water quality criteria and fish consumption advisories; these advisories are more stringent for high-risk populations (e.g., infants, children, pregnant and lactating women, women of childbearing age) in some states (e.g., *Delaware, New Jersey, Pennsylvania*). Overall,

target populations and RSCs differed among states, even if those states used the same critical endpoint or a similar RfD. The different exposure parameters resulted in different final guidelines.<sup>56</sup>

- **Relative Source Contribution:** Fourteen states reported using the default value for the RSC of 20 percent (as the EPA does in its LHAs for PFOA and PFOS) for various PFAS in drinking water, indicating that they allow 20 percent of the RfD to come from drinking water and 80 percent to come from other sources of exposure. *Three states* use a chemical-specific RSC of 50 percent in their drinking water guidelines. Some of these states base their guidelines on the higher exposure to breastfed infants predicted by the Goeden et al. (2019) model; in these states, the RSC of 50 percent is specific to infants. In 2024, *Minnesota* updated its guidance for PFOA and PFOS using an RSC of 20 percent for both chemicals at all life stages because available biomonitoring data and placental transfer data indicated that a broad swath of the population, including infants, is already exposed at levels comparable to the updated reference serum concentrations. *Wisconsin* does not use an RSC for PFAS in surface water, but uses a less conservative RSC of 80 percent for PFAS in other media, meaning 80 percent of the RfD comes from the source (e.g., drinking water) and only 20 percent is allocated to exposure to all other sources like diet or consumer products. *Alaska, Iowa, and Wisconsin* do not use an RSC (i.e., an RSC of 100 percent) in groundwater; at that guideline, exposures from other sources would raise the intake above the RfD. *Washington's* uses the subtraction method and biomonitoring data to define the aggregate exposure from all other PFAS sources, resulting in a variety of RSCs used to inform its drinking water action levels depending on the PFAS and the target population. For example, it uses an RSC of 20 percent for PFBS; an RSC of 50 percent for PFOA, PFNA, and PFHxS; and an RSC of 50 percent for infants and 20 percent for adults exposed to PFOS. Several states reported that the [EPA Decision Tree](#) (2000) is helpful in establishing an RSC.

**Human Epidemiological Data:** Thirteen states (*California, Connecticut, Florida, Hawaii, Illinois, Massachusetts, Michigan, Minnesota, New Hampshire, New Jersey, North Carolina, Washington, Wisconsin*) reported considering both animal and human epidemiological data to support their selections of critical endpoints from animal toxicity studies and guide their risk assessments.<sup>57</sup> *Minnesota* used human epidemiological data to derive its slope factor for PFOA and its non-cancer guidance levels for PFOA and PFOS, publicly released in January 2024. *California* also used human epidemiological data to derive its proposed slope factor for PFOA and its non-cancer guidance levels for PFOA and PFOS.

**Human-to-Animal Extrapolation Methods:** Human toxicity values for PFAS are primarily based on laboratory animal studies and rely on various approaches to account for the much longer half-lives in humans than in animals. Toxicologists consider the interspecies half-life difference in most PFAS risk assessments because the same daily dose of a PFAS results in a higher internal dose (blood serum PFAS level) in humans because of their slower excretion rate. In general, the serum PFAS levels from animal studies are converted to HEDs by applying a chemical-specific clearance factor (based on human half-life and volume of distribution) that relates serum levels to human-administered doses. The interspecies UF is reduced from the default value of 10 to 3 when these approaches are used since interspecies pharmacokinetic differences have already been accounted for.

<sup>56</sup> Some states develop groundwater standards based on the assumption that groundwater is used as drinking water, so the ingestion rates/exposure assumptions used for drinking water standards are applied to the groundwater standards.

<sup>57</sup> As with any risk assessment, human epidemiology is considered, at a minimum, to support using an animal study. In January 2024, *Minnesota* became the first state to finalize health-based drinking water guidance values that relied on human epidemiological data as the quantitative basis of a reference serum concentration for non-cancer values for PFOA and PFOS, as well as the basis of a cancer slope factor. *California* has public draft values that rely on human epidemiological data as the quantitative basis of an RfD derivation, based on effects that are supported by animal studies, for its proposed non-cancer drinking water guidance levels for PFOA and PFOS (see footnote 61). The current draft EPA Reference Doses for PFOA and PFOS are also based on human epidemiological data.

Seven states (*Alaska, Colorado, Connecticut, Maine, Massachusetts, Vermont, Wisconsin*) reported using the EPA approach (used in its derivation of the LHA for PFOA and PFOS), which estimates the HED using modeled serum concentrations at the POD in the animal study as the internal dose metric. A few other states, including *New Jersey, New Hampshire, and California*, use measured serum concentrations at the end of the dosing period in the animal study as the POD. *Washington* reported using ATSDR's modeled serum concentration when it was available for PFOA and PFNA, and measured serum concentrations at the end of the dosing period for when PFOS and PFHxS. For PFBS, it used the administered dose, not the serum level. *Connecticut* reported using a variety of approaches, including EPA's modeled serum concentration for PFOA, ATSDR's time-weighted average serum concentrations for PFNA and PFHxS, the measured serum concentration at the end of the dosing period for PFOS and 6:2 Cl-PFESA, and the administered dose for GenX, PFHxA, PFBA, and PFBS.

**Carcinogenicity:** 18 states (*Alaska, Arkansas, California, Connecticut, Delaware, Florida, Hawaii, Illinois, Indiana*,<sup>58</sup> *Massachusetts, Minnesota, New Hampshire, New Jersey, North Carolina, Pennsylvania*,<sup>59</sup> *Vermont, Washington, Wisconsin*) reported that they consider carcinogenicity as well as non-cancer endpoints in their evaluations. 14 of those states (*Alaska, Arkansas, California, Connecticut, Delaware, Florida, Hawaii, Illinois, Minnesota, New Jersey, North Carolina, Pennsylvania, Vermont, Wisconsin [PFOA only]*) quantify cancer risk with a slope factor and a cancer risk level of 1 in 100,000 ( $1 \times 10^{-5}$ ) or 1 in 1,000,000 ( $1 \times 10^{-6}$ ).<sup>60</sup> *California* uses cancer as the critical endpoint for PFOA (pancreatic and liver cancer in male rats) and PFOS (liver cancer in male rats) for their guidance level, as does *Illinois* for PFOA. *California* uses human kidney cancer data in its current draft guideline for PFOA.<sup>61</sup> *Minnesota* has cancer health-based values for both PFOA (based on human kidney cancer data) and PFOS (based on rat liver cancer data).

## Fish Consumption Advisories & Aquatic Life Criteria

In addition to health-based guidelines for PFAS in water, soil, and air, a number of states have established fish consumption advisories. These advisories may apply to one section of a waterbody or may impact a number of waterbodies statewide; specific values and PFAS are outlined in Appendix F. Many methods for establishing these advisories are similar to those outlined above in this Risk Assessment section. However, in the 2024 iteration of this report, ECOS asked states to share specific details on what their guidance is and/or how they establish fish consumption guidance:

- *Illinois* is a member of the Great Lakes Consortium for Fish Advisories and adopted the meal frequency criteria listed in the Consortium's 2019 [Best Practice for Perfluorooctane Sulfonate \(PFOS\) Guidelines](#) document, with slight modifications to the meal categories. The state's fish consumption [advisories](#) are updated annually.
- *Indiana* has three fish consumption advisories, based on PFOS concentrations, that follow the Great Lakes Consortium for Fish Consumption Advisories' [Best Practice for PFOS Guidelines](#) document (November 2019). *Indiana* routinely analyzes 35 PFAS in fish tissue samples from all basins in the state; however, most fish

<sup>58</sup> *Indiana* considers both endpoints for all compounds but currently, the EPA RSL's endpoints are all non-carcinogenic, so the state has not published any carcinogenic endpoints.

<sup>59</sup> *Pennsylvania* considers cancer-based toxicity values in calculating its medium-specific concentrations for PFOS, but not for PFOA or PFBS. Additionally, toxicologists from Drexel University's PFAS Advisory Group, which made recommendations on the MCL to the state's Department of Environmental Protection, determined that existing evidence did not support a cancer risk endpoint for drinking water.

<sup>60</sup> Cancer risk levels used in risk assessments are policy choices that vary among states and may be specified in a state's legislation or regulation.

<sup>61</sup> *California's* current draft guideline is a Public Health Goal, which serves as the scientific basis for future regulatory standard (MCL) setting. The previous guidance levels for PFOA and PFOS, based on cancer observed in animal studies, were notification level recommendations.

consumption advisories are based on the polychlorinated biphenyls and mercury concentrations. The state has a Do Not Eat advisory from Little Deer Creek and Government Ditch in Cass and Miami counties. These tributaries are thought to get runoff from fire training areas on Grissom Air Force Reserve Base. Indiana sampled them in 2018 and 2019, and most recently in 2023, although those results are not back yet. There are two other one meal-per-month advisories near Hartford City and near Shelbyville, based on PFOS in fish. These sources are not as well understood and could be due to a number of potential sources. The state sampled Treaty Creek in 2023 and based on the site history, that may be a location added to the advisory once data is available.

- Massachusetts' Department of Public Health in 2021 published a technical support document, [Evaluation of PFAS in Recreational Waterbodies in Massachusetts](#), which outlines the surface water and fish tissue action levels, waterbody-specific risk assessment criteria (e.g., exposure estimate, toxicity criteria, risk evaluation), and the fish consumption advisories. The state also updates its PFAS Fish and Surface Water Surveillance [webpage](#) with supporting documents and sampling data for specific waterbodies.
- Michigan published a [Fish Consumption Advisory Program](#) guidance document in 2016 that outlines the types of advisories it implements, methods for calculating the state's fish consumption screening values, and public health considerations for waterbody- and species-specific consumption guidelines.
- Minnesota said its methods for fish consumption guidance overlap with the general categories outlined above.
- New Jersey's Division of Science and Research in 2015 conducted a statewide pilot study of 13 PFAS in fish, sediments, and surface water from 14 state waterbodies. The state developed fish consumption triggers for PFOA, PFOS, and PFNA using the toxicity factors previously used for the drinking water standards for these three PFAS. More recently, New Jersey developed a toxicity factor and fish consumption triggers for PFUnDA, which was frequently detected in fish in the statewide pilot study. Details about the study (including a Phase II follow up study) and the triggers can be found on the state's PFAS [webpage](#) under the subheading Monitoring Study and Consumption Triggers for PFAS in Fish.
- North Carolina's Department of Health and Human Services recommends limits on the consumption of certain freshwater fish from the middle and lower Cape Fear River based on concerns about exposure to PFOS found in fish sampled from the area. In July 2023, the agency published a [press release](#), available in English and Spanish, about the advisory, what fish species it applies to, information about the sampling plan and levels of PFAS found in the fish species, and why the recommended consumption limits may be lower than in other states with site-specific PFAS fish advisories.
- Texas' 2022 [Lower Leon Creek Risk Characterization Addendum](#) summarizes the state's fish collection study from December 2021 and January 2022 and addresses public health implications of consuming fish contaminated with PFAS from the Lower Leon Creek, as well as suggests actions to protect humans from possible adverse health effects. The Addendum includes fish sampling methodology, risk assessment criteria used (e.g., RfDs, RSCs, etc.), and the results of the testing, leading to the state's fish consumption advisories.

The EPA in 2022 published draft aquatic life ambient water quality criteria for [PFOA](#) and [PFOS](#) under the CWA. These criteria reflect scientific knowledge regarding the effects of PFOA and PFOS on freshwater organisms. While not legally binding, states and authorized tribes can adopt the criteria, when finalized, into their water quality standards or can adopt science-based criteria dependent on local and site-specific conditions.

### Section III. Risk Management

Once their toxicologists assess potential health or ecological risks, states take steps to manage those risks and protect public health. This includes analyzing PFAS samples, establishing guidelines, and addressing resource issues. This could also include deciding whether to address PFAS individually or as a group (see the *Grouping PFAS* section

on page 13), deciding not to act based on their conclusions of the assessed risks, or looking at broader impacts of managing PFAS such as issuing discharge permits and availability of treatment removal technologies.

## Analytical Methods & Limitations

States use a variety of methods to test for PFAS in different media. The method most used among states is [EPA Method 537.1](#) (2018/2020, measures 18 PFAS in drinking water), which 33 states (*Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, Washington, Wisconsin*) report using.<sup>62</sup> This method supersedes [EPA Method 537](#) (2009, applies to 14 PFAS in drinking water); it analyzes the same 14 PFAS as EPA Method 537, which was used for UCMR3 analysis, and adds four other additional priority PFAS, including HFPO-DA (GenX). Both methods are designed for drinking water, which is expected to have relatively low total suspended or dissolved solids. Samples are prepared by using a solid phase extraction technique. The EPA's UCMR5 program specifies Method 537.1 for the measurement of four PFAS.

Some labs perform modifications to these methods to analyze for matrices other than drinking water, such as using isotope dilution, using a weak anion exchange (WAX) solid-phase extraction (SPE) cartridge, or not evaporating samples to dryness. These changes allow labs to analyze a greater number of analytes in additional matrices and may also allow for lower reporting limits, increased recovery, or greater accuracy.<sup>63</sup> For example, 21 states (*Alaska, Arizona, California, Connecticut, Delaware*<sup>64</sup>, *Indiana, Maine, Minnesota, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Pennsylvania, South Carolina, Texas, Utah, Vermont, Virginia, Wisconsin*) reported that they allow modifications to EPA Method 537.1 for non-drinking water media. Methods can be applied to analyze one, some, or all applicable PFAS to which the methods apply, depending on which PFAS a state considers. Importantly, while methods published by the EPA and consensus standard organizations (such as ASTM and Standard Methods) describe a standardized, validated approach and include quality assurance/quality control (QA/QC) procedures and criteria, the term “modified method” (e.g., Modified Method 537.1) can reflect different, laboratory-specific techniques. If those techniques are not documented and validated by the laboratory, the quality of the associated analytical results can be unknown.

Other methods and criteria for PFAS analysis include:

- [EPA Method 533](#): *Alaska, Arizona, California, Connecticut, Hawaii, Idaho, Illinois, Iowa, Maine, Michigan, Minnesota, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Oregon, Pennsylvania, South Carolina, Texas, Virginia, and Washington* use or allow labs to use this drinking water method.<sup>65</sup> Published in 2019, this isotope

<sup>62</sup> In the previous publications of this report, two states (*Florida, New Hampshire*) reported using this method, and nine states (*Alaska, Arizona, Connecticut, Indiana, Maine, Massachusetts, New Jersey, New Mexico, New York, Texas*) reported using both this method and EPA Method 537. *Delaware* has been using a state generated list that includes PFAS from EPA Method 537.1 and EPA Method 533 which the state calls 537M DNREC REM (for remediation), but said it intends to make EPA Method 1633 the preferred methodology and minimal list.

<sup>63</sup> However, modifying approved methods, when those methods are codified as prescribed for federal regulatory compliance monitoring, may limit the applicability of using the results for regulatory or compliance purposes.

<sup>64</sup> *Delaware* uses a unique modification to this method, called 537(M) DNREC REM, for 37 PFAS in non-drinking water media.

<sup>65</sup> *Oregon* specifies that it now recommends EPA Method 537.1 for drinking water, per EPA. And *Washington* said EPA Method 533 is the most common (and preferred) drinking water test method used in the state. *Connecticut* uses EPA Method 533 as its preferred drinking water method as it includes all ten PFAS for which it has established a drinking water action level, and *Michigan* now only uses EPA Method 533 for drinking water analysis.

dilution method uses a WAX SPE cartridge to improve recoveries of 25 short-chain<sup>66</sup> and long-chain PFAS. The method targets 25 PFAS, including all 14 PFAS from EPA Method 537 and 11 PFAS unique to this method. Additional isotope labeled stable standards can be added into this method. The EPA's UCMR5 program specifies Method 533 for the measurement of all 25 PFAS within its scope.

- EPA Solid Waste (SW)-846 Methods [3512](#) and [8327](#): *Illinois* uses these methods for surface water, groundwater, and wastewater; *Minnesota* has begun to receive results for stormwater and wastewater samples analyzed for PFAS using these methods; *Virginia* accepts these methods; and *Alaska* allows these methods to be used, although it notes that they are not the methods of choice. This direct injection sample preparation method (3512) and liquid chromatography-tandem mass spectrometry determinative method (8327) for non-drinking water aqueous samples were validated in 2019 for 24 target analytes, 14 of which are also found in EPA Method 537.1. While sensitivity was found in multi-laboratory validation to measure PFOA and PFOS below the EPA's 2016 LHA levels for drinking water, some laboratories may not be able to provide low-level detection (i.e., single ng/L), and the methods were only validated for testing of non-potable waters. The U.S. Department of Defense (DOD) published a memorandum stating that these methods do not meet its needs to support decision-making and advises their use for screening purposes only. The final versions of these methods were published in July 2021.
- [EPA Method 1633](#): The DOD and the EPA partnered to produce this multi-laboratory validated method for analyzing 40 PFAS in wastewater, surface water, groundwater, soil, biosolids, sediment, landfill leachate, and fish tissue. The method can be used in various applications, such as providing a consistent PFAS method tested in a wide variety of wastewaters and containing all required quality control procedures under the CWA for NPDES permits. The EPA released a final version of Method 1633 in January 2024 and subsequently prepared a list of minor [errata](#) as an adjunct to the publication.<sup>67</sup> The EPA expects to propose Method 1633 at 40 CFR Part 136 in the coming months. Some states used the method in draft form, and more states are now accepting this final method, including *Alabama (non-drinking water media)*, *Arizona (non-drinking water media)*, *Alaska*, *California (wastewater, surface water, and groundwater [other included matrices once method is final])*, *Colorado (biosolids, wastewater)*, *Connecticut (non-drinking water media, aquatic tissue analysis)*, *Delaware*, *Hawaii*, *Illinois*, *Iowa*, *Minnesota*, *Montana (fish tissue, surface water monitoring)*, *New Hampshire*, *New Jersey (non-potable water, solid and chemical materials, biological tissue)*, *New York (all non-drinking water media)*, *North Dakota (non-drinking water media)*, *Ohio (wastewater effluent, stream chemistry, macroinvertebrates, whole fish, fish muscle)*, *Oregon (non-drinking water media)*, *South Carolina*, *Utah*, *Virginia*, and *Washington*.<sup>68</sup>
- [EPA Other Test Method \(OTM\)-45](#): *Minnesota* and *New Hampshire* reported using this method, *New Hampshire* specifying that it had used it three times at one of its facilities and that OTM-45 will be the required test method for the state's stack tests in the future. This method was introduced in 2021 to test for 50 specific PFAS at stationary sources, as well as identify other PFAS that may be present in air samples, which will help improve emissions characterizations and inform the need for further testing.

<sup>66</sup> Short-chain PFAS are those with carbon chain lengths of 5 or lower for sulfonic acids like PFBS, and carbon chain lengths of 7 or lower for carboxylic acids like PFHxA.

<sup>67</sup> This method has gone through a number of drafts that were reported on in previous iterations of this report, as follows: The DOD noted that as of December 31, 2021, all new contracts and task orders shall require the use of this method for analyzing PFAS in matrices other than drinking water. In September 2021, the EPA posted the draft method on its website and encouraged review and feedback from laboratories and regulatory authorities. This review resulted in a more refined and current second draft of the method, released in June 2022. Both the DOD and the EPA supported a multi-laboratory validation study of the method, with a third version published in December 2022 that included some multi-laboratory validation data for the wastewater matrix. This followed with a fourth draft in July 2023, incorporating multi-validation data for all aqueous matrices (surface water, groundwater, and wastewater).

<sup>68</sup> In its January 2023 [report](#) on PFAS in biosolids, ECOS referenced which states used or plan to use Draft Method 1633 for analyzing biosolids samples. States not included in this report's list above may be included in the biosolids report as having already been accepting this method in draft form.

- **EPA Other Test Method (OTM)-50:** This is a new method published in 2024 and is intended to measure 30 volatile fluorinated compounds in air emissions from stationary sources. The method focuses on certain volatile fluorinated compounds, including potential products of incomplete thermal destruction. Due to its recent release, it is unknown which states have started using this highly-anticipated method.
- **EPA SW-846 Method 8321B,** High-Performance Liquid Chromatography/Thermospray/Mass Spectrometry or Ultraviolet Detection: *Washington* has allowed a modified use of this method for fish tissue. The EPA noted that it has not validated Method 8321B for use with PFAS, and that Method 8321B also does not include a preparation procedure for fish tissue samples. The agency clarified that *Washington's* state laboratory has adapted a QuECHERS extraction procedure based on an U.S. Food and Drug Administration (FDA) [method](#) and coupled it with extract cleanups to prepare samples for determinative analysis by liquid chromatography-tandem mass spectrometry.
- **EPA SW-846 Method 1312,** Synthetic Precipitation Leaching Procedure (SPLP): *New Hampshire* accepts this leachate preparatory method for soil analysis under its waste programs; *New York* uses it for soil; *Hawaii* and *Vermont* use it for soil and sludge; and *Virginia* accepts this method. The EPA has completed some research and development work to adapt Method 1312 for use with PFAS, but has not yet begun formal validation studies.
- **EPA SW-846 Method 1314,** Liquid-Solid Partitioning as a Function of Liquid-Solid Ratio for Constituents in Solid Materials Using an Up-Flow Percolation Column Procedure: *Hawaii* is developing guidance for modified use of this method (soil column leaching test) for use with testing of soil and sludge. This Method was validated and published in 2019 for use with inorganic chemicals, and the EPA is currently validating it for use with PFAS.
- **EPA Method 1621,** Adsorbable Organic Fluorine (AOF): *Arkansas* said it proposes to use this method, and *Connecticut* is considering utilizing this method as a complement to Method 1633 for future wastewater analysis. *California* offers this method for laboratories to receive accreditation. The EPA developed this method for the determination of AOF in aqueous matrices by combustion ion chromatography. The CWA method can be used as a screening method to measure organofluoride compounds from PFAS and non-PFAS fluorinated compounds such as pesticides and pharmaceuticals. The result is reported as the concentration of fluoride in the sample. Like Method 1633, the EPA expects to propose Method 1621 at 40 CFR Part 136 in the coming months.
- **DEP SOP LC-001-3:** *Florida* is NELAC Institute (TNI)-certified for its own Department of Environmental Protection standard operating procedure (SOP) method for PFAS in surface water, groundwater, wastewater, soil, and other solids. DEP SOP LC-001-3 references a modified EPA method 8321B and incorporates isotope dilution mass spectrometry consistent with EPA Method 1633 to report 36 PFAS analytes.
- **DOD Quality Systems Manual** Version 5.1 or later (i.e., 5.2, 5.3, 5.4): *Alaska, California, Colorado, Hawaii, Maine, New Hampshire, North Carolina, Rhode Island, South Carolina, Virginia, and Washington* use some or all of the versions of this manual for consideration as additional guidance and quality control requirements or at DOD sites. *Washington* recommends, and in some cases requires, in their Quality Assurance Project Plans that labs use a method that is compliant with the DOD Quality Systems Manual PFAS criteria when analyzing samples.
- **Total Oxidizable Precursor (TOP) Assay:** *Connecticut* accepts this assay for groundwater, surface water, AFFF, and fluorine-free foam in addition to other analytical methods; *Hawaii* uses it for soil, sludge, and groundwater<sup>69</sup>; *Maine* uses it for all matrices; *Minnesota* accepts this method; *New Hampshire* accepts it for soil and groundwater under its waste programs; *New York* uses it for soil and groundwater; *Pennsylvania* uses it for surface water; *Rhode Island* accepts this method; *Vermont* uses it for soil and groundwater; and *Washington* has used it for surface water and sediments. Techniques for “aggregate” measurement of PFAS are often used for screening purposes, though uses may vary state-to-state.<sup>70</sup>

<sup>69</sup> See Footnote 71.

<sup>70</sup> The EPA is working on developing a standardized method for the TOP assay, but it is not yet publicly available. Testing laboratories frequently base their TOP assay standard operating procedures on [Houtz and Sedlak](#) (2012) for aqueous samples, and some laboratories might couple it with extraction or direct oxidation for solid matrices.



- SGS Axys Analytical, SOP [MLA 110](#): *New Hampshire* uses this method for fish tissue; *Hawaii* uses it for soil and groundwater; *Maine* uses it for all matrices; *Minnesota* uses it for water/effluent, soil/sediment, biosolids, and tissue; *New York* uses it for biota; *Pennsylvania* uses it for surface water; *Vermont* uses it for sludge; and *Washington* has used it for groundwater, surface water, effluent, sediments, and tissue.
- [ISO 25101:2009](#): *New York* uses this method for drinking water.
- PACE ENV-SOP-MIN4-0178: *Indiana* uses for biological tissues. This proprietary method from Pace Analytical analyzes 36 PFAS by LC/MS/MS (Isotope Dilution), and complies with DOD Quality systems Manual 5.3 B-15.
- [Total PFAS Risk](#):<sup>71</sup> *Hawaii* uses for soil, sludge, and drinking water. As noted in the TOP Assay above, techniques for “aggregate” measurement of PFAS are often used for screening purposes, though uses may vary state-to-state.
- As long as the method is documented and validated, and meets program requirements and project objectives, some states defer to each lab’s preferred methods<sup>72</sup>: seven states (*Maine and Wisconsin [all matrices except drinking water, requires use of isotope dilution where isotopes are commercially available], Minnesota [drinking water], New Hampshire, New Jersey, New York, and Texas [remediation]*).

Several methods were not final when ECOS conducted the survey<sup>73</sup>, so it is unknown if or which states may already use them:

- SW-846 Isotope Dilution Methods: The EPA is developing these methods under RCRA for analyzing PFAS in solid waste under RCRA. The agency’s goal is to publish SW-846 guidance methods for preparation, cleanup, and analysis using the same validation studies on which Method 1633 was based. The method will be similar, but CWA methods are written in a more prescriptive manner than the SW-846 guidance methods. A state noted that isotope dilution is the gold standard for quantitation and is the only method that corrects results for potential matrix effects, and another state mentioned that this is particularly true when structurally identical isotopically labeled analogs of the target analytes are used as internal standards for quantitative analysis. *South Carolina* accepts these methods.
- Some states and the EPA are considering validating supplemental analysis (e.g., Total Organic Fluorine [TOF] and TOP assays) to more completely characterize total PFAS in various media including consumer and industrial products.
- Some states are utilizing non-targeted analysis data for identification of unknown site-related PFAS.
- Other federal agencies beyond the EPA and the DOD have developed methods, which are available on their websites.
  - Centers for Disease Control and Prevention [Laboratory Procedure Manual - Matrix: Serum](#)

<sup>71</sup> *Hawaii* in March 2024 released a draft update to its Environmental Action Levels. This outlines guidance on the method for calculating “[Total PFAS Risk](#)”, which incorporates use of TOP sample processing methods and data for Total Organic Fluorine (TOF) to identify and assess the risk posed by PFAS-related compounds that are either unreported by standard test methods or otherwise lack toxicity factors. TOPs and TOF testing of samples from several sites in *Hawaii* over the past year has identified a potentially significant underestimation of PFAS-related contamination in soil and groundwater and associated risk based on standard laboratory methods alone. Non-targeted analysis of samples indicated that this was due to the presence of unreported “precursor” PFAS compounds in the sample or the lack of toxicity factors and corresponding Action Levels for identified precursor compounds. *Hawaii*’s proposed approach for assessing Total PFAS Risk allows for consideration of these compounds in assessment of risk and design of remedial actions without the need to identify and assess each precursor compound separately. This method only addresses direct exposure to PFAS in soil (solids) and drinking water. Laboratory studies on improved soil leaching methods are currently underway, with updated guidance anticipated in late 2024. Comments on the approach are welcome and can be submitted to the contact noted in the guidance.

<sup>72</sup> State agencies have method performance expectations that they use to approve labs and determine whether or not the lab’s own method is considered suitable by state program standards.

<sup>73</sup> Additional information on EPA PFAS methods is available on their analytical methods development and sampling research [webpage](#).

- U.S. Department of Agriculture [Screening, Determination, and Confirmation of PFAS by UPLC-MS-MS](#) and [Evaluation of Blood and Tissue PFAs Levels in Unintentionally Contaminated Dairy Animals](#)
- FDA [PFAS Methods](#)
- U.S. Geological Survey [PFAS in Source Waters and Treated Public Water Supplies](#) and [Sampling Groundwater for PFAS](#)

Challenges that confound PFAS analysis include:

- There are decreasing detection levels for several PFAS (e.g., the interim LHAs for PFOA and PFOS which are below current detection levels for laboratories), making reporting of health-based limit exceedances and development of standards at health-based levels challenging.
- There are few low-level detection methods that are applicable to most PFAS in complex media, and there is a lack of a TOF method with detection limits in the low nanograms per liter range.
- Sample collection and analytical interference/contamination due to the presence of PFAS in common consumer products, sampling equipment, and lab materials can create challenges concerning quality control procedures in the laboratories.
- Matrix effects can interfere with accurate PFAS quantitation, as natural biological components and coexisting chemicals are often present in environmental samples but not in the solvent standards, leading to a difference in instrument response for equal concentrations in standards and samples.
- There are new challenges associated with many lesser studied PFAS. For example, there is a lack of analytical standards and stable isotope-labeled internal standards, which help optimize method accuracy, for many emerging PFAS. Several PFAS have also been found to be diprotic (meaning the molecule contains two acid functional groups which can cause multiple charged states) or to be early eluting PFAS (meaning the compounds elute too quickly from the high-performance liquid chromatography columns), and therefore many require lower mass spectrometer source temperatures and capillary voltage for ionization for optimum instrument signal and enhanced analytical accuracy. In addition, trifluoroacetic acid (TFA, a common environmental contaminant) interferes in the analysis of early elutes by suppressing the ionization of other coeluting PFAS. Lastly, several PFAS have been found to contain isomer forms (with more isomer forms present with increasing PFAS chain length), complicating analysis.
- There are financial and time constraints for existing lab methods. The *Minnesota* Department of Health reports that the turnaround time for their samples is 45 days and each water sample costs more than \$300. *Maine* said its water and soil samples take about 28 days (depending on the backlog) and cost about \$200 and \$275 per water and soil sample, respectively. *North Carolina* reports that samples it sends to a laboratory with a two-week turnaround time costs more than \$300, and *Wisconsin* has observed costs between \$275 and \$500 for most matrices and a two-week turnaround. *Texas* has a fixed price contract in place for drinking water samples. EPA Method 533 has a unit price under the contract of \$290 per sample; EPA Method 537.1 has a unit price under the contract of \$245 per sample. Sample collection costs \$420 per sample. *New York* reports that pricing for Draft Method 1633 analysis can double the cost of modified EPA Method 537.1.
- There are different and sometimes inconsistent laboratory procedures for non-EPA approved methods. Not every state has a state lab, and some labs are government contracted or private. Each could result in different costs, time constraints, and sampling procedures. State agencies verify labs for use based on their own criteria.
- There are concerns about sample consistency among states and federal agencies. The *Hawaii* Department of Health requires the collection and testing of at least 10 grams of “[Multi Increment](#)” samples for testing for PFAS in soil, sediment, and at least five grams for biosolids, in accordance with the state’s [Technical Guidance Manual](#). While this can increase the cost for analyzing samples, the state says the practice provides more reliable and representative data than the default guidance in the EPA’s laboratory method protocol, which require 0.5 grams of soil or other particulate matter from a discrete sample for testing. Hawaii noted that

advancements in science and data collection since the EPA established their methods warrant a review of standard procedure across all laboratories.

ECOS recommends conferring with other states and using resources like the ITRC's [Sampling and Analytical Methods fact sheet](#), or the Association of State Drinking Water Administrators' (ASDWA) [PFAS Laboratory Testing Primer](#) for guidance on selecting an analytical method, finding a qualified laboratory, specifying PFAS analytes and reporting limits, understanding sample collection procedures, and interpreting testing results and variability.

## *Establishing Guidelines*

States consider the health-based criteria from risk assessment and other technical factors in the establishment of their guidelines. Some states' risk assessment approaches and conclusions have resulted in the development and adoption of PFAS guidelines that are lower than guidelines for most other contaminants. Scientific considerations that may contribute to these values include:

- PFAS cause toxicological effects at very low doses, and doses linked with effects in humans are generally much lower than doses causing toxicity in lab animal studies.
- Risk assessments account for the higher bioaccumulation of certain PFAS in humans than in animals. The same dose given to a human will result in a much higher blood serum level than in a lab animal.
- Low levels of certain PFAS in blood serum are associated with human health effects, and some states will consider how much a certain level in drinking water will increase blood serum PFAS levels. Even low levels of PFAS in drinking water can cause considerable increases in blood serum PFAS levels.
- As mentioned in footnote 16, the health basis for standards for other contaminants of emerging concern may be as low as those for PFAS, but the final guideline is set at the analytical quantitation levels, which may be up to several orders of magnitude higher than the health-based levels. For PFAS, analytical quantitation levels are very low, such that the final standard or guidance can be set at the health-based criterion.

Additionally, some states are required to perform a cost-benefit analysis in setting their final standards.

## *PFAS Resource (Cost) Issues*

20 states (*Alaska, Arkansas, California, Delaware, Illinois, Indiana, Iowa, Maine, Massachusetts, Michigan, New Jersey, New Mexico, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Virginia, Washington, Wisconsin*) have conducted, are required by a state or federal law to conduct, or plan to consider costs or conduct cost-benefit analyses to define the economic impact of establishing guidelines for certain PFAS. Some states (e.g., *Idaho, New Mexico, North Carolina, Pennsylvania, Wisconsin*) require a cost-benefit analysis as part of their administrative procedures for developing MCLs, water quality criteria, or groundwater pollutant or other such standards, or are required to release compliance costs through rulemaking (*New York*). In June 2023, *Washington* [published](#) a cost-benefit analysis as part of a rulemaking to restrict PFAS in some consumer products and require reporting in others. As part of a provision in the state's 2023 budget, *Washington* is also in the process of developing a PFAS statewide funding strategy, building on the state's PFAS Chemical Action Plan recommendations to identify cost estimates for the 2025-2027 and 2027-2029 biennia. Other states (e.g., *New Jersey*) are not required to conduct a cost-benefit analysis prior to adopting guidelines into state regulation but factor costs into decision-making. One state noted that the operations and management costs for treatment (e.g., Granular Activated Carbon [GAC]) are detrimental to its and others' budgets,

especially for small public water systems that perform carbon changeouts regularly to ensure no arsenic MCL exceedances or other background factors when undergoing PFAS treatment procedures.<sup>74</sup>

14 states (*Arkansas, California, Connecticut, Iowa, Maine, Michigan, Minnesota, New Jersey, New Mexico, North Dakota, Pennsylvania, South Carolina, Texas, Wisconsin*) have conducted cost estimates for some PFAS efforts. Some actions may fall under a state's normal agency programmatic activity; others require more staff and time. For example:

- *Arkansas* has estimated the cost to assess the status of PFAS in its surface waters at approximately \$1.5 million over about five years, excluding costs associated with personnel and with costs incurred during the first year exceeding \$550,000. The state said additional costs would be incurred during the standards development and rulemaking process, and that it is required to conduct an economic impact analysis to the regulated community before initiating rulemaking to establish PFAS standards.
- *California* has FTEs dedicated to enforcement of the regulation but does not consider FTEs for rule development in its cost estimates.
- In 2020, *Connecticut* estimated it needed \$5 million to implement a 5-year statewide monitoring plan to study surface water and fish tissue (not including staff time); \$75,000 to evaluate influent and effluent PFAS values at approximately 30 publicly owned treatment works for 1 year; and \$90,000 to support the development of a geographic information system for risk assessment of groundwater, surface water, and drinking water.
- *Iowa* estimates contract costs for two rounds of PFAS sampling from 2021 to 2023 to total \$350,000; staffing costs for 0.5 FTEs for PFAS sampling and 2 FTEs for combined leadership and staff time related to PFAS issues in the state to total \$350,000; and annual travel costs to total \$25,000 per year. Iowa will now start a new sampling contract for \$180,000 with the State Hygienic Laboratory to complete sampling for 125 water supplies over the next three years.
- The *Maine* Department of Environmental Protection (Maine DEP) has expended over \$14 million from July 1, 2018 through November 30, 2023 on personnel and expenses related to PFAS (over \$5 million in personnel and over \$9 million in expenditures). Spending exponentially increased once the Maine legislature added 11 full-time employees (FTEs) and 6 limited period positions, as well as \$20 million to fund soil and groundwater sampling and install/maintain drinking water filtration systems for private drinking groundwater wells impacted by PFAS from the land application of residuals.<sup>75</sup> The Maine Department of Agriculture, Conservation, and Forestry (DACF) spent \$3.3 million in FY 2023 on PFAS-related activities. The PFAS Response Program has seven full-time positions and two part-time consultants to support agricultural producers impacted by PFAS contamination through technical and financial assistance. The PFAS Response Program provided over \$1.5 million in direct support to affected producers. Also in FY 2023, the Director of the Fund to Address PFAS Contamination led the strategic planning process to determine how to spend the Fund's \$60 million. The funds will begin to be dispersed in FY 2024 to augment existing financial supports to producers, fund research, purchase contaminated land from willing sellers, and support health-related initiatives. The DACF also received a \$5M grant from the U.S. Department of Agriculture to augment its existing assistance programs further and amplify research activities. As part of the grant, the DACF will share

<sup>74</sup> Small public water systems usually contain contaminants other than PFAS, including arsenic, manganese, nitrate, or bacteria that present health risks and are naturally occurring or originate from nearby land uses. Effectiveness of PFAS treatment will depend on how often filters are replaced and what levels of these other contaminants are present in the system. See more [here](#).

<sup>75</sup> Maine also obtained an additional \$5 million through the American Recovery Program to be used by the Maine DEP for providing clean drinking water to residents with PFAS impacted private drinking wells, as well as to the Maine Department of Agriculture, Conservation and Forestry (DACF), for two FTEs and \$10 million to coordinate with Maine DEP on investigation of PFAS in active agricultural operations. A breakdown of spent and projected costs on Maine DEP's soil and groundwater investigation is available in the Status of Maine's PFAS Soil and Groundwater Investigation at Sludge and Septage Land Application Sites report, [published](#) on January 13, 2023. Maine is also utilizing support for litigation through its Attorney General's Office.

best management practices and other data and learnings with farmers and state departments of agriculture nationally. The Maine Center for Disease Control and Prevention added 2 new positions for both its environmental health and toxicology program and its drinking water program to assist with the implementation of public health aspects of contamination, and the Maine Department of Inland Fisheries and Wildlife added 1 seasonal contract position and obtained \$1 million from the Maine legislature in support of better understanding impacts of PFAS to fish and wildlife.

- In 2021, *Michigan* allocated \$23.4 million and 131,296 staff hours to implement [PFAS activities](#).
- *Minnesota* conducted a [study](#) on potential statewide PFAS treatment and destruction costs for municipal wastewater, biosolids, landfill leachate, and compost contact water, using currently available technologies. The study concluded that over 20 years, it would take an estimated \$14-28 billion to remove and destroy PFAS from wastewater. Additionally, PFAS can be bought for \$50-1,000 per pound, but costs between \$2.7-18 million per pound to remove and destroy from municipal wastewater, depending on facility size. The report notes that new “short-chain” types of PFAS are more difficult and up to 70% more expensive to remove and destroy compared to old “long-chain” PFAS, and the state therefore concludes that these unaffordable costs reinforce the need to prioritize pollution prevention. As far as implementing the EPA’s draft drinking water MCLs, including investigation, treatment, and cleanup, the state said costs have exceeded \$1 billion.
- *New Jersey* utilized five FTEs for PFAS standard-setting efforts. New Jersey is also utilizing support for litigation through its Attorney General’s Office.
- *New Mexico* estimated 2020-2023 drinking water sampling efforts to total \$1.65 million, and the state legislature has authorized \$4 million for communities in two counties to plan, design, and construct improvements to water systems with PFAS contamination. A third water system has requested \$3.05 million for PFAS treatment.
- *North Dakota* estimates that from 2018 to present, its Department of Environmental Quality has spent \$427,000 on PFAS investigation efforts, including sampling and staff time (e.g., for webinars, meetings, sample collection, shipping, travel, etc.).
- *Pennsylvania’s* MCL rulemaking required a cost-benefit analysis. The state provided an in-depth cost-estimate chart of costs to the regulated community (i.e., public water systems) for the first four years, including total estimated annual treatment costs, as well as comparisons of costs and benefits for compliance monitoring, treatment, performance monitoring, and other costs associated with state health advisories, MCLs, and MCLGs for PFOA and PFOS. Pennsylvania said its Department of Environmental Protection’s Bureau of Safe Drinking Water has also incurred considerable costs to move forward with the MCL rulemaking, including toxicology contracts of \$180,367 for year one and \$250,000 for year two; sampling plan lab costs of \$361,151; sampling plan travel costs to collect samples of \$12,000, and personnel costs of about \$1,150,000, totaling about \$1,953,518 for MCL development.
- In 2022, the *South Carolina* legislature appropriated \$10 million to mitigate drinking water that has been impacted by PFAS. The state’s Department of Health and Environmental Control will also use carry-forward dollars from the previous year for additional personnel costs to support the Bureau of Water’s strategies due to the amount of time spent on additional projects. The state reported that the cost of investigation and ongoing monitoring to document PFAS fate and transport is expected to be significant.
- *Texas* expects about \$3 million in collection costs and \$7 million in sample analysis costs during the first 12-month monitoring period. The plan review process (including pilot study review, plans, and specifications) will require 188 staff hours to complete.
- Per state rulemaking requirements, the *Wisconsin* Department of Natural Resources has conducted more analysis for its [NR 140](#) Groundwater Pollutant Standards. The state also conducted a final economic impact analysis for its rulemaking process for setting PFAS standards for PFOA and PFOS in drinking water, estimating that costs associated with the rule will exceed \$10 million in a two-year period.

A couple of states noted that PFAS have required a somewhat swift and significant rebalancing of staff member projects; for example, a state may have difficulty hiring new employees to fill the previous positions of those now assigned to work on PFAS, or a state's other projects may fall by the wayside due to the demand of this issue.

Incurred costs extend beyond those for regulating PFAS and should factor in expenditures for: initial investigations to determine whether and to what degree there are PFAS releases or contaminated media; removal methods for contaminated media; disposal or long-term storage of AFFF; lab certification process development and equipment acquisition; chemical analysis; method-specific staff training; liabilities and legal fees; risk communication; water utilities (which may be passed on to consumers); and tracking the fate and transport of PFAS once they are released from an active source to the environment, requiring (re)sampling and treatment. For example, *Florida* has appropriated funding to assess and remediate PFAS at state-owned fire training facilities, as well as to assist homeowners with private wells that have PFAS-related contamination. Also, the *Maine* legislature set aside \$3.2 million in its 2022 supplemental budget to help fund the startup of laboratories to analyze for PFAS.<sup>76</sup> Many states, with and without PFAS guidelines, have, are currently, or are planning to sample all public water systems, requiring a large amount of resources, not including the money required to remediate contamination when it is discovered. *New Jersey* estimates that the average cost for lab analysis is \$300 per PFAS sample at each point of entry, and that this cost is expected to decrease as additional laboratories are certified for PFAS analysis and as market competition increases. The state also estimates that the cost of installing PFAS-specific GAC treatment for a PWS treating one million gallons per day (serving about 10,000 people) ranges from \$500,000 to \$1,000,000, with estimated operating costs of approximately \$80,000 per year. *New Jersey* notes that operating costs could increase depending on the number of wells requiring treatment and the level of contamination. While it has not yet calculated estimated costs expended on PFAS, *Ohio* said a holistic cost estimate should consider the lifecycle of PFAS (e.g., for drinking water, this would include not just the cost to remove PFAS but also the cost associated with managing waste streams and long-term management of treatment systems).

States identified several cost implications of regulating PFAS:

- Resource availability is driven by dedicated government appropriations. For most states, resources to investigate and address PFAS come from existing program budgets (i.e., no new funds). Agencies in some states like *Colorado* and *Michigan* have received funding from bills signed by their Governors, and *Connecticut* regulators received \$2 million in bond funding to support the development and implementation of an AFFF take-back program, limited private well sampling, and treatment where needed. The *New Mexico* legislature appropriated a total of \$330,000 for private well sampling in 2021 and 2023. *California's* 2022 state budget allocated \$15 million to monitor public water systems with wells that serve disadvantaged and severely disadvantaged communities, and to develop a broad spectrum test method and treatment-based regulatory approach. *Wisconsin* allocated \$1 million in their 2021-2023 biennial budget for a firefighting foam collection and disposal program. But these exemplify state-specific resources based on legislative priorities. Other states have received funding from settlements with PFAS manufacturers to use on regulation and/or restoration of contaminated sites, or rely on grant funding options to support PFAS regulations.
- Resource disparity exists. States with the fewest resources to address PFAS may be more significantly impacted by PFAS than others. Similarly, they may only have resources to address PFAS-related risks that are most studied in existing science and most salient among the public, rather than addressing risks unique to that state. The complexities of PFAS scientific information also create a barrier to understanding risk in a public forum. Given PFAS ubiquity, the ability for precursors (e.g., fluorotelomers) to transform to perfluoroalkyl acids and complicate site models, and complex transport mechanisms, especially at the air-water interface, states will

<sup>76</sup> Two facilities have been awarded grants through this program, and it is anticipated that the laboratories will need some time before they will be fully operational.

need to use more resources to test process-based conceptual site models and fully understand the size and source of PFAS plumes.

- Data gaps prevent confident decision-making on how resources are used to address PFAS. States want to develop regulations based on a sound understanding of the problem in their state and to be able to communicate that understanding to their constituents. However, various factors – the lack of information on the sources and fates of PFAS, how they can be removed from drinking water and aquifers, and resulting waste management issues – create barriers to state time and financial investment. One state noted that it is nearly impossible to calculate the total cost of regulating PFAS without knowing the regulatory requirements for all media, including PFAS waste.

In November 2021, President Biden signed into law the Infrastructure Investment and Jobs Act, also known as the Bipartisan Infrastructure Law (BIL). The law provides \$550 billion over fiscal years 2022 to 2026 in new federal investment in infrastructure, including \$5 billion to help communities address emerging contaminants like PFAS in drinking water. In early 2023, the EPA announced the availability of the first \$2 billion of the funding, which will be allocated to states and territories through the agency's Emerging Contaminants in Small or Disadvantaged Communities Grant Program, to prioritize infrastructure and source water treatment for pollutants and to conduct water quality testing. In April 2024, when the EPA announced the final NPDWR for six PFAS, it announced that it was also making available additional funding under this grant program, including funding for private well owners that are not subject to enforcing limits for the PFAS included in the MCLs. A number of states and territories have already been allotted some of the BIL funding; for example, in Delaware, funding is being directed to water systems statewide through an application process to address PWSs with detections above the EPA's proposed (at the time) MCLs, and New Mexico expects the BIL funding to enable certain PWSs to treat for PFAS below the MCLs, likely applying in particular to small and disadvantaged water systems. States hope to receive more to continue to work on these challenging issues.

A few states identified the need for water quality-based effluent limits (see the *Other Regulatory Developments* section on page 26), as well as the need for a cost conversation through national MCL or National Recommended Water Quality Criteria (NRWQC) processes, as many states do not have the resources to regulate PFAS on their own. These are SDWA and CWA processes driven by the EPA and involving states as co-regulators, and are one example of how the EPA is assessing potential changes to its regulatory processes to better respond to contaminants of emerging concern and be more inclusive of state priorities.<sup>77</sup> Additionally, a couple of states mentioned needing final federal 304(a) criteria or better cost information to implement surface water quality standards.

## Conclusion

ECOS asked states to list considerations and unanswered questions that will affect their PFAS guidelines in the future. States noted that the biggest questions for state PFAS regulations will be:

- How can regulators apply or develop guidelines to PFAS in less-explored media (e.g., food and agriculture, fish tissue, biosolids, landfills, foam, and air emissions), if at all?
- How can labs detect lower concentrations of PFAS for media other than drinking water?
- What new information on effects in exposed humans including sensitive human subpopulations, bioaccumulation in fish and shellfish, etc. will affect PFAS regulation?
- How will shifting use and chemistries of PFAS that have yet to be addressed complicate the responses? How many PFAS exist but are unknown to regulators due to confidentiality from manufacturers, etc.?

<sup>77</sup> For more information on states' recommendations for contaminants of emerging concern, see the Association of Clean Water Administrators (ACWA) and ASDWA joint [Recommendations Report for Contaminants of Emerging Concern](#).

- How will developing information about PFAS migration from soil into animal feed, food crops, etc. affect the need for guidance values and state actions in response?
- What are the challenges of managing PFAS in various media, specifically regarding transference of PFAS from one media to another (e.g., groundwater contamination and landfill leachate from accepting solid waste, consumer goods containing PFAS) and the capacity to manage byproducts from water and wastewater treatment that impact multiple environmental media?
- How will regulatory approaches for soil (for protection of groundwater) change based on the results of ongoing research into better understanding PFAS sorption and leaching?
- What analytical approaches and health effects data will be available to develop guidelines for replacement PFAS?
- What will happen to current and pending state guidelines when federally enforceable standards (MCLs, NRWQCs) are enacted?
- How will detections of UCMR 5 detections of PFAS, many of which have little or no toxicity data, impact future PFAS regulations, drinking water guidelines, and/or the establishment of PFAS toxicity factors?
- What kinds of new science are needed to more effectively regulate PFAS individually or as mixtures? How will more occurrence data help to better understand PFAS in various media including wastewater and biosolids, private drinking water supplies, soils, air, fish tissue, and surface water?
- How will guidelines affect PFAS management/cleanup liability, disposal, and other considerations? For example, what will be the impact of designating PFAS as hazardous substances or regulating discharges through the NPDES and remediation programs? Who will pay for mitigation or remediation? What role does pollution prevention play in prohibiting PFAS in consumer goods from passing through regulated facilities and entering the environment?
- How can PFAS be effectively remediated and/or disposed of, especially once designated as a hazardous substance or waste? How will data on PFAS disposal through landfills, wastewater treatment, composting, plant uptake, etc. be utilized for proper management?
- How do we decontaminate AFFF-contaminated units (e.g., fixed system fire suppression units, apparatus, aircraft rescue and firefighting, etc.) and how do we reliably demonstrate success of decontamination? Is complete decontamination feasible? If not, what is an acceptable level of contamination?
- How can we effectively prioritize and harmonize policies that focus on managing upstream processes to prevent downstream contamination (e.g., mandates that will minimize or eliminate the presence of PFAS/PFOS in compost, biosolids, and consumer products)?
- How does the presence of PFAS/PFOS in packaging and organic products impact the faith of consumers and policy makers to move forward with a circular economic model?
- How do we ensure that new chemicals developed to replace PFAS do not end up having similar or greater impacts on public health and the environment?
- How will funding from the Bipartisan Infrastructure Law continue to be allocated to states to monitor, remediate, and regulate PFAS contamination? And what other funding mechanisms can be made available for states to initiate pilot or other projects for PFAS treatment, concentration, and destruction technologies, among other activities?
- How can state and federal agencies better coordinate effective risk communication messaging?
- What considerations should be made for the compliance costs of drinking water providers that will be passed to their customers, especially those in disadvantaged communities?
- What is the impact of PFAS discharges from multiple onsite wastewater treatment systems (septic fields) on local groundwater quality and what is the role of states in addressing such non-point source contamination, which ends up contaminating nearby private drinking water wells?
- How can regulators utilize the lessons learned from dealing with PFAS to assist with or prevent additional emerging contaminant issues?



PFAS pose complex challenges that are new (e.g., drinking water contamination is not a major issue for other persistent, bioaccumulative, and toxic chemicals) and especially daunting. Their unique characteristics include mobility; persistence in the environment and the human body; toxicity to animals and human health effects at low doses; a lack of toxicological data for most PFAS detected in the environment and used in commerce; ubiquitous detection in human blood; and technical obstacles for remediation. These challenges are compounded by regulatory and policy developments that vary by state and are uncertain at the federal level. There is also heightened public pressure for swift risk management, encouraged through social media and news reports. For example, there have been large settlements of high-profile lawsuits (e.g., AFFF multi-district litigation from 3M (\$12.5 billion) and DuPont, Chemours, and Corteva (\$1.185 billion) in 2023, \$110 million from E.I. DuPont De Nemours and Co., et al to Ohio in 2023, \$850 million from 3M to Minnesota in 2018, \$671 million from DuPont to plaintiffs in West Virginia and Ohio in 2017).<sup>78</sup> Advocacy groups have convened community events and produced films inspired by PFAS contamination in cities like Parchment, Michigan; Decatur, Alabama; and Parkersburg, West Virginia. And public data from the UCMR3 reported that PFAS were detected in water supplies serving 16.5 million people in the U.S. and that more than six million people consumed water with PFAS concentrations above the EPA's 2016 LHA of 70 ppt for the total of PFOA and PFOS in 2015.<sup>79</sup> These numbers are expected rise as PWSs monitor for 29 PFAS - including the six included in UCMR3, with lower Reporting Levels - under UCMR5 in 2023-2025.<sup>80</sup> Results are available on the EPA's [UCMR5 Data Finder](#), which will be updated on a quarterly basis until completion of data reporting in 2026.

A few states followed the emerging scientific information on, evaluated occurrence of, and developed guidelines for PFAS for many years before they were widely known to the public. Some states are actively responding to the recent events mentioned above by establishing programs and guidelines to regulate PFAS-contaminated sites. Other states are aware of PFAS as a contaminant of emerging concern and addressing it as they can. Given these variations in state action and public knowledge of the issue, and especially if federal drinking water standards for PFAS are established, risk communication is going to be an increasingly important function. Additionally, regulators need more transparency about the uses of existing PFAS, the ongoing development of new PFAS by industry, and PFAS approval by the EPA under statutes like TSCA. As states seek to independently regulate PFAS, it is critical to coordinate with and learn from other states that have established and are establishing their own guidelines.

This compilation of state-developed PFAS guidelines is a moving target, as regulators are acting quickly to develop and/or update guidelines for PFAS in various environmental media. Some states are waiting to set guidelines until the EPA establishes a federally enforceable MCL. Other states have established guidance at levels below the EPA's 2016 LHA and/or for PFAS other than PFOA and PFOS, indicating that some regulators and toxicologists view the existing federal approach<sup>81</sup> as insufficiently protective. As stated earlier, however, the EPA's current draft toxicity assessments for PFOA and PFOS are much more stringent than almost all state assessments for these two PFAS. As not all states completed the survey (including some states known to have developed guidelines) and there will likely

---

<sup>78</sup> There have also been a number of state lawsuits that are pending; for example, in 2023, the *Delaware* Attorney General filed a lawsuit to hold numerous companies accountable for PFAS contamination resulting from use and disposal of AFFF. The lawsuit resulted from a detailed investigation conducted over a two-year period, including environmental sampling, forensic analysis, and review of corporate records. Delaware is seeking monetary damages, including natural resource damages and costs to test, monitor, assess, and respond to contamination. Also in 2023, the Washington state Attorney General filed a lawsuit against 20 manufacturers of PFAS, specifically relating to the use of AFFF around airports and military sites.

<sup>79</sup> Hu et al., 2016. "Detection of Poly- and Perfluoroalkyl Substances (PFASs) in U.S. Drinking Water Linked to Industrial Sites, Military Fire Training Areas, and Wastewater Treatment Plants." *Environmental Science & Technology Letters*, vol. 3, no. 10, 2016, pp. 344-350. ACS Publications, <https://doi.org/10.1021/acs.estlett.6b00260>.

<sup>80</sup> UCMR5 is providing data on the occurrence of 29 PFAS (plus Lithium) in finished drinking water from all U.S. PWSs serving at least 3,300 people (and some smaller systems). Many of the PFAS included in UCMR5 do not have toxicity factors or drinking water guidelines, and there is little or no toxicity data for some of them.

<sup>81</sup> I.e., its process as a whole, or in its choice of critical studies or factors for calculation.

continue to be state standard setting at concentrations below the EPA’s 2016 LHA and for PFAS other than PFOA and PFOS, ECOS hopes to compile additional information in the future.

This white paper is not intended to be a comprehensive compendium of state PFAS regulations. Rather, it aims to lay the foundation for states to dig deeper into the issue. ECOS hopes this paper will serve as a basis for future conversations, and encourages state-to-state, state-federal, and state-NGO partnerships and collaboration. In June 2020, the ASDWA published a [toolkit](#) of modules on assessing state resources, characterizing health impacts, identifying treatment, analyzing costs and benefits, and other considerations surrounding PFAS in source water. ECOS is also compiling a spreadsheet of PFAS that states monitor for, including those for which the state does not have guidelines. The spreadsheet will be available on ECOS’ [PFAS webpage](#) and will be updated as often as states submit new data. ECOS encourages states to use this white paper in combination with its additional PFAS resources, the ASDWA’s numerous reports, the ITRC [fact sheets](#) and [Technical/Regulatory Guidance document](#), and other relevant documents to fully understand the current status on PFAS regulation.

## State Agency Reports on PFAS Guidelines

These reports/resources were provided by state environmental and health agencies that responded to the ECOS survey. For a full list of individual state PFAS websites with information on how they developed their guidelines and on other PFAS efforts, see ECOS’ [PFAS webpage](#) or the “Overview” section of ECOS’ [PFAS Risk Communication Hub](#).

- [Arizona](#)
- [Alaska](#)
- [California](#)<sup>82</sup>
- [Colorado](#)
- [Connecticut](#)
- [Delaware](#)
- [Florida](#)
- [Hawaii](#)
- [Illinois](#)
- [Indiana](#)
- [Iowa](#)
- [Maine](#)
- [Maryland](#)
- [Massachusetts](#)
- [Michigan](#)
- [Minnesota](#)
- [Montana](#)
- [New Hampshire](#)
- [New Jersey](#)
- [New York](#)
- [North Carolina](#)
- [North Dakota](#)
- [Ohio](#)
- [Oregon](#)
- [Pennsylvania](#)
- [South Carolina](#)
- [Texas](#)
- [Utah](#)
- [Vermont](#)
- [Virginia](#)
- [Washington](#)
- [Wisconsin](#)

<sup>82</sup> California’s resources are listed as individual reports and documents which, in addition to the report linked above, include that on [PFBS notification level guidance](#), [PFHxS notification level guidance](#), [PFOA and PFOS proposed guidance based on human data](#), [PFOS and precursor cancer hazard identification](#), [PFOA hazard identification](#), and [PFNA male reproductive toxicity](#).

## Appendix A: State Drinking Water PFAS Guideline Criteria

| State | PFAS  | Guideline Level (ug/L)   | Toxicity Data                     | Critical Effect Study                       | Endpoint  | RSC (%) | POD                                | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions               | Target Populations                              | Resources |   |
|-------|-------|--|-----------------------------------|---|---|---------|------------------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|------------------------------------|---|-----------|---|
|       |       |  |                                   |   |   |         |                                    |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                                    |   |           | Sensitive Developmental Endpoints   |
| CA    | PFOA  | 0.0051 (based on health-based reference level of 0.1 ppt for cancer effects, 2 ppt for non-cancer effects [liver])         | Animals (mice/liver, rats/cancer) | Li et al., 2017; NTP, 2018                  | Hepatotoxicity in female mice; Cancer (pancreatic and liver) in male rats               | 20      | LOAEL (0.97 mg/L)                  |                 | 300   | 3            | 10           | 3              |                     |  |                 | 3   | Lifetime average of 0.053 L/kg/day | Oral ingestion as significant route of exposure |           | <a href="https://www.waterboards.ca.gov/pfas/">https://www.waterboards.ca.gov/pfas/</a><br><a href="https://oehha.ca.gov/water/notification-level/notification-level-recommendations-perfluorooctanoic-acid-pfoa">https://oehha.ca.gov/water/notification-level/notification-level-recommendations-perfluorooctanoic-acid-pfoa</a><br><a href="https://www.waterboards.ca.gov/drinking_water/certific/drinkingwater/PFOA_PFOs.html">https://www.waterboards.ca.gov/drinking_water/certific/drinkingwater/PFOA_PFOs.html</a> |
|       | PFOS  | 0.0065 (based on health-based reference level of 0.4 ppt for cancer effects, 7 ppt for non-cancer effects [immune system]) | Animals (mice/liver, rats/cancer) | Dong et al., 2009<br>Butenhoff et al., 2012 | Immunotoxicity in male mice; Cancer (liver, structural similarity to PFOA) in male rats | 20      | NOAEL (0.674 mg/L)                 |                 | 30    | 3            | 10           |                |                     |  |                 |   | Lifetime average of 0.053 L/kg/day |   |           | <a href="https://oehha.ca.gov/water/notification-level/notification-level-recommendations-perfluorooctanoic-acid-pfoa">https://oehha.ca.gov/water/notification-level/notification-level-recommendations-perfluorooctanoic-acid-pfoa</a>   |
|       | PFHxS | 0.003 (based on recommended health-protective concentration of 0.002 for thyroid effects)                                  | Animals (rats)                    | NTP, 2019                                   | Decreased total thyroxine (T4)  | 20      | BMDL <sub>15D</sub> (28.6 mg/L)    | 0.00243         | 1,000 | √10          |              | 10             | √10                 |  | 10              | 0.0000024   | 0.237 L/kg-day                     | 0-6 month infant drinking water intake rate     |           | <a href="https://oehha.ca.gov/media/pfhxsn031722.pdf">https://oehha.ca.gov/media/pfhxsn031722.pdf</a>   |
|       | PFBS  | 0.5  | Animals (mice)                    | Feng et al., 2017                           | Reduction of thyroid hormone, pregnant mice   | 20      | BMDL <sub>15D</sub> (22 mg/kg-day) | 0.06            | 100   |              | 3            | 10             |                     | 3  |                 | 0.0006  | 0.237 L/kg-day                     | 0-6 month infant drinking water intake rate     |           | <a href="https://oehha.ca.gov/media/downloads/water/chemicals/nl/pfbsnl011321.pdf">https://oehha.ca.gov/media/downloads/water/chemicals/nl/pfbsnl011321.pdf</a>   |
|       | PFOA  | (Proposed Public Health Goal) 0.007 × 10 <sup>-3</sup> (based on human kidney cancer)                                      | Humans (kidney cancer)            | Shearer et al., 2021; Vieira et al., 2013   | Cancer (kidney) in humans   |         | CSF (0.0026 per ng/kg-day)         |                 |       |              |              |                |                     |  |                 |   | Lifetime average of 0.053 L/kg-day | Oral ingestion as significant route of exposure |           | <a href="https://oehha.ca.gov/sites/default/files/media/downloads/cmr/pfoapfosphgdraft061021.pdf">https://oehha.ca.gov/sites/default/files/media/downloads/cmr/pfoapfosphgdraft061021.pdf</a>   |

| State | PFAS  | Guideline Level (ug/L)   | Toxicity Data                                 | Critical Effect Study  | Endpoint  | RSC (%) | POD                             | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions               | Target Populations   | Resources  |                                   |
|-------|-------|--|---|------------------------|---|---------|---------------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|------------------------------------|--|--|-----------------------------------|
|       |       |  |   |                        |   |         |                                 |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                                    |  |  | Sensitive Developmental Endpoints |
| CA    | PFOA  | (Proposed Health-Protective Concentration for noncancer effects) 0.003 (based on increased risk of liver damage) | Humans (increased risk of liver damage)       | Gallo et al., 2012     | Liver enzymes in human serum exceeding clinically based reference levels used by the International Federation of Clinical Chemistry and Laboratory Medicine | 20      | NOAEC (9.8 ng/ml)               | 9.8 ng/ml       | √10   |              | √10          |                |                     |  |                 | 0.00087   | Lifetime average of 0.053 L/kg-day | Oral ingestion as significant route of exposure            |  |                                   |
|       | PFOS  | (Proposed Public Health Goal) 0.001 (based on cancer effects in animals)   | Animals (liver and pancreatic tumors in rats) | Butenhoff et al., 2012 | Cancer (liver and pancreatic) in rats   |         | CSF (15.6 per mg/kg-day)        |                 |       |              |              |                |                     |  |                 |   | Lifetime average of 0.053 L/kg-day | Oral ingestion as significant route of exposure            |  |                                   |
|       | PFOS  | (Proposed Health-Protective Concentration for noncancer effects) 0.002 (based on increased total cholesterol)    | Humans (increased total cholesterol)          | Steenland et al., 2009 | Total cholesterol levels in humans exceeding clinical reference level published by the American Heart Association   | 20      | LOAEC (16.4 ng/ml)              | 16.4 ng/ml      | 10    |              | √10          | √10            |                     |  |                 | 0.00064   | Lifetime average of 0.053 L/kg-day | Oral ingestion as significant route of exposure            |  |                                   |
| CT    | PFOA  | 0.016  | animal (mice)                                 | Lau et al (2006)       | Developmental Effects   | 50%     | LOAEL: 38 mg/L (animal serum)   |                 | 1000  | 3            | 10           | 10             |                     |  |                 | 4.50E-06  | 0.143 L/kg-d                       | Infant (0-1 yr) average BW and 95th percentile intake rate | Infants; also protective of pregnant and lactating women |                                   |
|       | PFOS  | 0.010  | animal (mice)                                 | Dong et al (2009)      | Immune Suppression  | 50%     | NOAEL: 0.67 mg/L (animal serum) |                 | 30    | 3            | 10           |                |                     |  |                 | 2.90E-06  | 0.143 L/kg-d                       | Infant (0-1 yr) average BW and 95th percentile intake rate | Infants; also protective of pregnant and lactating women |                                   |
|       | PFNA  | 0.012  | animal (mice)                                 | Das et al (2015)       | Developmental Effects   | 50%     | NOAEL: 6.8 mg/L (animal serum)  |                 | 300   | 3            | 10           | 10             |                     |  |                 | 3.40E-06  | 0.143 L/kg-d                       | Infant (0-1 yr) average BW and 95th percentile intake rate | Infants; also protective of pregnant and lactating women |                                   |
|       | PFHxS | 0.049  | animal (rats)                                 | Butenhoff et al (2009) | Thyroid Effects   | 50%     | NOAEL: 73.2 mg/L (animal serum) |                 | 300   | 3            | 10           | 10             |                     |  |                 | 1.40E-05  | 0.143 L/kg-d                       | Infant (0-1 yr) average BW and 95th percentile intake rate | Infants; also protective of pregnant and lactating women |                                   |

https://oehha.ca.gov/sites/default/files/media/downloads/cmr/pfoapfosphgdraft061021.pdf

| State | PFAS               | Guideline Level (ug/L) | Toxicity Data           | Critical Effect Study                 | Endpoint                         | RSC (%) | POD  | HED (mg/kg/day) | UFs                                   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations  | Resources  |   |  |  |
|-------|--------------------|------------------------|-------------------------|---------------------------------------|----------------------------------|---------|--|-----------------|---------------------------------------|--------------|--------------|----------------|---------------------|--|-----------------|---|----------------------|---|--|---|--|--|
|       |                    |                        |                         |                                       |                                  |         |  |                 | Total                                 | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                      |   |  | Sensitive Developmental Endpoints   |  |  |
| CT    | GenX               | 0.019                  | animal (mice)           | Dupont 2010 (reevaluated by NTP 2019) | Liver effects                    | 20%     | BMDL <sub>10ER</sub> : 0.09 mg/kg/d                              |                 | 3000                                  | 3            | 10           |                |                     | 10   |                 |   | 4.0E-06              | 0.042 L/kg-d  | Lactating woman average BW and 95th percentile intake rate | Lactating woman; also protective of general population  |  |  |
|       | PFHxA              | 0.24                   | animal (rats)           | Loveless 2009                         | Developmental effects            | 20%     | BMDL <sub>5RD</sub> : 10.6 mg/kg/d                               |                 | 300                                   | 3            | 10           |                |                     | 10   |                 |   | 1.7E-04              | 0.142 L/kg-d  | Infant (0-1 yr) average BW and 95th percentile intake rate | Infant; also protective of general population   |  |  |
|       | PFBS               | 0.76                   | animal (mice)           | Feng 2017                             | Thyroid effects                  | 20%     | BMDL <sub>0.5SD</sub> : 22.5 mg/kg/d                             |                 | 100                                   | 3            | 10           |                |                     | 3  |                 |   | 5.4E-04              | 0.142 L/kg-d  | Infant (0-1 yr) average BW and 95th percentile intake rate | Infant; also protective of general population   |  |  |
|       | PFBA               | 1.8                    | animal (rats)           | Butenhoff 2012                        | Thyroid effects                  | 20%     | NOAEL: 6 mg/kg/d   |                 | 1000                                  | 3            | 10           |                |                     | 3  |                 |   | 1.3E-03              | 0.142 L/kg-d  | Infant (0-1 yr) average BW and 95th percentile intake rate | Infant; also protective of general population   |  |  |
|       | 6:2 CI-PFESA       | 0.002 (MDL)            | animal (mice)           | Zhang 2018                            | Liver effects                    | 20%     | NOAEL: 18.9 mg/L (animal serum)                                  |                 | 3000                                  | 3            | 10           |                |                     | 10   |                 |   | 1.7E-07              | 0.040 L/kg-d  | Adult average BW and 95th percentile intake rate           | General population  |  |  |
|       | 8:2 CI-PFESA       | 0.005 (MDL)            | animal (mice)           | surrogate: 6:2 CI-PFESA               | Liver effects                    | 20%     | NOAEL: 18.9 mg/L (animal serum) based on surrogate: 6:2 CI-PFESA |                 | 3000 based on surrogate: 6:2 CI-PFESA |              |              |                |                     |  |                 |   | 1.7E-07              | 0.040 L/kg-d  | Adult average BW and 95th percentile intake rate           | General population  |  |  |
| HI    | PFOA <sup>1</sup>  | 0.0120                 | ATSDR (2021)            |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 3.00E-06             |   |  |   |  |  |
|       | PFOS <sup>2</sup>  | 0.0077                 | ATSDR (2021)            |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 2.00E-06             |   |  |   |  |  |
|       | PFNA <sup>3</sup>  | 0.012                  | ATSDR (2021)            |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 3.00E-06             |   |  |   |  |  |
|       | PFBS <sup>4</sup>  | 1.7                    | USEPA 2021a             |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 3.00E-04             |   |  |   |  |  |
|       | PFHxS <sup>5</sup> | 0.077                  | ATSDR (2021)            |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 2.00E-05             |   |  |   |  |  |
|       | PFHpS <sup>6</sup> | 0.038                  | Zeilmaker et al. (2018) |                                       | Based on noncarcinogenic effects | 20      |  |                 |                                       |              |              |                |                     |  |                 |   | 1.00E-05             |   |  |   |  |  |
|       |                    |                        |                         |                                       |                                  |         |  |                 |                                       |              |              |                |                     |  |                 |   | 0.78                 | Default USEPA RSLs except assumed body weight of 55 kg for young women of childbearing age. | 0-6 yr old child (USEPA RSLs Nov 2023)                     | <a href="https://health.hawaii.gov/beer/guidance/ehe-and-eals/">https://health.hawaii.gov/beer/guidance/ehe-and-eals/</a> |  |  |



| State | PFAS                    | Guideline Level (ug/L) | Toxicity Data                | Critical Effect Study   | Endpoint   | RSC (%) | POD                                 | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day)        | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions  | Target Populations                                       | Resources   |                                   |
|-------|-------------------------|------------------------|------------------------------|-------------------------|--|---------|-------------------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|------------------------|---|---|--|---|-----------------------------------|
|       |                         |                        |                              |                         |  |         |                                     |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                        |   |   |  |   | Sensitive Developmental Endpoints |
| HI    | PFPeS <sup>*</sup>      | 0.620                  | after DMOE (2015)            |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     |  | 1.60E-04               | 0.78  | Default USEPA RSLs except assumed body weight of 55 kg for young women of childbearing age. | 0-6 yr old child (USEPA RSLs Nov 2023)                   | <a href="https://health.hawaii.gov/heer/guidance/ehe-and-eals/">https://health.hawaii.gov/heer/guidance/ehe-and-eals/</a>   |                                   |
|       | PFPrA <sup>*</sup>      | 0.510                  | USEPA (2023)                 |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     | 5.00E-04   |                        |   |   |  |   |                                   |
|       | ADONA <sup>*</sup>      | 1.2                    | WIDHS (2020) (DONA)          |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     | 3.00E-04   |                        |   |   |  |   |                                   |
|       | 6:2 FTOH <sup>*</sup>   | 5.0                    | Gibb and O'Leary (2023)      |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     | 1.30E-03   |                        |   |   |  |   |                                   |
|       | 8:2 FTOH <sup>*</sup>   | 4.2                    | Gibb and O'Leary (2023)      |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     | 1.10E-03   |                        |   |   |  |   |                                   |
|       | 6:2 FtTAoS <sup>*</sup> | 1.9                    | Gibb and O'Leary (2023)      |                         | Based on noncarcinogenic effects                 | 20      |                                     |                 |       |              |              |                |                     | 5.00E-04   |                        |   |   |  |   |                                   |
| IL    | PFOA                    | 0.002 (MRL)            | Animals (Rats/Cancer)        | NTP 2018. TR-598        | Liver/Pancreatic tumors                          |         | Slope factor 143 mg/kg/day          | 0.00035         |       |              |              |                |                     |  | 143 (SF <sub>6</sub> ) | 2   | Duration: 30 years. Frequency: 350 days/year  | Average adult  | <a href="https://epa.illinois.gov/topics/water-quality/pfas/pfas-healthadvisory.html">https://epa.illinois.gov/topics/water-quality/pfas/pfas-healthadvisory.html</a> |                                   |
|       | PFOS                    | 0.014                  | Animals (Rats/Developmental) | Luebker et al. 2005     | Decreased body weight/delayed eye opening        | 20      | NOAEL 0.1 mg/kg/day                 | 0.000515        | 300   | 3            | 10           | 1              |                     |  | 10                     | 0.000002  | 2   | Lifetime oral ingestion as significant route of exposure |   | Average adult                     |
|       | PFBS                    | 2.1                    | Animals (Mice/Thyroid)       | Feng, et al. 2017       | Decreased total serum T4 (thyroid) levels        | 20      | BMDL 0.095 mg/kg/day                | 0.095           | 300   | 3            | 10           | 1              | 10                  |  | 1                      | 0.0003  | 2   | Lifetime oral ingestion as significant route of exposure |   | Average adult                     |
|       | PFHxS                   | 0.14                   | Animals (Rats/Thyroid)       | Butenhoff, et al. 2009a | Thyroid follicular damage                        | 20      | NOAEL 1 mg/kg/day                   | 0.0047          | 300   | 3            | 10           |                | 10                  |  |                        | 0.00002   | 2   | Lifetime oral ingestion as significant route of exposure |   | Average adult                     |
|       | PFNA                    | 0.021                  | Animals (Mice/Developmental) | Das et al. 2015         | Decreased body weight/developmental delays       | 20      | NOAEL 1 mg/kg/day                   | 0.001           | 300   | 3            | 10           | 1              | 10                  |  |                        | 0.000003  | 2   | Lifetime oral ingestion as significant route of exposure |   | Average adult                     |
|       | PFHxA                   | 3.5                    | Animals (Rats/Developmental) | Loveless et al. 2009    | Decreased offspring body weight in neonatal rats | 20      | BMDL <sub>SRD</sub> 10.62 mg/kg/day | 0.048           | 100   | 3            | 10           |                | 3                   |  |                        | 0.005   | 2   | Lifetime oral ingestion as significant route of exposure |   | Average adult                     |

| State | PFAS                                 | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study                             | Endpoint   | RSC (%)   | POD   | HED (mg/kg/day)                            | UFs                         |              |              |                |                          | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified)  | Exposure assumptions                                      | Target Populations   | Resources  |   |
|-------|--------------------------------------|------------------------|----------------|---|--|---|---|--|-----------------------------|--------------|--------------|----------------|--------------------------|-----------------|--|---|--|--|---|
|       |                                      |                        |                |   |  |   |   |  | Total                       | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation      |                 |  |   |  |  | Duration of Exposure (i.e., Subchronic to Chronic)  |
| IN    | PFOA                                 | 0.06                   |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFOS                                 | 0.04                   |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFBS                                 | 6                      |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFHxS                                | 0.4                    |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFNA                                 | 0.06                   |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
| MA    | PFOS, PFOA, PFNA, PFHpA, PFHxS, PFDA | 0.020*                 | Animals        | Multiple  | Based on multiple endpoints and evidence of effects below EPA PODs for PFOA and PFOS; including: immunotoxicity, hepatotoxicity, thyroid effects, developmental effects. | 20; to account for dietary and other exposures to PFAS subgroup addressed as well as potentially higher infant exposures. | NOAEL for PFOS, LOAEL for PFOA, equivalent to EPA values. | Equivalent to EPA values for PFOA and PFOS | 1000 for PFOA, 100 for PFOS | 3            | 10           | 10 for PFOA    | 3 for both PFOA and PFOS |                 | 5x10 <sup>-6</sup> based on PFOS and PFOA value, which is applied to subgroup based on similarity in chemical structures, toxicities, long serum half-lives. | 0.054 L/kg/day (same as EPA value used in LHA derivation) | Body weight and water intake of lactating women (same as EPA value used in LHA derivation) | Lactating and pregnant women; fetus; nursing infants | <a href="https://www.mass.gov/lists/development-of-a-pfas-drinking-water-standard-mcl">https://www.mass.gov/lists/development-of-a-pfas-drinking-water-standard-mcl</a> |
| MD    | PFOA, PFOS                           | 0.07*                  |                |   |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFOA, PFOS                           | 0.035*                 |                |   |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
|       | PFHxS                                | 0.14                   |                |   |  |   |   |  |                             |              |              |                |                          |                 |  |   |  |  |   |
| ME    | PFOA, PFOS, PFNA, PFHxS, PFHpA, PFDA | 0.02*                  | Animals (mice) | EPA (2016)  | EPA (2016)   | 20  | EPA (2016)  |  | EPA (2016)                  |              |              |                |                          |                 |  |   |  |  |   |
| MI    | PFOA                                 | 0.008                  | Animals (mice) | Onishchenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations   | 50  | LOAEL   |  | 300                         | 3            | 10           | 3              | 3                        | 1               | 3.9x10 <sup>-6</sup>   | 95th percentile   |  |  | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFOS                                 | 0.016                  | Animals (mice) | Dong et al., 2009                                 | Immunotoxicity and Hepatotoxicity  | 50  | NOAEL   |  | 30                          | 3            | 10           | 1              | 1                        | 1               | 2.89x10 <sup>-6</sup>  | 95th percentile   |  |  | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFNA                                 | 0.006                  | Animals (mice) | Das et al., 2015                                  | Reduced pup body weight  | 50  | NOAEL   |  | 300                         | 3            | 10           | 1              | 10                       | 1               | 2.2x10 <sup>-6</sup>   | 95th percentile   |  |  | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFHxA                                | 400                    | Animals (rats) | Klaunig et al., 2015                              | Renal effects  | 20  | BMDL  |  | 300                         | 3            | 10           | 1              | 10                       | 1               | 8.3x10 <sup>-2</sup>   | 3.353   |  |  | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFHxS                                | 0.051                  | Animals (rats) | NTP 2018 Tox-96 Report                            | Thyroid effects  | 50  | BMDL  |  | 300                         | 3            | 10           | 1              | 10                       | 1               | 9.7x10 <sup>-6</sup>   | 95th percentile   |  |  | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |



| State | PFAS                                      | Guideline Level (ug/L)  | Toxicity Data  | Critical Effect Study           | Endpoint                                | RSC (%) | POD                             | HED (mg/kg/day)                 | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations   | Resources          |   |
|-------|---|---|----------------|---------------------------------|---|---------|---------------------------------|---------------------------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|----------------------|--|--------------------|---|
|       |   |   |                |                                 |   |         |                                 |                                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                      |  |                    | Sensitive Developmental Endpoints   |
| MI    | PFBS                                      | 0.42  | Animals (mice) | Feng et al., 2017               | Thyroid effects                         | 20      | BMDL                            |                                 | 300   | 3            | 10           | 1              | 10                  | 1  |                 | 3x10 <sup>-4</sup>  | 1.106                |  |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | GenX                                      | 0.37  | Animals (mice) | DuPont 18405-1037, 2010         | Reduced pup body weight, Hepatotoxicity | 20      | BMDL                            |                                 | 300   | 3            | 10           | 1              | 3                   | 3  |                 | 7.7x10 <sup>-5</sup>  | 3.353                |  |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
| MN    | PFOA (Short Term, Subchronic, Chronic)    | 0.00024   | Human          | Abraham et al. 2020             | Decreased antibodies                    | 20%     | 2.8 ng/mL (serum concentration) | 2.8 ng/mL (serum concentration) | 3     |              |              |                | 3                   |  |                 | 0.93 ng/mL (reference serum concentration)                    | 95th percentile      | Half-life 902 days; placental transfer 83%; breastmilk transfer 6.8% |                    | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf</a>   |
|       | PFOA (Cancer)                             | 0.0000079   | Human          | Shearer et al 2021              | Kidney Cancer                           |         | CSF = 0.0126 per ng/kg-d        |                                 |       |              |              |                |                     |  |                 |   |                      |  | Lifetime           | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf</a>   |
|       | PFOS (Short Term, Subchronic, Chronic)    | 0.0023  | Human          | Wikström et al 2012             | Low birth weight                        | 20%     | 7.7 ng/mL (serum concentration) | 7.7 ng/mL (serum concentration) | 3     |              |              |                | 3                   |  |                 | 2.6 ng/mL (reference serum concentration)                     | 95th percentile      | Half-life 996 days; placental transfer 39%, breastmilk transfer 3%   |                    | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf</a>   |
|       | PFOS (Cancer)                             | 0.0076  | Animal (Rat)   | Butenhoff et al 2012            | Liver cancer                            |         | CSF = 13 per mg/kg-d            |                                 |       |              |              |                |                     |  |                 |   |                      |  | Lifetime           | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf</a>   |
|       | PFBA (Short-term, Subchronic and chronic) | 7 [Short-term value was lower than calculated subchronic and chronic values. Therefore all durations set to short-term] | Animals (rats) | NOTOX, 2007 and Butenhoff, 2007 | Liver effects, Thyroid effects          | 50      | 3.01 mg/kg/day                  | 0.38                            | 100   | 3            | 10           |                | 3                   |  |                 | 3.8x10 <sup>-3</sup>  | 95th percentile      | Half-life 72 hrs; placental transfer ND; breastmilk transfer ND      | Infants and Adults | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfba2sum.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfba2sum.pdf</a>   |
|       | PFBS                                      | 0.1   | Animals (rats) | NTP 2019                        | Thyroid effects                         | 50      | 6.97 mg/kg-d                    | 0.0084                          | 100   | 3            | 10           |                | 3                   |  |                 | 8.40E-05  | 95th percentile      | Human half-life 1050 hours   | Adults             | Perfluorobutane Sulfonate (PFBS) Toxicological Summary, March 2022<br><a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfbssummary.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfbssummary.pdf</a> |

| State | PFAS                                       | Guideline Level (ug/L)  | Toxicity Data  | Critical Effect Study                       | Endpoint                        | RSC (%)   | POD                   | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified)     | Exposure assumptions               | Target Populations   | Resources                       |   |
|-------|--|---|----------------|---|---------------------------------|---|-----------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|------------------------------------|--|---------------------------------|---|
|       |  |   |                |   |                                 |   |                       |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                                    |  |                                 | Sensitive Developmental Endpoints   |
| MN    | PFHxS (Short-term, Subchronic and chronic) | 0.047   | Animals (rats) | NTP, 2018                                   | Thyroid effects, Liver effects  | 20 for older children and adults, 50 for infants/young children | 32.4 mg/L             | 0.00292         | 300   | 3            | 10           |                |                     |  |                 | 9.7x10 <sup>-6</sup>  | 95th percentile                    | Half-life 1935 days; placental transfer 70%; breastmilk transfer 1.4%                            | Fetus and Breastfeeding Infants | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfhxs.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfhxs.pdf</a> |
|       | PFHxA (Short-term, Subchronic and chronic) | 0.2 [Short-term value was lower than calculated subchronic and chronic values. Therefore all durations set to short-term] | Animals (rats) | NTP, 2019                                   | Developmental & Thyroid effects | 20 for all durations  | 25.9 mg/kg/day        | 0.0958          | 300   | 3            | 10           |                |                     |  |                 | 3.2x10 <sup>-4</sup> (short-term), 0.00015 (subchronic & chronic) | 95th percentile                    | Half-life 32 days [TK model was not used. Placental transfer 2.26; breastmilk transfer- No data] | General Population              | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfxa.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfxa.pdf</a>   |
| NC    | GenX                                       | 0.14  | Animals (mice) | DuPont-24459, 2008; DuPont-18405-1037, 2010 | Hepatotoxicity                  | 20  | 0.1 mg/kg/day (NOAEL) |                 | 1000  | 10           | 10           |                |                     |  |                 | 0.0001  | 1.1 L/day (95th percentile infant) | Bottle-fed infants of median weight  | Infants                         | <a href="https://epi.dph.ncdhs.gov/oe/pfas/NC%20DHH%20Health%20Goal%20Q&amp;A.pdf">https://epi.dph.ncdhs.gov/oe/pfas/NC%20DHH%20Health%20Goal%20Q&amp;A.pdf</a>                             |
| NH    | PFOA                                       | 0.012   | Animals (mice) | Loveless et al., 2006                       | Hepatotoxicity                  | 50  | BMDL10                |                 | 100   | 3            | 10           |                |                     |  |                 | 6.1x10 <sup>-6</sup>  | 95th percentile                    | MDH Model  | Fetus and Breastfeeding Infants |   |
|       | PFOS                                       | 0.015   | Animals (mice) | Dong et al., 2011                           | Immunosuppression               | 50  | NOAEL                 |                 | 100   | 3            | 10           |                |                     |  |                 | 3x10 <sup>-6</sup>  | 95th percentile                    | MDH Model  | Fetus and Breastfeeding Infants |   |
|       | PFNA                                       | 0.011   | Animals (mice) | Das et al., 2015                            | Hepatotoxicity                  | 50  | BMDL10                |                 | 100   | 3            | 10           |                |                     |  |                 | 4.3x10 <sup>-6</sup>  | 95th percentile                    | MDH Model  | Fetus and Breastfeeding Infants |   |
|       | PFHxS                                      | 0.018   | Animals (mice) | Chang et al., 2018 and Ali et al., 2019     | Infertility                     | 50  | BMDLSD                |                 | 300   | 3            | 10           |                |                     |  |                 | 4x10 <sup>-6</sup>  | 95th percentile                    | MDH Model  | Fetus and Breastfeeding Infants | <a href="https://pubmed.ncbi.nlm.nih.gov/31487490/">https://pubmed.ncbi.nlm.nih.gov/31487490/</a>   |
| NJ    | PFOA                                       | 0.014   | Animals (mice) | Loveless et al., 2006                       | Hepatotoxicity                  | 20  | BMDL                  |                 | 300   | 3            | 10           |                |                     |  |                 | 2x10 <sup>-6</sup>  | 2 (70 kg body wt)                  | Default adult  | Infants                         | <a href="https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendix-a.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendix-a.pdf</a>   |
|       | PFOS                                       | 0.013   | Animals (mice) | Dong et al., 2009                           | Immunotoxicity                  | 20  | NOAEL                 |                 | 30    | 3            | 10           |                |                     |  |                 | 1.8x10 <sup>-6</sup>  | 2 (70 kg body wt)                  | Default adult  | Infants                         | <a href="https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf</a>                 |
|       | PFNA                                       | 0.013   | Animals (mice) | Das et al., 2015                            | Hepatotoxicity                  | 50  | BMDL                  |                 | 1000  | 3            | 10           |                |                     |  |                 |   |                                    | 200:1 serum: drinking water ratio  |                                 | <a href="https://www.state.nj.us/dep/watersupply/pdf/pfna-health-effects.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfna-health-effects.pdf</a>                                       |

| State | PFAS                                 | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study                            | Endpoint                                      | RSC (%) | POD                         | HED (mg/kg/day) | UFs        |              |              |                |                     | RfD (mg/kg/day)  | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions                         | Target Populations  | Resources |
|-------|--------------------------------------|------------------------|----------------|--|---|---------|-----------------------------|-----------------|------------|--------------|--------------|----------------|---------------------|--|---|--|---|-----------|
|       |                                      |                        |                |  |   |         |                             |                 | Total      | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |  |   |  |   |           |
| NY    | PFOA                                 | 0.01                   |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
|       | PFOS                                 | 0.01                   |                |  | Liver, developmental, immune, thyroid effects |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
| OH    | PFOA, PFOS                           | 0.07*                  |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
|       | GenX                                 | 0.021                  |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
|       | PFHxS                                | 0.14                   |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
|       | PFNA                                 | 0.021                  |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
|       | PFBS                                 | 2.1                    |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
| OR    | PFOA, PFOS, PFNA, PFHxS              | 0.03*                  |                |  |   |         |                             |                 |            |              |              |                |                     | 0.000017 (PFOA), 0.0000041 (PFOS), 0.0000034 (PFNA), 0.0000057 (PFHxS) | Short- and long-term exposures                                | All persons, including sensitive populations | <a href="https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENT/OPERATIONS/PAGES/PFAS.aspx">https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENT/OPERATIONS/PAGES/PFAS.aspx</a> |           |
| PA    | PFOA                                 | 0.014                  |                | Koskela, et al., 2017, Onishchenko, et al., 2011 | Developmental effects                         |         | LOAEL and NOAEL (8.29 mg/L) |                 | 300        |              |              |                |                     |  |   |  | Children and women of childbearing age  |           |
|       | PFOS                                 | 0.018                  |                | Dong, et al., 2011                               | Immunotoxicity effects                        |         | LOAEL and NOAEL (2.36 mg/L) |                 | 100        |              |              |                |                     |  |   |  | Children and women of childbearing age  |           |
| RI    | PFOA, PFOS, PFHxS, PFNA, PFHpA, PFDA | 0.02*                  |                |  |   |         |                             |                 |            |              |              |                |                     |  |   |  |   |           |
| VT    | PFOA, PFOS, PFHxS, PFHpA, PFNA       | 0.02*                  | Animals (mice) | EPA (2016)                                       | EPA (2016)                                    | 20      |                             | EPA (2016)      | EPA (2016) |              |              |                |                     |  | 0.175 L/kg/day  |  | 0-1 year old  |           |

| State | PFAS | Guideline Level (ug/L)           | Toxicity Data  | Critical Effect Study                                 | Endpoint  | RSC (%)                  | POD   | HED (mg/kg/day)   | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions  | Target Populations  | Resources  |  |  |
|-------|------|----------------------------------|----------------|---|---|--------------------------|---|---|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|---|---|--|--|--|
|       |      |                                  |                |   |   |                          |   |   | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |   |   |  | Sensitive Developmental Endpoints  |  |
| WA    | PFOA | 0.01 (WA DOH State Action Level) | ATSDR, 2021    | Koskela et al., 2016                                  | Skeletal effects in mouse offspring in adulthood following gestational exposure | 50 (children and adults) | LOAEL (0.3 mg/kg-day; serum level of 8.29 mg/L) | 8.21E-04  | 300   | 3            | 10           | 10             |                     |  |                 |   | 3.00E-06  | MDH model   | PFAS contamination occurs via placental transfer, breast-milk ingestion, and tap water ingestion, and includes infants who are bottle-fed. Water intake rates of 90th percentile for chronic periods of exposure (child > 1yr and adults); 95th percentile drinking water intake rates for lactating women and formula-fed infants. Breastfed infants were assumed to be breastfed exclusively for six months. | Human exposure (birth to adult) to PFAS contamination via placental transfer, breast-milk ingestion, and tap water ingestion, and includes infants who are bottle-fed. |  |
|       | PFOS | 0.015                            | Animals (Mice) | Dong et al., 2011 (with support by Dong et al., 2009) | Immune effects  | 20 adults; 50 infants    | NOAEL (2.36 mg/L serum concentration)           | 0.000307  | 100   | 3            | 10           | 1              | 3                   | 1  | 1               | 0.0000031   | MDH transgenerational toxicokinetic model (Goeden et al 2019) | Limiting population was adults at 90th percentile drinking water intake over chronic period. Infants also modelled for 12 months breast feeding (1st 6 months = exclusive BF); 95th percentile DW ingestion by lactating women and infants in 1st year, then 90th percentile age-specific DW ingestion rates > 1 years old. | Adults, fetus, infants   | 331-673.pdf (wa.gov)   |  |
|       | PFNA | 0.009                            | Animals (mice) | Das et al. 2015                                       | Reduced pup weight and developmental delays                                     | 0.5                      | NOAEL (6.8 mg/L serum concentration)            | 0.000734. using half-life estimate of 3.52 years (1,285 days) from Yu et al. 2021 | 300   | 3            | 10           | 1              | 10                  | 1  | 1               | 0.0000025   | MDH transgenerational toxicokinetic model (Goeden et al 2019) | 12 months breast feeding (1st 6 months = exclusive BF); 95th percentile DW ingestion by lactating women and infants in 1st year, then 90th percentile age-specific DW ingestion rates > 1 years old.  | Fetus, infants   | 331-673.pdf (wa.gov)   |  |

| State | PFAS                             | Guideline Level (ug/L) | Toxicity Data           | Critical Effect Study          | Endpoint   | RSC (%) | POD                                  | HED (mg/kg/day) | UFs   |              |              |                |                     | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations  | Resources  |  |   |
|-------|----------------------------------|------------------------|-------------------------|--------------------------------|--|---------|--------------------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|-----------------|---|----------------------|---|--|--|---|
|       |                                  |                        |                         |                                |  |         |                                      |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |                 |   |                      |   |  | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints   |
| WA    | PFHxS                            | 0.065                  | Animals (rats)          | NTP, 2018                      | Thyroid hormone level reduction  | 50      | BMDL (32.4 mg/L serum concentration) | 0.00292         | 300   | 3            | 10           | 1              | 10                  | 1               | 1   | 0.0000097            | MDH transgenerational toxicokinetic model (Goeden et al 2019) | 12 months breast feeding (1st 6 months = exclusive BF); 95th percentile DW ingestion by lactating women and infants in 1st year, then 90th percentile age-specific DW ingestion rates > 1 years old. | Fetus, infants                                     | 331-673.pdf (wa.gov)  |
|       | PFBS                             | 0.345                  | Animals (mice)          | Feng et al., 2017              | Thyroid hormone level reduction (developmental)                        | 20      | BMDL (22.1 mg/kg/day)                | 0.095           | 300   | 3            | 10           | 1              | 10                  | 1               | 1   | 0.0003               | 0.174 L/kg/day  | 95th percentile water intake rate for birth - 1 year old.  | Infants  | 331-673.pdf (wa.gov)  |
| WI    | PFOA                             | 0.02 (combined)*       | Animals (mice)          | Lau et al., 2006               | Developmental (reduced ossification)                                   | 100     | LOAEL                                |                 | 300   | 10           | 3            | 10             |                     |                 |   |                      |   |  |  | <a href="https://www.dhs.wisconsin.gov/water/gws.htm">https://www.dhs.wisconsin.gov/water/gws.htm</a>                 |
|       | PFOS                             | 0.02 (combined)*       | Animals (mice)          | Luebker et al., 2005           | Reduced pup body weight  | 100     | NOAEL                                |                 | 30    | 3            | 10           |                |                     |                 |   |                      |   | 1 (10 kg body wt)  | Gestation and infancy (including breastfeeding)    |   |
|       | FOSA, NETFOSA, NETFOSAA, NETFOSE | 0.02 (combined)*       | PFOA and PFOS Precursor |                                | Combined standard for PFOS, PFOA, FOSA, NETFOSE, NETFOSA, and NETFOSAA | 100     |                                      |                 |       |              |              |                |                     |                 |   |                      |   | Combined   |  |   |
|       | PFTeA                            | 10                     | Animals (rats)          | Hirata-Koizumi et al., 2015    | Body weight  | 100     | NOAEL (1 mg/kg/day)                  |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 0.001   | 1  |  |   |
|       | PFHxA                            | 150                    | Animals (rats)          | Klaunig, 2015                  | Clinical effects   | 100     | NOAEL (15 mg/kg/day)                 |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 0.015   | 1  |  |   |
|       | PFUnA                            | 3                      | Animals (rats)          | Takahashi et al., 2014         | Body weight  | 100     | NOAEL (0.3 mg/kg/day)                |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 0.0003  | 1  |  | <a href="https://www.dhs.wisconsin.gov/water/gws-cycle11.htm">https://www.dhs.wisconsin.gov/water/gws-cycle11.htm</a> |
|       | PFDoA                            | 0.5                    | Animals (rats)          | Shi, 2009                      | Body weight and testosterone levels                                    | 100     | NOAEL (0.05 mg/kg/day)               |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 5x10 <sup>-5</sup>  | 1  |  |   |
|       | PFBA                             | 10                     | Animals (rats)          | van Otterdyk, Buttenholf 2012b | Hemotoxicity, hepatotoxicity, and thyroid toxicity                     | 100     | BMDL (MN) (3 mg/kg/day)              |                 | 3000  | 10           | 10           | 1              | 10                  | 3               | 1   |                      | 0.001   | 1  |  |   |
|       | PFBS                             | 450                    | Animals (rats)          | Lieder, 2009b                  | Nephrotoxicity   | 100     | BMDL (MN) (45 mg/kg/day)             |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 0.045   | 1  |  |   |
|       | PFNA                             | 0.03                   | Animals (mice)          | Das, 2015                      | Reproductive toxicity  | 100     | NOAEL (1 mg/kg/day)                  | 0.0011          | 300   | 3            | 10           | 1              | 1                   | 1               | 10  |                      | 3x10 <sup>-6</sup>  | 1  |  |   |
|       | PFDA                             | 0.3                    | Animals (mice)          | Harris and Birnbaum 1989       | Developmental (Fetal growth)   | 100     | NOAEL (0.03 mg/kg/day)               |                 | 1000  | 10           | 10           | 1              | 10                  | 1               | 1   |                      | 3x10 <sup>-5</sup>  | 1  |  |   |

| State | PFAS  | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study | Endpoint  | RSC (%) | POD                   | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources |   |
|-------|-------|------------------------|----------------|-----------------------|---|---------|-----------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|----------------------|--------------------|-----------|---|
|       |       |                        |                |                       |   |         |                       |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                      |                    |           | Sensitive Developmental Endpoints                   |
| WI    | PFHxS | 0.04                   | Animals (rats) | Cheng, 2018           | Developmental and reproductive toxicity (Maternal and fetal growth) | 100     | NOAEL (0.3 mg/kg/day) |                 | 300   | 3            | 10           | 1              | 10                  | 1  | 1               |   | 4x10 <sup>-6</sup>   | 1                  |           | https://www.dhs.wisconsin.gov/water/gws-cycle11.htm |
|       | PFODA | 400                    | Animals (rats) | Hirata-Koizumi, 2012  | Body weight   | 100     | NOAEL (40 mg/kg/day)  |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.04                 | 1                  |           |   |
|       | Gen X | 0.3                    | Animals (mice) | Dupont, 2010b         | Nephrotoxicity and hepatotoxicity                                   | 100     | NOAEL (0.1 mg/kg/day) |                 | 3000  | 10           | 10           | 1              | 10                  | 3  | 1               |   | 3x10 <sup>-5</sup>   | 1                  |           |   |
|       | DONA  | 3                      | Animals (rats) | Gordon, 2011          | Hemotoxicity and hepatotoxicity                                     | 100     | NOAEL (1 mg/kg/day)   |                 | 3000  | 10           | 10           | 1              | 10                  | 3  | 1               |   | 0.0003               | 1                  |           |   |

\*= Advisory level is based on the total of more than one PFAS

## Appendix B: State Groundwater PFAS Guideline Criteria

| State | PFAS                           | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study | Endpoint   | RSC (%)  | POD        | HED (mg/kg/day) | UFs        |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations                                | Resources & Notes |   |
|-------|--------------------------------|------------------------|----------------|-----------------------|--|--|------------|-----------------|------------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|---|-------------------|---|
|       |                                |                        |                |                       |  |  |            |                 | Total      | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |   |                   | Modifying Factor  |
| AK    | PFOA                           | 0.4                    | Animals (mice) | Lau et al., 2006      | Decreased ossification of pup proximal phalanges, accelerated preputial separation | None (but does not include an RSC in cleanup level calculations, so essentially use an RSC of 100) | EPA (2016) |                 | EPA (2016) |              |              |                |                     |  |   |                 | EPA (2016)  | 0.78                 | Residential exposure for 6 yrs old child receptor | Child             | <a href="http://dec.alaska.gov/media/7543/201802_01_pccl.pdf">http://dec.alaska.gov/media/7543/201802_01_pccl.pdf</a> |
|       | PFOS                           | 0.4                    | Animals (mice) | Luebker et al., 2005  | Reduced pup body weight  | None (but does not include an RSC in cleanup level calculations, so essentially use an RSC of 100) | EPA (2016) |                 | EPA (2016) |              |              |                |                     |  |   |                 | EPA (2016)  | 0.78                 | Residential exposure for 6 yrs old child receptor | Child             | <a href="http://dec.alaska.gov/media/7543/201802_01_pccl.pdf">http://dec.alaska.gov/media/7543/201802_01_pccl.pdf</a> |
| CO    | PFOA, PFOS, PFNA               | 0.07*                  | Animals (mice) | EPA (2016)            | EPA (2016)   | 20   | EPA (2016) |                 | EPA (2016) |              |              |                |                     |  |   |                 | EPA (2016)  | EPA (2016)           | EPA (2016)  | EPA (2016)        |   |
|       | PFBS                           | 400                    | Animals (mice) | EPA RSL               | EPA RSL  | EPA RSL  | EPA RSL    |                 | EPA RSL    |              |              |                |                     |  |   |                 | EPA RSL   | EPA RSL              | EPA RSL   | EPA RSL           |   |
|       | PFHxS                          | 0.7                    | Animals (mice) |                       |  |  |            |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |   |
| CT    | PFOA, PFOS, PFHxS, PFHpA, PFNA | 0.07*                  |                |                       |  |  |            |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   | CT DEEP Remediation and Groundwater Protection Criteria   |

| State | PFAS    | Guideline Level (ug/L)              | Toxicity Data  | Critical Effect Study | Endpoint   | RSC (%) | POD        | HED (mg/kg/day) | UFs   |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes |                    |                    |                |                          |                          |  |
|-------|---------|-------------------------------------|----------------|-----------------------|--|---------|------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|--------------------|-------------------|--------------------|--------------------|----------------|--------------------------|--------------------------|--|
|       |         |                                     |                |                       |  |         |            |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |                    |                   | Modifying Factor   |                    |                |                          |                          |  |
| DE    | PFOA    | 6 ng/L (water), 0.019 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFOS    | 4 ng/L (water), 0.013 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFHxS   | 39 ng/L (water), 0.13 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFNA    | 6 ng/L (water), 0.019 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFBS    | 600 ng/L (water), 1.9 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFHxA   | 610 ng/L (water), 3.2 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | PFBA    | 1800 ng/L (water), 7.8 mg/kg (soil) |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
|       | HFPO-DA | 6 ng/L (water), 0.023 mg/kg (soil)  |                |                       |  |         |            |                 |       |              |              |                |                     |  |   |                 |   |                      |                    |                   |                    |                    |                |                          |                          |  |
| FL    | PFOA    | 0.07                                | Animals (mice) | Lau et al., 2006      | Decreased ossification of pup proximal phalanges, accelerated preputial separation | 20      | EPA (2016) |                 | 300   | 3            |              |                |                     |  |   |                 |   |                      |                    | 10                | 2x10 <sup>-5</sup> | 0.054 L/kg/day     |                | Pregnant/lactating women |                          |  |
|       | PFOS    | 0.07                                | Animals (mice) | Luebker et al., 2005  | Decreased offspring body weight  | 20      | EPA (2016) |                 | 30    | 3            |              |                |                     |  |   |                 |   |                      |                    |                   | 10                 | 2x10 <sup>-5</sup> | 0.054 L/kg/day |                          | Pregnant/lactating women |  |









| State | PFAS                                 | Guideline Level (ug/L)                           | Toxicity Data  | Critical Effect Study                             | Endpoint   | RSC (%)   | POD   | HED (mg/kg/day)                            | UFs                         |              |              |                |                          |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified)  | Exposure assumptions                                      | Target Populations   | Resources & Notes                                    |   |
|-------|--------------------------------------|--|----------------|---|--|---|---|--|-----------------------------|--------------|--------------|----------------|--------------------------|--|---|-----------------|--|---|--|--|---|
|       |                                      |  |                |   |  |   |   |  | Total                       | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation      | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |  |   |  |  | Modifying Factor  |
| IN    | PFHxS                                | 0.4  |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
|       | PFNA                                 | 0.06   |                | EPA RSL Tables                                    |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
|       | Sodium Perfluorohexanoate            | 1.00E+01   | EPA RSL        | EPA RSL   | EPA RSL  | EPA RSL   | EPA RSL   | EPA RSL                                    | EPA RSL                     | EPA RSL      | EPA RSL      | EPA RSL        | EPA RSL                  | EPA RSL  | EPA RSL   | EPA RSL         | EPA RSL  | EPA RSL   | EPA RSL  | EPA RSL  |   |
| MA    | PFOS, PFOA, PFNA, PFHpA, PFHxS, PFDA | 0.020*   | Animals        | Multiple  | Based on multiple endpoints and evidence of effects below EPA PODs for PFOA and PFOS; including: immunotoxicity, hepatotoxicity, thyroid effects, developmental effects. | 20; to account for dietary and other exposures to PFAS subgroup addressed as well as potentially higher infant exposures. | NOAEL for PFOS, LOAEL for PFOA, equivalent to EPA values. | Equivalent to EPA values for PFOA and PFOS | 1000 for PFOA, 100 for PFOS | 3            | 10           | 10 for PFOA    | 3 for both PFOA and PFOS |  |   |                 | 5x10 <sup>-6</sup> based on PFOS and PFOA value, which is applied to subgroup based on similarity in chemical structures, long serum half-lives. | 0.054 L/kg/day (same as EPA value used in LHA derivation) | Body weight and water intake of lactating women (same as EPA value used in LHA derivation) | Lactating and pregnant women; fetus; nursing infants | <a href="https://www.mass.gov/lists/development-of-a-pfas-drinking-water-standard-mcl">https://www.mass.gov/lists/development-of-a-pfas-drinking-water-standard-mcl</a> |
| ME    | PFOA                                 | 750 (construction worker)                        |                |   |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
|       | PFOS                                 | 750 (construction worker)                        |                |   |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
|       | PFBS                                 | 400 (residential), 100,000 (construction worker) |                |   |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
|       | PFOS, PFOA, PFNA, PFHxS, PFHpA       | 0.07* (residential)                              |                |   |  |   |   |  |                             |              |              |                |                          |  |   |                 |  |   |  |  |   |
| MI    | PFOA                                 | 0.008  | Animals (mice) | Onishchenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations   | 50  | LOAEL   |  | 300                         | 3            | 10           | 3              | 3                        | 1  |   |                 | 3.9x10 <sup>-6</sup>   | 95th percentile   |  |  | <a href="#">Health-Based Drinking Water Value. Recommendations for PFAS in Michigan Report</a>  |

| State | PFAS                                 | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study                            | Endpoint   | RSC (%) | POD   | HED (mg/kg/day) | UFs   |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|--------------------------------------|------------------------|----------------|--|--|---------|-------|-----------------|-------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|--------------------|---|
|       |                                      |                        |                |  |  |         |       |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |                    |   |
| MI    | PFOS                                 | 0.016                  | Animals (mice) | Dong et al., 2009                                | Immunotoxicity and Hepatotoxicity                | 50      | NOAEL |                 | 30    | 3            | 10           | 1              | 1                   | 1  |   |                 | 2.89x10 <sup>-6</sup>   | 95th percentile      |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFNA                                 | 0.006                  | Animals (mice) | Das et al., 2015                                 | Reduced pup body weight                          | 50      | NOAEL |                 | 300   | 3            | 10           | 1              | 10                  | 1  |   |                 | 2.2x10 <sup>-6</sup>  | 95th percentile      |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFHxA                                | 400                    | Animals (rats) | Klaunig et al., 2015                             | Renal effects                                    | 20      | BMDL  |                 | 300   | 3            | 10           | 1              | 10                  | 1  |   |                 | 8.3x10 <sup>-2</sup>  | 3.353                |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFHxS                                | 0.051                  | Animals (rats) | NTP 2018 Tox-96 Report                           | Thyroid effects                                  | 50      | BMDL  |                 | 300   | 3            | 10           | 1              | 10                  | 1  |   |                 | 9.7x10 <sup>-6</sup>  | 95th percentile      |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFBS                                 | 0.42                   | Animals (mice) | Feng et al., 2017                                | Thyroid effects                                  | 20      | BMDL  |                 | 300   | 3            | 10           | 1              | 10                  | 1  |   |                 | 3x10 <sup>-4</sup>  | 1.106                |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | GenX                                 | 0.37                   | Animals (mice) | DuPont 18405-1037, 2010                          | Reduced pup body weight, Hepatotoxicity          | 20      | BMDL  |                 | 300   | 3            | 10           | 1              | 3                   | 3  |   |                 | 7.7x10 <sup>-5</sup>  | 3.353                |                    | <a href="#">Health-Based Drinking Water Value Recommendations for PFAS in Michigan Report</a>   |
|       | PFOA (GSI for drinking water source) | 0.066                  | Animals (mice) | Onischenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations |         | LOAEL |                 | 300   | 3            | 10           | 3              | 3                   | 1  |   |                 | 3.88x10 <sup>-6</sup>   | 2                    |                    | https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values<br><br>3x Database uncertainty factor included in Total UF |

| State | PFAS                                 | Guideline Level (ug/L) | Toxicity Data      | Critical Effect Study                            | Endpoint   | RSC (%) | POD   | HED (mg/kg/day) | UFs   |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|--------------------------------------|------------------------|--------------------|--|--|---------|-------|-----------------|-------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|--------------------|---|
|       |                                      |                        |                    |  |  |         |       |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |                    |   |
| MI    | PFOA (GSI)                           | 0.17                   | Animals (mice)     | Onischenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations       |         | LOAEL |                 | 300   | 3            | 10           | 3              | 3                   | 1  |   |                 |   |                      |                    | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>3x Database uncertainty factor included in Total UF  |
|       | PFOS (GSI for drinking water source) | 0.011                  | Animals (primates) | Seacat et al., 2002                              | Decreased body weight, hepatotoxicity, thyroid effects |         | NOAEL |                 | 30    | 3            | 10           | 1              | 1                   | 1  |   |                 |   |                      |                    | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a>   |
|       | PFOS (GSI)                           | 0.012                  | Animals (primates) | Seacat et al., 2002                              | Decreased body weight, hepatotoxicity, thyroid effects |         | NOAEL |                 | 30    | 3            | 10           | 1              | 1                   | 1  |   |                 |   |                      |                    | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a>   |
|       | PFBS (GSI for drinking water source) | 8.3                    | Animals (mice)     | Feng et al., 2017                                | Thyroid effects  |         | BMDL  |                 | 300   | 3            | 10           | 1              | 10                  | 1  |   |                 |   |                      |                    | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |

| State | PFAS                                      | Guideline Level (ug/L)  | Toxicity Data  | Critical Effect Study           | Endpoint                       | RSC (%) | POD                             | HED (mg/kg/day)                 | UFs   |              |              |                |                     |  |   | RfD (mg/kg/day)                            | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions   | Target Populations | Resources & Notes   |
|-------|---|---|----------------|---------------------------------|--------------------------------|---------|---------------------------------|---------------------------------|-------|--------------|--------------|----------------|---------------------|--|---|--|---|--|--------------------|---|
|       |   |   |                |                                 |                                |         |                                 |                                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |  |   |  |                    |   |
| MI    | PFBS (GSI)                                | 670   | Animals (mice) | Feng et al., 2017               | Thyroid effects                |         | BMDL                            |                                 | 300   | 3            | 10           | 1              | 10                  | 1  |   | 1.13x10 <sup>-3</sup>                      | 0.01  |  |                    | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |
| MN    | PFOA (Short Term, Subchronic, Chronic)    | 0.00024   | Human          | Abraham et al. 2020             | Decreased antibodies           | 20%     | 2.8 ng/mL (serum concentration) | 2.8 ng/mL (serum concentration) | 3     |              |              |                | 3                   |  |   | 0.93 ng/mL (reference serum concentration) | 95th percentile   | Half-life 902 days; placental transfer 83%; breastmilk transfer 6.8% |                    | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf</a>   |
|       | PFOA (Cancer)                             | 0.0000079   | Human          | Shearer et al 2021              | Kidney Cancer                  |         | CSF = 0.0126 per ng/kg-d        |                                 |       |              |              |                |                     |  |   |  |   |  | Lifetime           | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfoa2024.pdf</a>   |
|       | PFOS (Short Term, Subchronic, Chronic)    | 0.0023  | Human          | Wikström et al                  | Low birth weight               | 20%     | 7.7 ng/mL (serum concentration) | 7.7 ng/mL (serum concentration) | 3     |              |              |                | 3                   |  |   | 2.6 ng/mL (reference serum concentration)  | 95th percentile   | Half-life 996 days; placental transfer 39%, breastmilk transfer 3%   |                    | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf</a>   |
|       | PFOS (Cancer)                             | 0.0076  | Animal (Rat)   | Butenhoff et al 2012            | Liver cancer                   |         | CSF = 13 per mg/kg-d            |                                 |       |              |              |                |                     |  |   |  |   |  | Lifetime           | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfos.pdf</a>   |
|       | PFBA (Short-term, Subchronic and chronic) | 7 [Short-term value was lower than calculated subchronic and chronic values. Therefore all durations set to short-term] | Animals (rats) | NOTOX, 2007 and Butenhoff, 2007 | Liver effects, Thyroid effects | 50      | 3.01 mg/kg/day                  | 0.38                            | 100   | 3            | 10           |                | 3                   |  |   | 3.8x10 <sup>-3</sup>                       | 95th percentile   | Half-life 72 hrs; placental transfer ND; breastmilk transfer ND      | Infants and Adults | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfba2summ.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/gw/pfba2summ.pdf</a>   |





| State | PFAS  | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study  | Endpoint               | RSC (%) | POD                                  | HED (mg/kg/day) | UFs   |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes    |                      |                                   |                                 |  |   |
|-------|---|------------------------|----------------|--|------------------------|---------|--------------------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|--------------------|----------------------|----------------------|-----------------------------------|---------------------------------|--|---|
|       |   |                        |                |  |                        |         |                                      |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |                    |                      | Modifying Factor     |                                   |                                 |  |   |
| NH    | PFOA  | 0.012                  | Animal (mice)  | Loveless et al., 2007  | Hepatotoxicity         | 50      | BMDL10                               |                 | 100   | 3            | 10           |                | 3                   |  |   |                 |   |                      |                    | 6.1x10 <sup>-6</sup> | 95th percentile      | MDH Model                         | Fetus and Breastfeeding Infants |  |   |
|       | PFOS  | 0.015                  | Animal (mice)  | Dong et al., 2011  | Immunosuppression      | 50      | NOAEL                                |                 | 100   | 3            | 10           |                | 3                   |  |   |                 |   |                      |                    | 3x10 <sup>-6</sup>   | 95th percentile      | MDH Model                         | Fetus and Breastfeeding Infants |  |   |
|       | PFNA  | 0.011                  | Animal (mice)  | Das et al., 2015   | Hepatotoxicity         | 50      | BMDL10                               |                 | 100   | 3            | 10           |                | 3                   |  |   |                 |   |                      |                    | 4.3x10 <sup>-6</sup> | 95th percentile      | MDH Model                         | Fetus and Breastfeeding Infants |  |   |
|       | PFHxS   | 0.018                  | Animal (mice)  | Chang et al., 2018 and Ali et al., 2019  | Infertility            | 50      | BMDLSD                               |                 | 300   | 3            | 10           |                | 3                   | 3  |   |                 |   |                      |                    | 4x10 <sup>-6</sup>   | 95th percentile      | MDH Model                         | Fetus and Breastfeeding Infants | c  |   |
| NJ    | PFOA  | 0.014                  | Animals (mice) | Loveless et al., 2006  | Hepatotoxicity         | 20      | BMDL                                 |                 | 300   | 3            | 10           |                |                     |  |   | 10              |   |                      |                    | 2x10 <sup>-6</sup>   | 2 (70 kg body wt)    | Default adult                     |                                 | Note: MCLs for PFOA, PFOS, and PFNA are also used as Ground Water Quality Standards. |   |
|       | PFOS  | 0.013                  | Animals (mice) | Dong et al., 2009  | Immunotoxicity         | 20      | NOAEL                                |                 | 30    | 3            | 10           |                |                     |  |   |                 |   |                      |                    | 1.8x10 <sup>-6</sup> | 2 (70 kg body wt)    | Default adult                     |                                 |  |   |
|       | PFNA  | 0.013                  | Animals (mice) | Das et al., 2015   | Hepatotoxicity         | 50      | BMDL                                 |                 | 1000  | 3            | 10           |                | 3                   | 10   |   |                 |   |                      |                    |                      |                      | 200:1 serum: drinking water ratio |                                 |  |   |
|       | Chloroperfluoropolyether carboxylates (CIPFPECAs) | 0.002                  | Animals (rats) | RTC. 2016. Posted at <a href="https://www.nj.gov/dep/dsr/13-week-oral-toxicity-study-in-rats-2016.pdf">https://www.nj.gov/dep/dsr/13-week-oral-toxicity-study-in-rats-2016.pdf</a> | Hepatotoxicity         | 20      | BMDL                                 |                 | 3000  | 3            | 10           |                | 10                  | 10   |   |                 |   |                      |                    |                      | 2.8x10 <sup>-7</sup> | 2.4 (80 kg body wt)               |                                 |  | Interim Specific Ground Water Quality Standard <a href="https://www.state.nj.us/dep/wms/bears/gwqs.htm">https://www.state.nj.us/dep/wms/bears/gwqs.htm</a> and <a href="https://www.nj.gov/dep/dsr/supportdocs/CIPFPECAs-tsd.pdf">https://www.nj.gov/dep/dsr/supportdocs/CIPFPECAs-tsd.pdf</a>    |
|       | HFPO-DA and its ammonium salt (GenX)              | 0.02                   | Animals (mice) | DuPont 18405-1037 (2010)   | Hepatic histopathology | 20      | BMDL <sub>10</sub> of 0.09 mg/kg/day | 0.01            | 3000  | 3            | 10           |                | 1                   | 10   | 10  | NA              | NA  |                      |                    |                      | 3 x 10 <sup>-6</sup> | 2.4                               | 80 kg body weight               | General population adult   | Interim Specific Ground Water Criterion and Standard. See <a href="https://www.nj.gov/dep/wms/bears/gwqs.htm">https://www.nj.gov/dep/wms/bears/gwqs.htm</a> and <a href="https://dep.nj.gov/dsr/igwqc-technical-support-documents/">https://dep.nj.gov/dsr/igwqc-technical-support-documents/</a> |

| State | PFAS  | Guideline Level (ug/L)                 | Toxicity Data           | Critical Effect Study                  | Endpoint   | RSC (%) | POD   | HED (mg/kg/day)  | UFs   |              |              |                |                     | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations          | Resources & Notes   |  |   |
|-------|-------|--|-------------------------|--|--|---------|---|--|-------|--------------|--------------|----------------|---------------------|-----------------|---|----------------------|-----------------------------|---|--|---|
|       |       |  |                         |  |  |         |   |  | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |                 |   |                      |                             |   | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations   |
| NM    | PFOA  | 0.07*                                  |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
|       | PFOS  | 0.07*                                  |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
|       | PFHxS | 0.07*                                  |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
| NY    | PFOA  | 0.01                                   |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
|       | PFOS  | 0.01                                   |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
| PA    | PFOA  | 0.07                                   |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
|       | PFOS  | 0.07                                   |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
|       | PFBS  | 10 (residential), 29 (non-residential) |                         |  |  |         |   |  |       |              |              |                |                     |                 |   |                      |                             |   |  |   |
| TX    | PFBA  | 24                                     | Animals (male rats)     | Butenhoff et al., 2012                 | hepatocellular hypertrophy and decreased total thyroxine (T4)    |         | 5.4 mg/kg-d (BMDL10 for hepatocellular hypertrophy) and 6 mg/kg-d (NOAEL for decreased total thyroxine) | 1.15 mg/kg-d (hepatocellular hypertrophy) and 1.27 mg/kg-d (decreased total thyroxine) | 1000  | 3            | 10           |                | 3                   | 10              |   |                      | 1x10 <sup>-3</sup>          | See the equations and input values in §350.74 of the Texas Risk Reduction Program (TRRP) rule | residents (adult, child)                           | TRRP rule website <a href="https://www.tceq.texas.gov/remediation/trrp">https://www.tceq.texas.gov/remediation/trrp</a> |
|       | PFBuS | 34                                     | Animals (mice)          | Leider et al., 2009, York et al., 2002 | Systemic Toxicity  |         | NOAEL (60 mg/kg/d)  |  | 42600 | 1            | 10           |                | 10                  | 3               |   |                      | 1.4x10 <sup>-3</sup>        |   |  |   |
|       | PFPeA | 12                                     | Animals (mice)          | Surrogate PFHxA                        | Developmental (decreased offspring body weight)                  |         | 10.62 mg/kg-day   | 0.048 mg/kg-day  | 100   | 3            | 10           |                | 3                   |                 |   |                      | 5E-4 mg/kg-day <sup>2</sup> |   |  | Surrogate PFHxA   |
|       | PFHxS | 0.093                                  | Animals (mice)          | Hoberman and York, 2003                | Hematotoxicity   |         | NOAEL (0.3 mg/kg/d)   |  | 78900 | 1            | 10           |                | 3                   | 10              |   |                      | 3.8x10 <sup>-6</sup>        |   |  |   |
|       | PFHxA | 12                                     | Animals (pregnant rats) | Loveless et al., 2009                  | decreased offspring body weight in neonatal male and female rats |         | 10.62 mg/kg-d (BMDL5)   | 0.048 mg/kg-d  | 100   | 3            | 10           |                | 3                   |                 |   |                      | 5x10 <sup>-4</sup>          | See the equations and input values in §350.74 of the Texas Risk Reduction Program (TRRP) rule | residents (adult, child)                           | TRRP rule website <a href="https://www.tceq.texas.gov/remediation/trrp">https://www.tceq.texas.gov/remediation/trrp</a> |
|       | PFHpA | 0.56                                   | Animals (mice)          | Surrogate: PFOS                        | Neurodevelopment   |         | NOAEL (0.6 mg/kg/d)   |  | 26300 | 1            | 10           |                | 10                  | 1               |   |                      | 2.3x10 <sup>-5</sup>        |   |  |   |
|       | PFOS  | 0.56                                   | Animals (mice)          | Zeng et al., 2011                      | Neurodevelopment   |         | NOAEL (0.6 mg/kg/d)   |  | 26300 | 1            | 10           |                | 10                  | 1               |   |                      | 2.3x10 <sup>-5</sup>        |   |  |   |

| State | PFAS                             | Guideline Level (ug/L) | Toxicity Data           | Critical Effect Study  | Endpoint   | RSC (%) | POD                 | HED (mg/kg/day) | UFs        |              |              |                |                     |  |   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations                              | Resources & Notes |                  |              |   |
|-------|----------------------------------|------------------------|-------------------------|------------------------|--|---------|---------------------|-----------------|------------|--------------|--------------|----------------|---------------------|--|---|-----------------|---|----------------------|---|-------------------|------------------|--------------|---|
|       |                                  |                        |                         |                        |  |         |                     |                 | Total      | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints/ Subpopulations |                 |   |                      |   |                   | Modifying Factor |              |   |
| TX    | PFOA                             | 0.29                   | Animals (mice)          | Macon et al., 2011     | Mammary gland development  |         | NOAEL (0.3 mg/kg/d) |                 | 24300      | 1            | 10           | 30             | 1                   |  |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFOSA                            | 0.29                   | Animals (mice)          | Surrogate: PFOA        | Mammary gland development  |         | NOAEL (0.3 mg/kg/d) |                 | 24300      | 1            | 10           | 30             | 1                   |  |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFNA                             | 0.29                   | Animals (mice)          | Fang et al., 2010      | Spleen Cell Death  |         | NOAEL (1 mg/kg/d)   |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFDeA                            | 0.37                   | Animals (mice)          | Kawashima et al., 1995 | Hepatotoxicity   |         | NOAEL (1.2 mg/kg/d) |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.5x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFDS                             | 0.29                   | Animals (mice)          | Surrogate: PFDoA       | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)   |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFOA                             | 0.29                   | Animals (mice)          | Surrogate: PFDoA       | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)   |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFDoA                            | 0.29                   | Animals (mice)          | Shi et al., 2007       | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)   |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
|       | PFTeDA                           | 0.29                   | Animals (mice)          | Surrogate: PFDoA       | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)   |                 | 81000      | 1            | 10           |                | 10                  | 10   |   |                 |   | 1.2x10 <sup>-5</sup> |   |                   |                  |              |   |
| VT    | PFOA, PFOS, PFHxS, PFHpA, PFNA   | 0.02*                  | Animals (mice)          | EPA (2016)             | EPA (2016)   | 20      | EPA (2016)          |                 | EPA (2016) |              |              |                |                     |  |   |                 |   |                      | 0.175 L/kg/day                                  |                   |                  | 0-1 year old |   |
| WA    | PFOA                             | 10 ng/L                |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
|       | PFOS                             | 15 ng/L                |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
|       | PFNA                             | 9 ng/L                 |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
|       | PFHxS                            | 65 ng/L                |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
|       | PFBS                             | 345 ng/L               |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
|       | HFPO-DA (GenX)                   | 24 ng/L                |                         |                        |  |         |                     |                 |            |              |              |                |                     |  |   |                 |   |                      |   |                   |                  |              |   |
| WI    | PFOA                             | 0.02 (combined)*       | Animals (mice)          | Lau et al., 2006       | Developmental (reduced ossification)                                   | 100     | LOAEL               |                 | 300        | 10           | 3            | 10             |                     |  |   |                 |   |                      |   |                   |                  |              | <a href="https://www.dhs.wisconsin.gov/water/gws.htm">https://www.dhs.wisconsin.gov/water/gws.htm</a>                 |
|       | PFOS                             | 0.02 (combined)*       | Animals (mice)          | Luebker et al., 2005   | Reduced pup body weight  | 100     | NOAEL               |                 | 30         | 3            | 10           |                |                     | 10   |   |                 |   | 1 (10 kg body wt)    | Gestation and infancy (including breastfeeding) |                   |                  |              |   |
|       | FOSA, NETFOSA, NETFOSAA, NETFOSE | 0.02 (combined)*       | PFOA and PFOS Precursor |                        | Combined standard for PFOS, PFOA, FOSA, NETFOSE, NETFOSA, and NETFOSAA | 100     |                     |                 |            |              |              |                |                     |  |   |                 |   | Combined             |   |                   |                  |              | <a href="https://www.dhs.wisconsin.gov/water/gws-cycle11.htm">https://www.dhs.wisconsin.gov/water/gws-cycle11.htm</a> |

| State | PFAS  | Guideline Level (ug/L) | Toxicity Data  | Critical Effect Study         | Endpoint  | RSC (%) | POD                      | HED (mg/kg/day) | UFs   |              |              |                |                     |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes |   |   |
|-------|-------|------------------------|----------------|-------------------------------|---|---------|--------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|--|-----------------|---|----------------------|--------------------|-------------------|---|---|
|       |       |                        |                |                               |   |         |                          |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) |                 |   |                      |                    |                   | Sensitive Developmental Endpoints/ Subpopulations | Modifying Factor  |
|       | PFTeA | 10                     | Animals (rats) | Hirata-Koizumi et al., 2015   | Body weight   | 100     | NOAEL (1 mg/kg/day)      |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.001                | 1                  |                   |   |   |
|       | PFHxA | 150                    | Animals (rats) | Klaunig, 2015                 | Clinical effects  | 100     | NOAEL (15 mg/kg/day)     |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.015                | 1                  |                   |   |   |
|       | PFUnA | 3                      | Animals (rats) | Takahashi et al., 2014        | Body weight   | 100     | NOAEL (0.3 mg/kg/day)    |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.0003               | 1                  |                   |   |   |
|       | PFDoA | 0.5                    | Animals (rats) | Shi, 2009                     | Body weight and testosterone levels                                 | 100     | NOAEL (0.05 mg/kg/day)   |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 5x10 <sup>-5</sup>   | 1                  |                   |   |   |
|       | PFBA  | 10                     | Animals (rats) | van Otterdyk, Buitenhof 2012b | Hemotoxicity, hepatotoxicity, and thyroid toxicity                  | 100     | BMDL (MN) (3 mg/kg/day)  |                 | 3000  | 10           | 10           | 1              | 10                  | 3  | 1               |   | 0.001                | 1                  |                   |   |   |
|       | PFBS  | 450                    | Animals (rats) | Lieder, 2009b                 | Nephrotoxicity  | 100     | BMDL (MN) (45 mg/kg/day) |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.045                | 1                  |                   |   | <a href="https://www.dhs.wisconsin.gov/water/gws-cycle11.htm">https://www.dhs.wisconsin.gov/water/gws-cycle11.htm</a> |
|       | PFNA  | 0.03                   | Animals (mice) | Das, 2015                     | Reproductive toxicity   | 100     | NOAEL (1 mg/kg/day)      | 0.0011          | 300   | 3            | 10           | 1              | 1                   | 1  | 10              |   | 3x10 <sup>-6</sup>   | 1                  |                   |   |   |
|       | PFDA  | 0.3                    | Animals (mice) | Harris and Birnbaum 1989      | Developmental (Fetal growth)  | 100     | NOAEL (0.03 mg/kg/day)   |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 3x10 <sup>-5</sup>   | 1                  |                   |   |   |
|       | PFHxS | 0.04                   | Animals (rats) | Cheng, 2018                   | Developmental and reproductive toxicity (Maternal and fetal growth) | 100     | NOAEL (0.3 mg/kg/day)    |                 | 300   | 3            | 10           | 1              | 10                  | 1  | 1               |   | 4x10 <sup>-6</sup>   | 1                  |                   |   |   |
|       | PFODA | 400                    | Animals (rats) | Hirata-Koizumi, 2012          | Body weight   | 100     | NOAEL (40 mg/kg/day)     |                 | 1000  | 10           | 10           | 1              | 10                  | 1  | 1               |   | 0.04                 | 1                  |                   |   |   |
|       | Gen X | 0.3                    | Animals (mice) | Dupont, 2010b                 | Nephrotoxicity and hepatotoxicity                                   | 100     | NOAEL (0.1 mg/kg/day)    |                 | 3000  | 10           | 10           | 1              | 10                  | 3  | 1               |   | 3x10 <sup>-5</sup>   | 1                  |                   |   |   |
|       | DONA  | 3                      | Animals (rats) | Gordon, 2011                  | Hemotoxicity and hepatotoxicity                                     | 100     | NOAEL (1 mg/kg/day)      |                 | 3000  | 10           | 10           | 1              | 10                  | 3  | 1               |   | 0.0003               | 1                  |                   |   |   |

\*= Advisory level is based on the total of more than one PFAS







| State | PFAS                         | Guideline Level (ug/L) | Toxicity Data                                   | Critical Effect Study                            | Endpoint   | POD   | UFs   |              |              |                |  | RfD (mg/kg/day)       | Drinking Water Intake Rate (L/day) | Resources & Notes   |
|-------|------------------------------|------------------------|---|--|--|-------|-------|--------------|--------------|----------------|--|-----------------------|------------------------------------|---|
|       |                              |                        |   |  |  |       | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Duration of Exposure (i.e., Subchronic to Chronic) |                       |                                    |   |
| IL    | PFOA                         | 94                     |   |  |  |       |       |              |              |                |  |                       |                                    | US EPA Draft Water Quality Criteria   |
|       | PFOS                         | 8.4                    |   |  |  |       |       |              |              |                |  |                       |                                    | US EPA Draft Water Quality Criteria   |
| MA    | PFOA, PFDA, PFHpA, PFNA      | 40,000                 | Based on MN PCA (2007) SW target value for PFOA |  |  |       |       |              |              |                |  |                       |                                    | Minnesota Pollution Control Agency (2007) surface water target value for PFOA - 1705 ug/L * DAF of 25<br>See <a href="https://www.mass.gov/doc/summary-of-proposed-mcp-method-1-standards-revisions/download">https://www.mass.gov/doc/summary-of-proposed-mcp-method-1-standards-revisions/download</a><br>Concentrations based on the potential environmental effects resulting from contaminated groundwater discharging to surface water. |
|       | PFOS, PFHxS                  | 500                    | Based on MN PCA (2007) SW target value for PFOS |  |  |       |       |              |              |                |  |                       |                                    | Minnesota Pollution Control Agency (2007) surface water target value for PFOS - 19 ug/L * DAF of 25<br>See <a href="https://www.mass.gov/doc/summary-of-proposed-mcp-method-1-standards-revisions/download">https://www.mass.gov/doc/summary-of-proposed-mcp-method-1-standards-revisions/download</a><br>Concentrations based on the potential environmental effects resulting from contaminated groundwater discharging to surface water.   |
| MI    | PFOA (drinking water source) | 0.066                  | Animals (mice)                                  | Onischenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations | LOAEL | 300   | 3            | 10           | 3              | 1  | 3.88x10 <sup>-6</sup> | 2                                  | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>3x Database uncertainty factor included in Total UF  |
|       | PFOA                         | 0.17                   | Animals (mice)                                  | Onischenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations | LOAEL | 300   | 3            | 10           | 3              | 1  | 3.88x10 <sup>-6</sup> | 0.01                               | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>3x Database uncertainty factor included in Total UF  |



| State | PFAS                         | Guideline Level (ug/L) | Toxicity Data      | Critical Effect Study | Endpoint   | POD   | UFs   |              |              |                |  | RfD (mg/kg/day)       | Drinking Water Intake Rate (L/day) | Resources & Notes   |
|-------|------------------------------|------------------------|--------------------|-----------------------|--|-------|-------|--------------|--------------|----------------|--|-----------------------|------------------------------------|---|
|       |                              |                        |                    |                       |  |       | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Duration of Exposure (i.e., Subchronic to Chronic) |                       |                                    |   |
| MI    | PFOS (drinking water source) | 0.011                  | Animals (primates) | Seacat et al., 2002   | Decreased body weight, hepatotoxicity, thyroid effects | NOAEL | 30    | 3            | 10           |                |  | 1.37x10 <sup>-5</sup> | 2                                  | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a>   |
|       | PFOS                         | 0.012                  | Animals (primates) | Seacat et al., 2002   | Decreased body weight, hepatotoxicity, thyroid effects | NOAEL | 30    | 3            | 10           |                |  | 1.37x10 <sup>-5</sup> | 0.01                               | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a>   |
|       | PFBS (drinking water source) | 8.3                    | Animals (mice)     | Feng et al., 2017     | Thyroid effects  | BMDL  | 300   | 3            | 10           |                |  | 1.13x10 <sup>-3</sup> | 2                                  | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |
|       | PFBS                         | 670                    | Animals (mice)     | Feng et al., 2017     | Thyroid effects  | BMDL  | 300   | 3            | 10           |                |  | 1.13x10 <sup>-3</sup> | 0.01                               | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |
|       | PFNA (drinking water source) | 0.019                  | Animals (mice)     | Das et al., 2015      | Reduced pup body weight, developmental effects         | NOAEL | 300   | 3            | 10           |                |  | 2.2x10 <sup>-6</sup>  | 2                                  | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |
|       | PFNA                         | 0.03                   | Animals (mice)     | Das et al., 2015      | Reduced pup body weight, developmental effects         | NOAEL | 300   | 3            | 10           |                |  | 2.2x10 <sup>-6</sup>  | 0.01                               | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>10x Database uncertainty factor included in Total UF |

| State | PFAS                          | Guideline Level (ug/L)                                  | Toxicity Data  | Critical Effect Study | Endpoint   | POD  | UFs                              |              |              |                |  | RfD (mg/kg/day)       | Drinking Water Intake Rate (L/day) | Resources & Notes  |
|-------|-------------------------------|---|----------------|-----------------------|--|------|----------------------------------|--------------|--------------|----------------|--|-----------------------|------------------------------------|--|
|       |                               |   |                |                       |  |      | Total                            | Interspecies | Intraspecies | LOAEL to NOAEL | Duration of Exposure (i.e., Subchronic to Chronic) |                       |                                    |  |
| MI    | PFHxS (drinking water source) | 0.059   | Animals (rats) | NTP, 2019             | Thyroid effects  | BMDL | 1000                             | 3            | 10           |                | 10   | 2.92x10 <sup>-6</sup> | 2                                  | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>3x Database uncertainty factor included in Total UF |
|       | PFHxS                         | 0.21  | Animals (rats) | NTP, 2019             | Thyroid effects  | BMDL | 1000                             | 3            | 10           |                | 10   | 2.92x10 <sup>-6</sup> | 0.01                               | <a href="https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values">https://www.michigan.gov/egle/about/organization/Water-Resources/assessment-michigan-waters/rule-57-water-quality-values</a><br><br>3x Database uncertainty factor included in Total UF |
| MN    | PFOS                          | 0.37 ng/g (fish tissue)<br>0.00005 ug/L (surface water) | Animals (mice) | Dong et al., 2011     | Immunotoxicity, adrenal, developmental effects, liver effects, thyroid effects           |      | Based on MDH toxicity assessment |              |              |                |  | 3.1x10 <sup>-6</sup>  |                                    | For more information visit the MPCA site-specific water quality criteria webpage:<br><a href="https://www.pca.state.mn.us/business-with-us/site-specific-water-quality-criteria">https://www.pca.state.mn.us/business-with-us/site-specific-water-quality-criteria</a>   |
|       | PFBS                          | 0.14 (Class 1/2A/2Bd)<br>0.35 (Class 2B/2D)             | Animals (rats) | NTP 2019              | thyroid (endocrine)  |      | Based on MDH toxicity assessment |              |              |                |  | 8.40E-05              |                                    |  |
|       | PFBA                          | 5.7 (Class 1/2A/2Bd)<br>10 (Class 2B/2D)                | Animals (rats) | NOTOX 2007            | developmental, hematological (blood) system, hepatic (liver) system, thyroid (endocrine) |      | Based on MDH toxicity assessment |              |              |                |  | 2.90E-03              |                                    |  |
|       | PFHxS                         | 0.020 (Class 1/2A/2Bd)<br>0.036 (Class 2B/2D)           | Animals (rats) | NTP 2018              | hepatic (liver), thyroid (endocrine)   |      | Based on MDH toxicity assessment |              |              |                |  | 9.70E-06              |                                    |  |

| State | PFAS  | Guideline Level (ug/L)                        | Toxicity Data  | Critical Effect Study | Endpoint  | POD | UFs                              |              |              |                |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day) | Resources & Notes   |
|-------|---|---|----------------|-----------------------|---|-----|----------------------------------|--------------|--------------|----------------|--|-----------------|------------------------------------|---|
|       |   |   |                |                       |   |     | Total                            | Interspecies | Intraspecies | LOAEL to NOAEL | Duration of Exposure (i.e., Subchronic to Chronic) |                 |                                    |   |
| MN    | PFHxA   | 0.22 (Class 1/2A/2Bd)<br>0.95 (Class 2B/2D)   | Animals (rats) | Loveless et al. 2009  | developmental, hepatic (liver) system, respiratory system, thyroid (endocrine)        |     | Based on MDH toxicity assessment |              |              |                |  | 1.50E-04        |                                    | For more information visit the MPCA site-specific water quality criteria webpage: <a href="https://www.pca.state.mn.us/business-with-us/site-specific-water-quality-criteria">https://www.pca.state.mn.us/business-with-us/site-specific-water-quality-criteria</a> |
|       | PFOA  | 0.025 (Class 1/2A/2Bd)<br>0.088 (Class 2B/2D) | Animals (mice) | Lau et al. 2006       | developmental, hepatic (liver), immune, pancreas, renal (kidney), thyroid (endocrine) |     | Based on MDH toxicity assessment |              |              |                |  | 1.80E-05        |                                    |   |
| MT    | PFOA, PFOS  | 0.07*   |                |                       |   |     |                                  |              |              |                |  |                 |                                    |   |
| NM    | PFOA, PFOS  | 0.07*   |                |                       |   |     |                                  |              |              |                |  |                 |                                    |   |
|       | HFPO-DA, NEtFOSAA, NMeFOSAA, PFBS, PFDA, PFDoA, PFHpA, PFHxS, PFHxA, PFNA, PFTA, PFTTrDA, PFUnA, 11 C1-PF3OUdS, 9C1-PF3ONS, ADONA |   |                |                       |   |     |                                  |              |              |                |  |                 |                                    | Coverage under EPA's 2021 MSGP in NM requires monitoring and analyzing for 18 PFAS compounds using modified EPA Method 537.1. Only PFOA + PFOS are used for screening.  |
| NY    | PFOA  | 0.0067 Human Health                           |                |                       |   |     |                                  |              |              |                |  |                 |                                    | Human Health value is for protection of ambient surface waters used as a drinking water source. Fact sheet - <a href="https://extapps.dec.ny.gov/docs/water_pdf/pfoahumanhealth.pdf">https://extapps.dec.ny.gov/docs/water_pdf/pfoahumanhealth.pdf</a>              |

| State | PFAS                                 | Guideline Level (ug/L)   | Toxicity Data  | Critical Effect Study           | Endpoint                     | POD                       | UFs   |              |              |                |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day) | Resources & Notes  |
|-------|--------------------------------------|--|----------------|---------------------------------|------------------------------|---------------------------|-------|--------------|--------------|----------------|--|-----------------|------------------------------------|--|
|       |                                      |  |                |                                 |                              |                           | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Duration of Exposure (i.e., Subchronic to Chronic) |                 |                                    |  |
| NY    | PFOS                                 | 0.0027 Human Health; 160 Aquatic Chronic Fresh; 710 Aquatic Acute Fresh; 41 Aquatic Chronic Saline; 190 Aquatic Acute Saline |                |                                 |                              |                           |       |              |              |                |  |                 |                                    | Human Health value is for protection of ambient surface waters used as a drinking water source. Fact sheet - <a href="https://extapps.dec.ny.gov/docs/water_pdf/pfoshumanhealth.pdf">https://extapps.dec.ny.gov/docs/water_pdf/pfoshumanhealth.pdf</a> Aquatic life fact sheet - <a href="https://extapps.dec.ny.gov/docs/water_pdf/pfosaquaticlife.pdf">https://extapps.dec.ny.gov/docs/water_pdf/pfosaquaticlife.pdf</a> |
| OR    | PFOA                                 | 24   |                |                                 |                              |                           |       |              |              |                |  |                 |                                    | Note: The Oregon wastewater initiation levels were adopted into rule (OAR 340-045-0100, Table A) in 2011. The PFAS are 5 chemicals on a list of 118 persistent priority pollutants for water that Oregon DEQ developed in  |
|       | PFOS                                 | 300  |                |                                 |                              |                           |       |              |              |                |  |                 |                                    |  |
|       | PFNA                                 | 1  |                |                                 |                              |                           |       |              |              |                |  |                 |                                    |  |
|       | PFOSA                                | 0.2  |                |                                 |                              |                           |       |              |              |                |  |                 |                                    |  |
|       | PFHpA                                | 300  |                |                                 |                              |                           |       |              |              |                |  |                 |                                    |  |
| RI    | PFOA, PFOS, PFHxS, PFNA, PFHpA, PFDA | 0.02*  |                |                                 |                              |                           |       |              |              |                |  |                 |                                    |  |
| WI    | PFOS                                 | 0.008  | Animals (rats) | Luebker et al. 2005             | Reduced pup body weight gain | 0.00051 (NOAEL)           | 30    | 3            | 10           | 1              | 1  | 0.00002         |                                    | This criterion applies to waters that contain fish or are connected to waters that contain fish. The Technical Support Document for this rule can be found at: <a href="https://dnr.wisconsin.gov/sites/default/files/topic/SurfaceWater/WY-23-19PFOS-PFOA_TechSupportDoc.pdf">https://dnr.wisconsin.gov/sites/default/files/topic/SurfaceWater/WY-23-19PFOS-PFOA_TechSupportDoc.pdf</a>                                   |
|       | PFOA                                 | 0.02   | Animals (mice) | Lau et al. 2006, Kieskam et al. | Reduced ossification at      | 0.00054 mg/kg-d (HED from | 300   | 10           | 3            | 10             | 1  | 0.00002         | 1                                  | The 20 ppt criterion applies to surface waters that are used as a source of drinking water,  |
|       | PFOA                                 | 0.095  |                |                                 |                              |                           |       |              |              |                |  |                 | 0.21                               |  |

\*= Advisory level is based on the total of more than one PFAS

## Appendix D: State Soil PFAS Guideline Criteria

| State | PFAS                           | Guideline Level (mg/kg, unless otherwise specified)  | Toxicity Data  | Critical Effect Study | Endpoint   | RSC (%) | POD                            | UFs        |              |              |                |                     |  |                                   | RfD (mg/kg/day)    | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions  | Target Populations | Resources & Notes   |
|-------|--------------------------------|--|----------------|-----------------------|--|---------|--------------------------------|------------|--------------|--------------|----------------|---------------------|--|-----------------------------------|--------------------|---|---|--------------------|---|
|       |                                |  |                |                       |  |         |                                | Total      | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                    |   |   |                    |   |
| AK    | PFOA                           | 2.2 in Arctic Zone, 1.6 under 40" zone, 1.3 over 40" zone, 0.003 migration to groundwater  | Animals (mice) | Lau et al., 2006      | Decreased ossification of pup proximal phalanges, accelerated preputial separation | 100     | EPA (2016)                     | EPA (2016) |              |              |                |                     |  |                                   |                    |   | Residential exposure for 6 yrs old child receptor                       | Child              | <a href="http://dec.alaska.gov/media/7543/20180201_pccl.pdf">http://dec.alaska.gov/media/7543/20180201_pccl.pdf</a> |
|       | PFOS                           | 2.2 in Arctic Zone, 1.6 under 40" zone, 1.3 over 40" zone, 0.0017 migration to groundwater   | Animals (mice) | Luebker et al., 2005  | Reduced pup body weight  | 100     | EPA (2016)                     | EPA (2016) |              |              |                |                     |  |                                   |                    |   | Residential exposure for 6 yrs old child receptor                       | Child              | <a href="http://dec.alaska.gov/media/7543/20180201_pccl.pdf">http://dec.alaska.gov/media/7543/20180201_pccl.pdf</a> |
| CT    | PFOA, PFOS, PFHxS, PFHpA, PFNA | 1.35 (residential), 41 (industrial/ commercial), 1.4 ug/kg (GA pollutant mobility criteria), 14 ug/kg (GB pollutant mobility criteria) |                |                       |  |         |                                |            |              |              |                |                     |  |                                   |                    |   | Residential and industrial/ commercial are for direct exposure criteria |                    |   |
| FL    | PFOA                           | 1.3 (residential), 25 (industrial/ commercial), 0.002 (leachability) Soil Cleanup Target Levels  | Animals (mice) | Lau et al., 2006      | Decreased ossification of pup proximal phalanges, accelerated preputial separation | 20      | 5.3x10 <sup>-3</sup> mg/kg/day | 300        | 3            |              |                |                     |  | 10                                | 2x10 <sup>-5</sup> | 0.054 L/kg/day  | Children- 200 mg/day, worker- 50 mg/day, oral                           | Children ages 0-6  |   |
|       | PFOS                           | 1.3 (residential), 25 (industrial/ commercial), 0.007 (leachability) Soil Cleanup Target Levels  | Animals (mice) | Luebker et al., 2005  | decreased weight   | 20      | 5.1x10 <sup>-4</sup> mg/kg/day | 30         | 3            |              |                |                     |  | 10                                | 2x10 <sup>-5</sup> | 0.054 L/kg/day  | Risk target level of 10 <sup>-6</sup> and hazard quotient of 1          | Children ages 0-6  |   |



| State | PFAS               | Guideline Level (mg/kg, unless otherwise specified)   | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions   | Target Populations | Resources & Notes   |
|-------|--------------------|---|---------------|-----------------------|----------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|--|-----------------|---|--|--------------------|---|
|       |                    |   |               |                       |          |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |  |                 |   |  |                    |   |
| HI    | PFHpS <sup>-</sup> | 0.13 (residential), 1.1 (industrial/commercial), 0.0079 (dw leaching to gw), 0.0079 (non-dw leaching to gw)   |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | Noncancer HQ = 1.0, RSC = 20% and USEPA RSL default exposure parameter values. SESOIL leaching model.                                      |                    |   |
|       | PFDS <sup>-</sup>  | 0.13 (residential), 1.1 (industrial/commercial), 0.025 (dw leaching to gw), 0.025 (non-dw leaching to gw)     |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | Consideration of TOPs and TOF data and calculation of cumulative Hazard Index required for all sites using approach in                     |                    |   |
|       | PFBA <sup>-</sup>  | 48 (residential), 430 (industrial/commercial), 0.19 (dw leaching to gw), 11 (non-dw leaching to gw)           |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | accompanying HDOH guidance or approved, alternative approach. SPLP data +/- Method 1314 soil column data recommended to assess             |                    | <a href="https://health.hawaii.gov/health/guidance/ehe-and-eals/">https://health.hawaii.gov/health/guidance/ehe-and-eals/</a> |
|       | PFPeA <sup>-</sup> | 5.1 (residential), 45 (industrial/commercial), 0.0059 (dw leaching to gw), 0.0059 (non-dw leaching to gw)     |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | leaching risk to groundwater when SESOIL-based action level exceeded. Drinking water action  |                    |   |
|       | PFHxA <sup>-</sup> | 6.3 (residential), 5 (industrial/commercial), 0.0064 (dw leaching to gw), 21 (non-dw leaching to gw)          |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | preliminarily applied to groundwater that is not a source of drinking water when aquatic toxicity action levels not available. Alternative |                    |   |
|       | PFHpA <sup>-</sup> | 0.25 (residential), 2.3 (industrial/commercial), 0.00055 (dw leaching to gw), 0.00055 (non-dw leaching to gw) |               |                       |          | 20      |     |       |              |              |                |                     |  |                                   |  |                 |   | target groundwater action levels and soil leaching action levels can be proposed on a site-specific basis.                                 |                    |   |







| State | PFAS    | Guideline Level (mg/kg, unless otherwise specified)   | Toxicity Data         | Critical Effect Study | Endpoint                         | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)                 | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|---------|---|-----------------------|-----------------------|----------------------------------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|---------------------------------|---|----------------------|--------------------|---|
|       |         |   |                       |                       |                                  |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                                 |   |                      |                    |   |
| IA    | PFOA    | 35  |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 1.5E-09                         |   |                      | Residential        | EPA   |
|       | PFOS    | 0.00048   |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 7.9E-09                         |   |                      | Residential        | EPA   |
|       | PFBS    | 18  |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 0.0003                          |   |                      | Residential        | EPA   |
|       | PFHxS   | 1.6   |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 0.00002                         |   |                      | Residential        | ATSDR   |
|       | PFNA    | 0.18  |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 0.000003                        |   |                      | Residential        | ATSDR   |
|       | HFPO-DA | 0.18  |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 0.000003                        |   |                      | Residential        | EPA/PPRTV   |
|       | PFBA    | 61  |                       |                       |                                  |         |     |       |              |              |                |                     |  |                                   | 0.001                           |   |                      | Residential        | EPA   |
| IL    | PFBA    | Resident: 78.2 mg/kg<br>Industrial Commercial: 2040 mg/kg<br>Construction Worker: 1220 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.0493 mg/kg                    |                       |                       |                                  | 20      |     |       |              |              |                |                     |  |                                   | 1E-3 chronic<br>6E-3 subchronic | Noncancer<br>HQ = 1   |                      |                    | IRIS toxicity value   |
|       | PFHxA   | Resident: 39.1 mg/kg<br>Industrial Commercial: 1020 mg/kg<br>Construction Worker: 102 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.0169 mg/kg                     |                       |                       |                                  | 20      |     |       |              |              |                |                     |  |                                   | 5.00E-04                        | Noncancer<br>HQ = 1   |                      |                    | IRIS toxicity value   |
|       | PFOA    | Resident: 0.00448 mg/kg<br>Industrial Commercial: 0.04 mg/kg<br>Construction Worker: 0.612 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.000181 mg/kg <sup>b</sup> | Animals (Rats/Cancer) | NTP 2018. TR-598      | Cancer (Liver/Pancreatic tumors) | 20      |     |       |              |              |                |                     |  |                                   | 3E-6 SF=143                     | Noncancer<br>HQ = 1   |                      |                    | ATSDR/Cal OEHHA toxicity values <sup>b</sup> Part 620 requires if a calculated health-based groundwater standard is less than the LCMRL or LLOQ for a chemical, the LCMRL or LLOQ becomes the standard/Health Advisory Level. |

| State | PFAS            | Guideline Level (mg/kg, unless otherwise specified)   | Toxicity Data                | Critical Effect Study | Endpoint                                   | RSC (%) | POD | UFs   |              |              | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes    |
|-------|-----------------|---|------------------------------|-----------------------|--|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|-----------------|---|----------------------|--------------------|----------------------|
|       |                 |   |                              |                       |  |         |     | Total | Interspecies | Intraspecies |                |                     |  |                                   |                 |   |                      |                    |                      |
| IL    | PFNA            | Resident: 0.235 mg/kg<br>Industrial Commercial: 6.13 mg/kg<br>Construction Worker: 0.612 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.00176 mg/kg   | Animals (Mice/Developmental) | Das et al. 2015       | Decreased body weight/developmental delays | 20      |     |       |              |              |                |                     |  |                                   | 3.00E-06        | Noncancer<br>HQ = 1   |                      |                    | ATSDR toxicity value |
|       | PFUnA (PFUDA)   | Resident: 23.5 mg/kg<br>Industrial Commercial: 613 mg/kg<br>Construction Worker: 61.2 mg/kg<br>Soil Component of Groundwater Ingestion Class I: 0.313 mg/kg<br>Soil Component of Groundwater Ingestion Class II: 1.57 mg/kg |                              |                       |  | 20      |     |       |              |              |                |                     |  |                                   | 3.00E-04        | Noncancer<br>HQ = 1   |                      |                    | WI toxicity value    |
|       | PFDODA (PFDODA) | Resident: 3.91 mg/kg<br>Industrial Commercial: 102 mg/kg<br>Construction Worker: 10.2 mg/kg<br>Soil Component of Groundwater Ingestion Class I: 1.19 mg/kg<br>Soil Component of Groundwater Ingestion Class II: 5.96 mg/kg  |                              |                       |  | 20      |     |       |              |              |                |                     |  |                                   | 5.00E-05        | Noncancer<br>HQ = 1   |                      |                    | WI toxicity value    |
|       | PFTA            | Resident: 78.2 mg/kg<br>Industrial Commercial: 2040 mg/kg<br>Construction Worker: 204 mg/kg<br>Soil Component of Groundwater Ingestion Class I: 65.5 mg/kg<br>Soil Component of Groundwater Ingestion Class II: 328 mg/kg   |                              |                       |  | 20      |     |       |              |              |                |                     |  |                                   | 1.00E-03        | Noncancer<br>HQ = 1   |                      |                    | WI toxicity value    |

| State | PFAS    | Guideline Level (mg/kg, unless otherwise specified)  | Toxicity Data                | Critical Effect Study   | Endpoint  | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)                 | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|---------|--|------------------------------|-------------------------|---|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|---------------------------------|---|----------------------|--------------------|---|
|       |         |  |                              |                         |   |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                                 |   |                      |                    |   |
| IL    | PFBS    | Resident: 23.5 mg/kg<br>Industrial Commercial: 613 mg/kg<br>Construction Worker: 184 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.021 mg/kg                    | Animals (Mice/Thyroid)       | Feng, et al. 2017       | Decreased total serum T4 (thyroid) levels                 | 20      |     |       |              |              |                |                     |  |                                   | 3E-4 chronic<br>9E-4 subchronic | Noncancer<br>HQ = 1   |                      |                    | PPRTV toxicity value  |
|       | PFHxS   | Resident: 1.56 mg/kg<br>Industrial Commercial: 40.9 mg/kg<br>Construction Worker: 4.08 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.00119 mg/kg                | Animals (Rats/Thyroid)       | Butenhoff, et al. 2009a | Thyroid follicular damage                                 | 20      |     |       |              |              |                |                     |  |                                   | 2.00E-05                        | Noncancer<br>HQ = 1   |                      |                    | ATSDR toxicity value  |
|       | PFOS    | Resident: 0.156 mg/kg<br>Industrial Commercial: 4.09 mg/kg<br>Construction Worker: 0.408 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.00213 mg/kg              | Animals (Rats/Developmental) | Luebker et al. 2005     | Decreased body weight/delayed eye opening                 | 20      |     |       |              |              |                |                     |  |                                   | 2.00E-06                        | Noncancer<br>HQ = 1   |                      |                    | ATSDR toxicity value  |
|       | HFPO-DA | Resident: 0.235 mg/kg<br>Industrial Commercial: 6.13 mg/kg<br>Construction Worker: 6.12 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.000426 mg/kg <sup>b</sup> | Animals (mice)               | DuPont 18405-1037, 2010 | Developmental (Reproductive effects/Developmental Delays) | 20      |     |       |              |              |                |                     |  |                                   | 3E-6 chronic<br>3E-5 subchronic | Noncancer<br>HQ = 1   |                      |                    | US EPA Office of Water toxicity value <sup>b</sup> Part 620 requires if a calculated health-based groundwater standard is less than the LCMRL or LLOQ for a chemical, the LCMRL or LLOQ becomes the standard/Health Advisory Level. |
|       | HQ-11   | Resident: 23.5 mg/kg<br>Industrial Commercial: 613 mg/kg<br>Construction Worker: 61.2 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.135 mg/kg                   |                              |                         |   | 20      |     |       |              |              |                |                     |  |                                   | 3.00E-04                        | Noncancer<br>HQ = 1   |                      |                    | US EPA ORD toxicity value   |

| State | PFAS  | Guideline Level (mg/kg, unless otherwise specified)  | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD     | UFs     |              |              |                |                     |  |                                   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes         |
|-------|-------|--|---------------|-----------------------|----------|---------|---------|---------|--------------|--------------|----------------|---------------------|--|-----------------------------------|-----------------|---|----------------------|--------------------|---------------------------|
|       |       |  |               |                       |          |         |         | Total   | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                 |   |                      |                    |                           |
| IL    | PFPrA | Resident: 39.1 mg/kg<br>Industrial Commercial: 1020 mg/kg<br>Construction Worker: 102 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.0148 mg/kg  |               |                       |          | 20      |         |         |              |              |                |                     |  |                                   | 5.00E-04        | Noncancer<br>HQ = 1   |                      |                    | US EPA ORD toxicity value |
|       | TFSI  | Resident: 23.5 mg/kg<br>Industrial Commercial: 613 mg/kg<br>Construction Worker: 61.2 mg/kg<br>Soil Component of Groundwater Ingestion Class I and II: 0.0135 mg/kg  |               |                       |          | 20      |         |         |              |              |                |                     |  |                                   | 3.00E-04        | Noncancer<br>HQ = 1   |                      |                    | US EPA ORD toxicity value |
|       | PFODA | Resident: 3130 mg/kg<br>Industrial Commercial: 81800 mg/kg<br>Construction Worker: 8160 mg/kg<br>Soil Component of Groundwater Ingestion Class I: 1510 mg/kg<br>Soil Component of Groundwater Ingestion Class II: 7570 mg/kg |               |                       |          | 20      |         |         |              |              |                |                     |  |                                   | 4.00E-02        | Noncancer<br>HQ = 1   |                      |                    | WI toxicity value         |
| IN    | PFOA  | 0.3  | EPA RSL       | EPA RSL               | EPA RSL  | EPA RSL | EPA RSL | EPA RSL | EPA RSL      | EPA RSL      | EPA RSL        | EPA RSL             | EPA RSL  | EPA RSL                           | EPA RSL         | EPA RSL   | 254 days/yr          | EPA RSL            |                           |
|       | PFOS  | 0.2  | EPA RSL       | EPA RSL               | EPA RSL  | EPA RSL | EPA RSL | EPA RSL | EPA RSL      | EPA RSL      | EPA RSL        | EPA RSL             | EPA RSL  | EPA RSL                           | EPA RSL         | EPA RSL   | 253 days/yr          | EPA RSL            |                           |



| State | PFAS  | Guideline Level (mg/kg, unless otherwise specified)   | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|-------|---|---------------|-----------------------|----------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|-----------------|---|----------------------|--------------------|---|
|       |       |   |               |                       |          |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                 |   |                      |                    |   |
| ME    | PFOA  | 0.017 (leaching to groundwater), 0.26 (residential), 3.4 (commercial worker), 0.74 (park user), 0.85 (recreator sediment), 0.77 (construction worker) |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a> |
|       | PFOS  | 0.001 (leaching to groundwater), 0.17 (residential), 2.2 (commercial worker), 0.49 (park user), 0.57 (recreator sediment), 0.51 (construction worker) |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a> |
|       | PFBS  | 0.11 (leaching to groundwater), 26 (residential), 340 (commercial worker), 74 (park user), 85 (recreator sediment), 230 (construction worker)         |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a> |
|       | PFBA  | 0.36 (leaching to groundwater), 110 (residential), 1,600 (commercial worker), 300 (park user), 350 (recreator sediment), 2,000 (construction worker)  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a> |
|       | PFHxS | 0.00047 (leaching to groundwater), 1.7 (residential), 22 (commercial worker), 4.9 (park user), 5.7 (recreator sediment), 5.1 (construction worker)    |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a> |

| State | PFAS  | Guideline Level (mg/kg, unless otherwise specified)  | Toxicity Data      | Critical Effect Study                            | Endpoint   | RSC (%) | POD   | UFs   |              |              | LOEL to NOEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes   |
|-------|-------|--|--------------------|--|--|---------|-------|-------|--------------|--------------|--------------|---------------------|--|-----------------------------------|-----------------|---|----------------------|--------------------|---|
|       |       |  |                    |  |  |         |       | Total | Interspecies | Intraspecies |              |                     |  |                                   |                 |   |                      |                    |   |
| ME    | PFHxA | 0.13 (leaching to groundwater), 43 (residential), 560 (commercial worker), 120 (park user), 140 (recreator sediment), 130 (construction worker)        |                    |  |  |         |       |       |              |              |              |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a>   |
|       | PFNA  | 0.0046 (leaching to groundwater), 0.26 (residential), 3.4 (commercial worker), 0.74 (park user), 0.85 (recreator sediment), 0.77 (construction worker) |                    |  |  |         |       |       |              |              |              |                     |  |                                   |                 |   |                      |                    | <a href="https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf">https://www.maine.gov/dep/spills/publications/guidance/rags/Maine-Remedial-Action-Guidelines-2023-11-15.pdf</a>   |
| MI    | PFOS  | 2.4x10 <sup>-4</sup>   | Animals (primates) | Seacat et al., 2002                              | Decreased body weight, hepatotoxicity, thyroid effects |         | NOAEL | 30    | 3            | 10           | 1            | 1                   | 1  | 1.37x10 <sup>-5</sup>             |                 |   |                      |                    | Table 2: Soil - Residential<br><br><a href="https://www.michigan.gov/egle/-/media/Project/Websites/egle/Documents/Programs/RRD/Remediation/Rules--Criteria/table-2-soil-residential.pdf?rev=83f3560a75ca41c4b89013dc932455e5&amp;hash=9FED789A3710738F909B80D1B2788238">https://www.michigan.gov/egle/-/media/Project/Websites/egle/Documents/Programs/RRD/Remediation/Rules--Criteria/table-2-soil-residential.pdf?rev=83f3560a75ca41c4b89013dc932455e5&amp;hash=9FED789A3710738F909B80D1B2788238</a>                                      |
|       | PFOA  | 10   | Animals (mice)     | Onischenko et al., 2011 and Koskela et al., 2016 | Neurobehavioral effects and skeletal alterations       |         | LOAEL | 300   | 3            | 10           | 3            | 1                   | 1  | 3.88x10 <sup>-6</sup>             |                 |   |                      |                    | Table 2: Soil - Residential, 3x Database UF included in Total UF<br><br><a href="https://www.michigan.gov/egle/-/media/Project/Websites/egle/Documents/Programs/RRD/Remediation/Rules--Criteria/table-2-soil-residential.pdf?rev=83f3560a75ca41c4b89013dc932455e5&amp;hash=9FED789A3710738F909B80D1B2788238">https://www.michigan.gov/egle/-/media/Project/Websites/egle/Documents/Programs/RRD/Remediation/Rules--Criteria/table-2-soil-residential.pdf?rev=83f3560a75ca41c4b89013dc932455e5&amp;hash=9FED789A3710738F909B80D1B2788238</a> |



| State | PFAS                           | Guideline Level (mg/kg, unless otherwise specified) | Toxicity Data  | Critical Effect Study   | Endpoint                                       | RSC (%) | POD                           | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)      | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions                                    | Target Populations  | Resources & Notes   |
|-------|--------------------------------|---|----------------|-------------------------|--|---------|-------------------------------|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|----------------------|---|---|---------------------|---|
|       |                                |   |                |                         |  |         |                               | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                      |   |   |                     |   |
| MN    | PFOA                           | 0.24 (res/rec)<br>3.0 (com/ind)                     | Animals (mice) | Lau et al. 2006         | Developmental, liver, immune, kidney           | 20%     | 38 mg/L serum concentration   | 300   | 3            | 10           | 3              | 3                   |  |                                   | 1.80E-05             |   | Residential/Recreational, Commercial/Industrial         | Children and adults | Refer to MPCA website for the most up-to-date soil reference values (SRVs)<br><br><a href="https://www.pca.state.mn.us/business-with-us/cleanup-guidance-and-assistance">https://www.pca.state.mn.us/business-with-us/cleanup-guidance-and-assistance</a> |
|       | PFOS                           | 0.041 (res/rec)<br>0.54 (com/ind)                   | Animals (mice) | Dong et al. 2011        | Developmental, liver, thyroid, immune, adrenal | 20%     | 2.36 mg/L serum concentration | 100   | 3            | 10           |                | 3                   |  |                                   | 3.10E-06             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
|       | PFBA                           | 49 (res/rec)<br>250 (com/ind)                       | Animals (rats) | NOTOX 2007              | Liver, thyroid, developmental, blood           | 20%     | 6.9 mg/kg/day                 | 300   | 3            | 10           |                | 10                  |  |                                   | 2.90E-03             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
|       | PFBS                           | 1.1 (res/rec)<br>14 (com/ind)                       | Animals (rats) | NTP 2019                | Thyroid  | 20%     | 6.97 mg/kg/day                | 100   | 3            | 10           |                | 3                   |  |                                   | 8.40E-05             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
|       | PFHxS                          | 0.13 (res/rec)<br>1.6 (com/ind)                     | Animals (rats) | NTP 2018                | Liver, thyroid                                 | 20%     | 32.4 mg/L serum concentration | 300   | 3            | 10           |                | 10                  |  |                                   | 9.70E-06             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
|       | PFHxA                          | 1.9 (res/rec)<br>24 (com/ind)                       | Animals (rats) | Loveless et al. 2009    | Liver, respiratory                             | 20%     | 22.5 mg/kg/day                | 300   | 3            | 10           |                | 10                  |  |                                   | 1.50E-04             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
| MT    | PFOA, PFOS, PFHxS, PFHpA, PFNA | 4.9   |                |                         |  |         |                               |       |              |              |                |                     |  |                                   |                      |   |   |                     |   |
| NC    | HFPO-DA                        | 0.066 (res/rec)<br>0.97 (com/ind)                   | Animals (mice) | Dupont 18405-1037, 2010 | Liver  | 20%     | 0.01 mg/kg/day                | 3000  | 3            | 10           |                | 10                  | 10   |                                   | 3.00E-06             |   | Residential/Recreational, Commercial/Industrial         | Children and adults |   |
| NH    | PFOA                           | 0.2 (residential), 1.3 (maintenance worker)         |                |                         |  | 0.2     |                               |       |              |              |                |                     |  |                                   | 6.1x10 <sup>-6</sup> |   | Residential (young child), Maintenance worker (outdoor) |                     | <a href="https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf">https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf</a>   |

| State | PFAS  | Guideline Level (mg/kg, unless otherwise specified)   | Toxicity Data  | Critical Effect Study | Endpoint       | RSC (%) | POD   | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)   | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions                                    | Target Populations | Resources & Notes  |
|-------|-------|---|----------------|-----------------------|----------------|---------|-------|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|---|---|---|--------------------|--|
|       |       |   |                |                       |                |         |       | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |   |   |   |                    |  |
| NH    | PFOS  | 0.1 (residential), 0.6 (maintenance worker)   |                |                       |                | 0.2     |       |       |              |              |                |                     |  |                                   | 3x10 <sup>-6</sup>  |   | Residential (young child), Maintenance worker (outdoor) |                    | <a href="https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf">https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf</a>  |
|       | PFHxS | 0.1 (residential), 0.9 (maintenance worker)   |                |                       |                | 0.2     |       |       |              |              |                |                     |  |                                   | 4x10 <sup>-6</sup>  |   | Residential (young child), Maintenance worker (outdoor) |                    | <a href="https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf">https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf</a>  |
|       | PFNA  | 0.1 (residential), 0.9 (maintenance worker)   |                |                       |                | 0.2     |       |       |              |              |                |                     |  |                                   | 4.3x10 <sup>-6</sup>  |   | Residential (young child), Maintenance worker (outdoor) |                    | <a href="https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf">https://www4.des.state.nh.us/nh-pfas-investigation/wp-content/uploads/PFAS-DCRB-value-121119.pdf</a>  |
| NJ    | PFOA  | Interim Soil Remediation Standard - Ingestion-Dermal Exposure Pathway. Residential - 0.13; Non-residential-1.8.   | Animals (mice) | Loveless et al., 2006 | Hepatotoxicity |         | BMDL  | 300   | 3            | 10           |                |                     |  |                                   | 2x10 <sup>-6</sup><br><a href="https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendix.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendix.pdf</a>                                     |   | Assumed dermal absorption fraction is 0.1               |                    |  |
|       | PFOS  | Interim Soil Remediation Standard - Ingestion-Dermal Exposure Pathway. Residential - 0.11; Non-residential-1.6.   | Animals (mice) | Dong et al., 2009     | Immunotoxicity |         | NOAEL | 30    | 3            | 10           |                |                     |  |                                   | 1.8x10 <sup>-6</sup><br><a href="https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf</a> |   | Assumed dermal absorption fraction is 0.1               |                    | <a href="https://www.nj.gov/dep/srp/guidance/rs/soil_ingestion_pathway_factsheet.pdf">https://www.nj.gov/dep/srp/guidance/rs/soil_ingestion_pathway_factsheet.pdf</a><br><a href="https://www.nj.gov/dep/srp/guidance/rs/interim_soil_ia_rs.html">https://www.nj.gov/dep/srp/guidance/rs/interim_soil_ia_rs.html</a> |
|       | PFNA  | Interim Soil Remediation Standard - Ingestion-Dermal Exposure Pathway. Residential - 0.047; Non-residential-0.67. | Animals (mice) | Das et al., 2015      | Hepatotoxicity |         | BMDL  | 1000  | 3            | 10           |                | 3                   | 10   |                                   | 7.4x10 <sup>-7</sup><br><a href="https://www.state.nj.us/dep/watersupply/pdf/pfna-health-effects.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfna-health-effects.pdf</a>                       |   | Assumed dermal absorption fraction is 0.1               |                    |  |



| State | PFAS  | Guideline Level (mg/kg, unless otherwise specified)  | Toxicity Data       | Critical Effect Study                  | Endpoint  | RSC (%) | POD   | UFs  |              |              |                |                     |  |                                   | RfD (mg/kg/day)      | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes  |
|-------|-------|--|---------------------|--|---|---------|---|--|--------------|--------------|----------------|---------------------|--|-----------------------------------|----------------------|---|----------------------|--------------------|--|
|       |       |  |                     |  |   |         |   | Total  | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                      |   |                      |                    |  |
| NY    | PFOA  | 0.66 ug/kg (unrestricted), 6.6 ug/kg (residential), 33 ug/kg (restricted residential), 500 ug/kg (commercial), 600 ug/kg (industrial), 1.1 ug/kg (protection of groundwater) |                     |  |   |         |   |  |              |              |                |                     |  |                                   |                      |   |                      |                    |  |
|       | PFOS  | 0.88 ug/kg (unrestricted), 8.8 ug/kg (residential), 44 ug/kg (restricted residential), 440 ug/kg (commercial), 440 ug/kg (industrial), 3.7 ug/kg (protection of groundwater) |                     |  |   |         |   |  |              |              |                |                     |  |                                   |                      |   |                      |                    |  |
| PA    | PFOA  | 4.4 (residential), 64 (non-residential)  |                     |  |   |         |   |  |              |              |                |                     |  |                                   |                      |   |                      |                    |  |
|       | PFOS  | 4.4 (residential), 64 (non-residential)  |                     |  |   |         |   |  |              |              |                |                     |  |                                   |                      |   |                      |                    |  |
|       | PFBS  | 66 (residential), 960 (non-residential)  |                     |  |   |         |   |  |              |              |                |                     |  |                                   |                      |   |                      |                    |  |
| TX    | PFBA  | 0.067  | Animals (male rats) | Butenhoff et al. 2012                  | hepatocellular hypertrophy and decreased total thyroxine (T4) |         | 5.4 mg/kg-d (BMDL10 for hepatocellular hypertrophy) and 6 mg/kg-d (NOAEL for decreased total thyroxine) | 1.15 mg/kg-d (hepatocellular hypertrophy) and 1.27 mg/kg-d (decreased total thyroxine) | 1000         | 3            | 10             |                     | 3  | 10                                |                      | 1x10-3  |                      |                    | Note: Residential GWSoiling PCLs (0.5 acre source area) <a href="https://www.tceq.texas.gov/downloads/toxicology/pfc/pfcs.pdf/view">https://www.tceq.texas.gov/downloads/toxicology/pfc/pfcs.pdf/view</a> . Direct contact residential soil comparison values are also available in Texas but are typically higher than the soil values that are protective of groundwater, which are the values listed in this table. |
|       | PFBuS | 0.11   | Animals (mice)      | Leider et al., 2009, York et al., 2002 | Systemic Toxicity   |         | NOAEL (60 mg/kg/d)  | 42600  | 1            | 10           |                | 10                  | 3  |                                   | 1.4x10 <sup>-3</sup> |   |                      |                    |  |

| State | PFAS   | Guideline Level (mg/kg, unless otherwise specified) | Toxicity Data           | Critical Effect Study   | Endpoint   | RSC (%) | POD                   | UFs           |              |              | LOEL to NOEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints | RfD (mg/kg/day)      | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes  |
|-------|--------|---|-------------------------|-------------------------|--|---------|-----------------------|---------------|--------------|--------------|--------------|---------------------|--|-----------------------------------|----------------------|---|----------------------|--------------------|--|
|       |        |   |                         |                         |  |         |                       | Total         | Interspecies | Intraspecies |              |                     |  |                                   |                      |   |                      |                    |  |
| TX    | PFPeA  | 4.20E-02  | Animals (mice)          | Surrogate PFHxA         | Developmental (decreased offspring body weight)                  |         |                       | 100           | 3            | 10           |              | 3                   |  |                                   | 5E-4 mg/kg-day       |   |                      |                    | Note: Residential GWSoiling PCLs (0.5 acre source area) direct contact residential soil comparison values are also available in Texas but are typically higher than the soil values that are protective of groundwater, which are the values listed in this table. |
|       | PFHxS  | 0.002   | Animals (mice)          | Hoberman and York, 2003 | Hematotoxicity   |         | NOAEL (0.3 mg/kg/d)   | 78900         | 1            | 10           | 3            | 10                  |  |                                   | 3.8x10 <sup>-6</sup> |   |                      |                    |  |
|       | PFHxA  | 0.063   | Animals (pregnant rats) | Loveless et al. 2009    | decreased offspring body weight in neonatal male and female rats |         | 10.62 mg/kg-d (BMDL5) | 0.048 mg/kg-d | 100          | 3            | 10           |                     | 3  |                                   |                      | 5x10 <sup>-4</sup>  |                      |                    |  |
|       | PFHpA  | 0.0046  | Animals (mice)          | Surrogate: PFOS         | Neurodevelopment   |         | NOAEL (0.6 mg/kg/d)   | 26300         | 1            | 10           | 10           | 1                   |  |                                   | 2.3x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFOS   | 0.05  | Animals (mice)          | Zeng et al., 2011       | Neurodevelopment   |         | NOAEL (0.6 mg/kg/d)   | 26300         | 1            | 10           | 10           | 1                   |  |                                   | 2.3x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFOA   | 0.003   | Animals (mice)          | Macon et al., 2011      | Mammary gland development  |         | NOAEL (0.3 mg/kg/d)   | 24300         | 1            | 10           | 30           | 1                   |  |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFOSA  | 0.92  | Animals (mice)          | Surrogate: PFOA         | Mammary gland development  |         | NOAEL (0.3 mg/kg/d)   | 24300         | 1            | 10           | 30           | 1                   |  |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFNA   | 0.0031  | Animals (mice)          | Fang et al., 2010       | Spleen Cell Death  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFDeA  | 0.022   | Animals (mice)          | Kawashima et al., 1995  | Hepatotoxicity   |         | NOAEL (1.2 mg/kg/d)   | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.5x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFDS   | 0.04  | Animals (mice)          | Surrogate: PFDoA        | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFUA   | 0.018   | Animals (mice)          | Surrogate: PFDoA        | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFDoA  | 0.034   | Animals (mice)          | Shi et al., 2007        | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFTrDA | 0.061   | Animals (mice)          | Surrogate: PFDoA        | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |
|       | PFTeDA | 0.11  | Animals (mice)          | Surrogate: PFDoA        | Reduced Body Weight  |         | NOAEL (1 mg/kg/d)     | 81000         | 1            | 10           |              | 10                  | 10   |                                   | 1.2x10 <sup>-5</sup> |   |                      |                    |  |

| State | PFAS                           | Guideline Level (mg/kg, unless otherwise specified) | Toxicity Data  | Critical Effect Study | Endpoint   | RSC (%) | POD        | UFs        |              |              |                |                     |  |                                   |  | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes  |
|-------|--------------------------------|---|----------------|-----------------------|------------|---------|------------|------------|--------------|--------------|----------------|---------------------|--|-----------------------------------|--|-----------------|---|----------------------|--------------------|--|
|       |                                |   |                |                       |            |         |            | Total      | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |  |                 |   |                      |                    |  |
| VT    | PFOA, PFOS, PFHxS, PFHpA, PFNA | 1.22*   | Animals (mice) | EPA (2016)            | EPA (2016) | 20      | EPA (2016) | EPA (2016) |              |              |                |                     |  |                                   |  | 0.175 L/kg/day  |   |                      |                    |  |
| WA    | PFOA                           | 6.30E-05  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | PFOS                           | 1.70E-04  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | PFNA                           | 8.00E-05  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | PFHxS                          | 4.10E-04  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | PFBS                           | 1.80E-03  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | HFPO-DA (GenX)                 | 1.00E-04  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - vadose zone contamination.    |
|       | PFOA                           | 4.00E-06  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |
|       | PFOS                           | 9.90E-06  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |
|       | PFNA                           | 4.80E-06  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |
|       | PFHxS                          | 2.60E-05  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |
|       | PFBS                           | 1.20E-04  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |
|       | HFPO-DA                        | 7.20E-06  |                |                       |            |         |            |            |              |              |                |                     |  |                                   |  |                 |   |                      |                    | Soil CUL protective of groundwater - saturated zone contamination. |

| State | PFAS           | Guideline Level (mg/kg, unless otherwise specified) | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day) | Drinking Water Intake Rate (L/day unless otherwise specified) | Exposure assumptions | Target Populations | Resources & Notes |   |
|-------|----------------|---|---------------|-----------------------|----------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|-----------------|---|----------------------|--------------------|-------------------|---|
|       |                |   |               |                       |          |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic) | Sensitive Developmental Endpoints |                 |   |                      |                    |                   |   |
| WA    | PFOA           | 0.24  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | PFOS           | 0.24  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | PFNA           | 0.2   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | PFHxS          | 0.78  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | PFBS           | 24  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | HFPO-DA (GenX) | 0.24  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for unrestricted land use (Method B). |
|       | PFOA           | 11  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for industrial land use (Method C).   |
|       | PFOS           | 11  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for industrial land use (Method C).   |
|       | PFNA           | 8.8   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                 |   |                      |                    |                   | Soil CUL protective of the direct contact pathway for industrial land use (Method C).   |

| State | PFAS           | Guideline Level (mg/kg, unless otherwise specified)      | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)    | Drinking Water Intake Rate (L/day unless otherwise specified)  | Exposure assumptions          | Target Populations | Resources & Notes   |
|-------|----------------|--|---------------|-----------------------|----------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|--------------------|--|-------------------------------|--------------------|---|
|       |                |  |               |                       |          |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic)                                       | Sensitive Developmental Endpoints |                    |  |                               |                    |   |
| WA    | PFHxS          | 34   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |  |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
|       | PFBS           | 1,100  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |  |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
|       | HFPO-DA (GenX) | 11   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |  |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
| WI    | PFOA           | 1.26 (residential), 16.4 (composite [industrial] worker) |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 2x10 <sup>-5</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker)<br><br>THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |
|       | PFOS           | 1.26 (residential), 16.4 (composite [industrial] worker) |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 2x10 <sup>-5</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker)<br><br>THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |
|       | PFBS           | 19 (residential), 246 (composite [industrial] worker)    |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 3x10 <sup>-4</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker)<br><br>THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |



| State | PFAS           | Guideline Level (mg/kg, unless otherwise specified)      | Toxicity Data | Critical Effect Study | Endpoint | RSC (%) | POD | UFs   |              |              |                |                     |  |                                   | RfD (mg/kg/day)    | Drinking Water Intake Rate (L/day unless otherwise specified)                   | Exposure assumptions  | Target Populations            | Resources & Notes  |   |
|-------|----------------|--|---------------|-----------------------|----------|---------|-----|-------|--------------|--------------|----------------|---------------------|--|-----------------------------------|--------------------|---|---|-------------------------------|--------------------|---|
|       |                |  |               |                       |          |         |     | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation | Duration of Exposure (i.e., Subchronic to Chronic)                                       | Sensitive Developmental Endpoints |                    |   |   |                               |                    |   |
| WA    | PFHxS          | 34   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |   |   |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
|       | PFBS           | 1,100  |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |   |   |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
|       | HFPO-DA (GenX) | 11   |               |                       |          |         |     |       |              |              |                |                     |  |                                   |                    |   |   |                               |                    | Soil CUL protective of the direct contact pathway for industrial land use (Method C). |
| WI    | PFOA           | 1.26 (residential), 16.4 (composite [industrial] worker) |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 2x10 <sup>-5</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker) | THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |
|       | PFOS           | 1.26 (residential), 16.4 (composite [industrial] worker) |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 2x10 <sup>-5</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker) | THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |
|       | PFBS           | 19 (residential), 246 (composite [industrial] worker)    |               | EPA RSL Tables        |          |         |     |       |              |              |                |                     | 26 yrs, 350 days/yr, 24 hrs (residential), 25 yrs, 250 days/yr, 8 hrs (composite worker) |                                   | 3x10 <sup>-4</sup> | Vary through life (residential), 80 kg wt, 100 mg/day intake (composite worker) | THQ=1, cancer risk 1x10 <sup>-6</sup> , other default assumptions | Residential, Composite Worker | EPA RSL calculator |   |

\*= Advisory level is based on the total of more than one PFAS

## Appendix E: State Air PFAS Guideline Criteria

| State | PFAS              | Guideline Level (µg/m³)                      | Toxicity Data  | Critical Effect Study            | Endpoint   | POD                              | HED (mg/kg/day)                    | UFs                            |                           |                              |                |                     | RfD (mg/kg/day)             | Route-to-Route Extrapolation | Exposure Parameters                            | Target Populations  | Resources                       |   |   |
|-------|-------------------|--|----------------|----------------------------------|--|----------------------------------|------------------------------------|--------------------------------|---------------------------|------------------------------|----------------|---------------------|-----------------------------|------------------------------|--|---|---------------------------------|---|---|
|       |                   |  |                |                                  |  |                                  |                                    | Total                          | Interspecies              | Intraspecies                 | LOAEL to NOAEL | Database Limitation |                             |                              |  |   |                                 | Duration of Exposure (i.e., Subchronic to Chronic)  |   |
| MN    | PFOS (st, sc, c)  | 0.011  | Animals (mice) | Dong et al., 2011                | Adrenal, Developmental, Hepatic (liver) system, Immune, Thyroid                      | 2.36 mg/L serum conc             | 0.000307                           | 100                            | 3                         | 10                           |                |                     | 3                           |                              | RfD (mg/kg-d) x (70 kg/20 m³-d) x (1000 µg/mg) | inhalation rate per day of 20m³/d and average body weight of 70kg | Fetus and Breastfeeding Infants | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfos.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfos.pdf</a>   |   |
|       | PFHxS (st, sc, c) | 0.034  | Animals (rat)  | NTP, 2018                        | Hepatic (liver) system, Thyroid  | 32.4 mg/L serum conc             | 0.00292                            | 300                            | 3                         | 10                           |                |                     | 10                          |                              | RfD (mg/kg-d) x (70 kg/20 m³-d) x (1000 µg/mg) | inhalation rate per day of 20m³/d and average body weight of 70kg | Fetus and Breastfeeding Infants | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfhxs.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfhxs.pdf</a> |   |
|       | PFBA (st, sc, c)  | 10   | Animals (rat)  | NOTOX, 2007 and Butenhoff, 2007  | st -liver and thyroid; sc and c - Developmental, blood system, liver system, Thyroid | st = 3.01<br>sc = 6.9<br>c = 6.9 | st = 0.38<br>sc = 0.86<br>c = 0.86 | st =100<br>sc = 300<br>c = 300 | st = 3<br>sc = 3<br>c = 3 | st = 10<br>sc = 10<br>c = 10 |                |                     | st = 3<br>sc = 10<br>c = 10 |                              | RfD (mg/kg-d) x (70 kg/20 m³-d) x (1000 µg/mg) | inhalation rate per day of 20m³/d and average body weight of 70kg | Infants and Adults              | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfba.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfba.pdf</a>   |   |
|       | PFBS (st, sc, c)  | 0.3  | Animals (rats) | NTP, 2019                        | Thyroid  | 6.97 mg/kg-d                     | 0.0084                             | 100                            | 3                         | 10                           |                |                     | 3                           |                              | 0.000084 - st,<br>0.00054 - sc,<br>0.00018 - c | RfD( (mg/kg-d) x (70 kg/20 m³-d) x (1000 ug/mg)                   |                                 |   | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfbs.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfbs.pdf</a>   |
|       | PFHxA             | 1 (short-term), 0.5 (subchronic and chronic) | Animals (rats) | NTP, 2019; Loveless et al., 2009 | Developmental, thyroid - st; hepatic (liver) system, respiratory system - sc         | 22.5 mg/kg-d                     | 0.0958 - st,<br>0.045 - sc, c      | 300                            | 3                         | 10                           |                |                     |                             | 3 - st, 10 - sc, c           |  | RfD( (mg/kg-d) x (70 kg/20 m³-d) x (1000 ug/mg)                   |                                 |   | <a href="https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfhxa.pdf">https://www.health.state.mn.us/communities/environment/risk/docs/guidance/air/pfhxa.pdf</a> |

| State | PFAS  | Guideline Level (µg/m³) | Toxicity Data    | Critical Effect Study                        | Endpoint   | POD                         | HED (mg/kg/day) | UFs   |              |              |                |                     | RfD (mg/kg/day)              | Route-to-Route Extrapolation       | Exposure Parameters                   | Target Populations                    | Resources   |   |   |   |
|-------|---|-------------------------|------------------|--|--|-----------------------------|-----------------|-------|--------------|--------------|----------------|---------------------|------------------------------|------------------------------------|---------------------------------------|---------------------------------------|---|---|---|---|
|       |   |                         |                  |  |  |                             |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |                              |                                    |                                       |                                       |   | Duration of Exposure (i.e., Subchronic to Chronic)  |   |   |
| MN    | PFOA (st, sc, c)  | 0.063                   | Maternal animals | Lau et al., 2006; EPA, 2016                  | Developmental, Hepatic (Liver) system, Immune system, and Renal (Kidney) system, Pancreas, and Thyroid | 38 mg/L serum concentration | 0.0053          | 300   | 3            | 10           | 3              | 3                   |                              |                                    |                                       |                                       | Air Toxicological Summary Sheet June 2022 (state.mn.us)   |   |   |   |
| MI    | PFOA (initial threshold screening level; ITSL)  | 0.07                    | Animals (mice)   | EPA, 2016; Butenhoff et al., 2004; Lau, 2006 | Acute, Reproductive/ Developmental   |                             | 0.0053; 0.0064  | 300   | 3            | 10           | 10             |                     | 2 generations +developmental | Air Value (ITSL) = RfD x 70kg/20m³ | Continuous over time period= 24 hours | Sensitive individuals                 | <a href="http://www.deq.state.mi.us/aps/downloads/ATSL/335-67-1/335-67-1_24hr_ITSL.pdf">http://www.deq.state.mi.us/aps/downloads/ATSL/335-67-1/335-67-1_24hr_ITSL.pdf</a>     |   |   |   |
|       | PFOA (initial threshold screening level; ITSL)  | 0.07                    | Animals (rats)   | EPA, 2016; Luebker et al., 2005              | Acute, Reproductive/ Developmental   |                             | 0.00051         | 30    | 10           | 3            |                |                     | 2 generations +developmental | Air Value (ITSL) = RfD x 70kg/20m³ | Continuous over time period= 24 hours | Sensitive individuals                 | <a href="http://www.deq.state.mi.us/aps/downloads/ATSL/1763-23-1/1763-23-1_24hr_ITSL.pdf">http://www.deq.state.mi.us/aps/downloads/ATSL/1763-23-1/1763-23-1_24hr_ITSL.pdf</a> |   |   |   |
|       | 6:2 FTS   | 1                       | Animals (rats)   | ECHA, 2020; Rat, subchronic, oral            | Cardiac  | NOAEL 5 mg/kg               | 1.18            | 3000  | 3            | 10           |                |                     | 10                           | 10                                 | 10                                    | 0.00039                               | Air Value (ITSL) = RfD x 70kg/20m³  | Continuous over time period= annual (chronic)   | Sensitive individuals   | <a href="http://www.deq.state.mi.us/aps/downloads/ATSL/27619-97-2/">http://www.deq.state.mi.us/aps/downloads/ATSL/27619-97-2/</a> |
|       | 1,1,1,2-tetrafluoroethane   | 80,000                  | Animals (rats)   | Collins et al., 199                          | Leydig cell hyperplasia  | BMC10 46,000 mg/m³          | 46,000 mg/m³    | 100   | 3            | 10           |                |                     | 3                            | chronic                            |                                       |                                       | Sensitive individuals   | <a href="https://www.egle.state.mi.us/aps/downloads/ATSL/811-97-2/811-97-2_annual_ITSL.pdf">https://www.egle.state.mi.us/aps/downloads/ATSL/811-97-2/811-97-2_annual_ITSL.pdf</a> |   |   |
|       | perfluorobutyl ethylene dichlormethyl (3,3,4,4,5,5,6,6,6 nonafluorohexyl) silane (CAS # 38436-16-7) | 2                       | Animals (rats)   | ECHA (2021)                                  | LD50   | LD50                        | 890 mg/kg       | ##### |              |              |                |                     |                              |                                    | acute                                 | weight/inhalation (0.29kg/0.31m³/day) | single dose gavage  | Sensitive individuals   | <a href="https://www.egle.state.mi.us/aps/downloads/ATSL/38436-16-7/38436-16-7_annual_ITSL.pdf">https://www.egle.state.mi.us/aps/downloads/ATSL/38436-16-7/38436-16-7_annual_ITSL.pdf</a> |   |

| State | PFAS   | Guideline Level ( $\mu\text{g}/\text{m}^3$ ) | Toxicity Data  | Critical Effect Study               | Endpoint                          | POD   | HED (mg/kg/day) | UFs   |              |              |                |                     | RfD (mg/kg/day) | Route-to-Route Extrapolation | Exposure Parameters  | Target Populations   | Resources          |  |  |
|-------|--|--|----------------|-------------------------------------|-----------------------------------|-------|-----------------|-------|--------------|--------------|----------------|---------------------|-----------------|------------------------------|--|--|--------------------|--|--|
|       |  |  |                |                                     |                                   |       |                 | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |                 |                              |  |  |                    | Duration of Exposure (i.e., Subchronic to Chronic)   |  |
| NH    | APFO (CAS #3825-26-1; 24-hr Ambient Air Limit)     | Regulatory Level 0.05                        | Animals (rats) | ACGIH TLV                           | Acute, Reproductive/Developmental |       |                 |       |              |              |                |                     |                 |                              |  |  |                    |  |  |
|       | APFO (CAS #3825-26-1; Annual Ambient Air Limit)    | Regulatory Level 0.024                       | Animals (rats) | ACGIH TLV                           | Acute, Reproductive/Developmental |       |                 |       |              |              |                |                     |                 |                              |  |  |                    |  |  |
| NJ    | PFOA (Reference Concentration)                     | 0.007  | Animals (mice) | Loveless et al., 2006               | Hepatotoxicity                    | BMDL  |                 | 300   | 3            | 10           |                |                     | 10              | $2 \times 10^{-6}$           | Reference Concentration = RfD x $70\text{kg}/20\text{m}^3$ | 30 day averaging time                                      | Infants and Adults | Based on route-to-route extrapolation from RfD (2 ng/kg/day) used for NJ MCL <a href="https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendixa.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfoa-appendixa.pdf</a>                                   |  |
|       | PFOS (Reference Concentration)                     | 0.006  | Animals (mice) | Dong et al., 2009                   | Immunotoxicity                    | NOAEL |                 | 30    | 3            | 10           |                |                     | 10              | $1.8 \times 10^{-6}$         | Reference Concentration = RfD x $70\text{kg}/20\text{m}^3$ | 30 day averaging time                                      | Infants and Adults | Based on route-to-route extrapolation from RfD (1.8 ng/kg/day) used for NJ MCL <a href="https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf">https://www.state.nj.us/dep/watersupply/pdf/pfos-recommendation-appendix-a.pdf</a> |  |
|       | HFPO-DA (GenX) (Screening Reference Concentration) | 0.01   | Animals (mice) | DuPont 18405-1037, 2010; NTP, 2019. | Hepatotoxicity                    | BMDL  |                 | 3000  | 3            | 10           |                |                     | 10              | 10                           | $3 \times 10^{-6}$   | Reference Concentration = RfD x $70\text{kg}/20\text{m}^3$ |                    | Infants and Adults   | Based on route-to-route extrapolation from EPA RfD (3 ng/kg/day) <a href="https://www.epa.gov/system/files/documents/2021-10/genx-chemicals-toxicity-assessment_tech-edited_oct-21-508.pdf">https://www.epa.gov/system/files/documents/2021-10/genx-chemicals-toxicity-assessment_tech-edited_oct-21-508.pdf</a> |

| State | PFAS  | Guideline Level (µg/m³) | Toxicity Data       | Critical Effect Study                  | Endpoint  | POD   | HED (mg/kg/day)  | UFs   |              |              |                |                     | RfD (mg/kg/day) | Route-to-Route Extrapolation | Exposure Parameters                       | Target Populations | Resources |  |
|-------|-------|-------------------------|---------------------|--|---|---|--|-------|--------------|--------------|----------------|---------------------|-----------------|------------------------------|---|--------------------|-----------|--|
|       |       |                         |                     |  |   |   |  | Total | Interspecies | Intraspecies | LOAEL to NOAEL | Database Limitation |                 |                              |   |                    |           | Duration of Exposure (i.e., Subchronic to Chronic) |
| TX    | PFBA  | 3.50E+00                | Animals (male rats) | Butenhoff et al., 2012                 | hepatocellular hypertrophy and decreased total thyroxine (T4) | 5.4 mg/kg-d (BMDL10 for hepatocellular hypertrophy) and 6 mg/kg-d (NOAEL for decreased total thyroxine) | 1.15 mg/kg-d (hepatocellular hypertrophy) and 1.27 mg/kg-d (decreased total thyroxine) | 1000  | 3            | 10           |                | 3                   | 10              | 1x10-3                       | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFBS  | 4.90E+00                | Animals (mice)      | Leider et al., 2009, York et al., 2002 | Systemic Toxicity   | NOAEL (60 mg/kg/d)  |  | 42600 | 1            | 10           |                | 10                  | 3               | 1.40E-03                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFHxS | 1.30E-02                | Animals (mice)      | Hoberman and York, 2003                | Hematotoxicity  | NOAEL (0.3 mg/kg/d)   |  | 78900 | 1            | 10           | 3              | 10                  |                 | 3.80E-06                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFOS  | 8.10E-02                | Animals (mice)      | Zeng et al., 2011                      | Neurodevelopment  | NOAEL (0.6 mg/kg/d)   |  | 26300 | 1            | 10           | 10             | 1                   |                 | 2.30E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFOA  | 4.10E-03                | Animals (mice)      | Macon et al., 2011                     | Mammary gland development                                     | NOAEL (0.3 mg/kg/d)   |  | 24300 | 1            | 10           | 30             | 1                   |                 | 1.20E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFOSA | 4.10E-03                | Animals (mice)      | Surrogate: PFOA                        | Mammary gland development                                     | NOAEL (0.3 mg/kg/d)   |  | 24300 | 1            | 10           | 30             | 1                   |                 | 1.20E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFNA  | 2.80E-02                | Animals (mice)      | Fang et al., 2010                      | Spleen Cell Death   | NOAEL (1 mg/kg/d)   |  | 81000 | 1            | 10           |                | 10                  | 10              | 1.20E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFDA  | 5.30E-02                | Animals (mice)      | Kawashima et al., 1995                 | Hepatotoxicity  | NOAEL (1.2 mg/kg/d)   |  | 81000 | 1            | 10           |                | 10                  | 10              | 1.50E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |
|       | PFDoA | 4.20E-02                | Animals (mice)      | Shi et al., 2007                       | Reduced Body Weight   | NOAEL (1 mg/kg/d)   |  | 81000 | 1            | 10           |                | 10                  | 10              | 1.20E-05                     | Reference Concentration = RfD x 70kg/20m³ |                    |           |  |

\*= Advisory level is based on the total of more than one PFAS

## Appendix F: State Fish and Wildlife Consumption PFAS Guideline Criteria

| State | Media                 | PFAS | Guideline Level (unit specified) | Frequency                | Target Populations   | Resources & Notes  |
|-------|-----------------------|------|----------------------------------|--------------------------|----------------------|--|
| AL    | Fish                  | PFOS | >156 ppb                         | 1 meal per week          | General Population   |  |
|       | Fish                  | PFOS | >800 ppb                         | Do Not Eat               | General Population   |  |
| CT    | Finfish and shellfish | PFOS | < 4 ppb                          | Unlimited consumption    | General population   | Rusnak 2023  |
|       | Finfish and shellfish | PFOS | ≥ 4 to < 8 ppb                   | 1 meal/week              | General population   | Rusnak 2023  |
|       | Finfish and shellfish | PFOS | ≥ 8 to < 31 ppb                  | 1 meal/month             | General population   | Rusnak 2023  |
|       | Finfish and shellfish | PFOS | ≥ 31 ppb                         | Do not eat               | General population   | Rusnak 2023  |
| IL    | Fish                  | PFOS | > 200 µg/kg                      | Do not eat               |                      | <a href="https://epa.illinois.gov/topics/water-quality/pfas/pfas-fish-sampling.html">https://epa.illinois.gov/topics/water-quality/pfas/pfas-fish-sampling.html</a>  |
|       | Fish                  | PFOS | 51 µg/kg - 200 µg/kg             | 1 meal per month         |                      |  |
|       | Fish                  | PFOS | 11 µg/kg - 50 µg/kg              | 1 meal per week          |                      |  |
|       | Fish                  | PFOS | 0 - 10 µg/kg                     | Unrestricted             |                      |  |
| IN    | Fish                  | PFOS | <20 ppb                          | Unrestricted Consumption | All Populations      | <a href="#">Best Practice for Perfluorooctane Sulfonate (PFOS) Guidelines; RfD is from the 2016 EPA Drinking Water Health Advisory for PFOS (2x10<sup>-5</sup> mg/kg/day); This Best Practice document is currently under revision to take into consideration new RfDs</a> |
|       | Fish                  | PFOS | 20-50 ppb                        | 1 meal per week          | All Populations      |  |
|       | Fish                  | PFOS | 50-200 ppb                       | 1 meal per month         | All Populations      |  |
|       | Fish                  | PFOS | >200 ppb                         | Do Not Eat               | All Populations      |  |
| MA    | Fish                  | PFOS | > 81.1 ug/kg                     | Do not consume           | Sensitive population | <a href="https://www.mass.gov/doc/technical-basis-for-issuing-fish-advisories-0/download">https://www.mass.gov/doc/technical-basis-for-issuing-fish-advisories-0/download</a>  |
|       |                       |      | ≤ 0.22 ug/kg                     | 1 meal/day               | Sensitive population |  |
|       |                       |      | > 183 ug/kg                      | Do not consume           | General population   |  |
|       |                       |      | ≤ 0.50 ug/kg                     | 1 meal/day               | General population   |  |
|       |                       | PFBS | > 36,500 ug/kg                   | Do not consume           | Sensitive population |  |

| State | Media              | PFAS        | Guideline Level (unit specified) | Frequency      | Target Populations              | Resources & Notes  |
|-------|--------------------|-------------|----------------------------------|----------------|---------------------------------|--|
| MA    |                    |             | ≤ 100 ug/kg                      | 1 meal/day     | Sensitive population            |  |
|       |                    |             | > 82,200 ug/kg                   | Do not consume | General population              |  |
|       |                    |             | ≤ 225 ug/kg                      | 1 meal/day     | General population              |  |
|       |                    | PFHxS       | > 811 ug/kg                      | Do not consume | Sensitive population            |  |
|       |                    |             | ≤ 2.22 ug/kg                     | 1 meal/day     | Sensitive population            |  |
|       |                    |             | > 1820 ug/kg                     | Do not consume | General population              |  |
|       |                    |             | ≤ 5.01 ug/kg                     | 1 meal/day     | General population              |  |
|       |                    | PFOA        | > 122 ug/kg                      | Do not consume | Sensitive population            |  |
|       |                    |             | ≤ 0.33 ug/kg                     | 1 meal/day     | Sensitive population            |  |
|       |                    |             | > 274 ug/kg                      | Do not consume | General population              |  |
|       |                    |             | ≤ 0.75 ug/kg                     | 1 meal/day     | General population              |  |
|       |                    | PFNA        | > 122 ug/kg                      | Do not consume | Sensitive population            |  |
|       |                    |             | ≤ 0.33 ug/kg                     | 1 meal/day     | Sensitive population            |  |
|       |                    |             | > 274 ug/kg                      | Do not consume | General population              |  |
|       |                    |             | ≤ 0.75 ug/kg                     | 1 meal/day     | General population              |  |
| MD    | Fish and Shellfish | PFOS / PFOA | < 24.0 ppb                       | No limit       | General "High Risk" Populations | Rfd from 2016 EPA Drinking Water Health Advisory for PFOS and PFOA |
|       | Fish and Shellfish | PFOS / PFOA | > 24.0 - 27.2 ppb                | 8              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 27.2 - 31.4 ppb                | 7              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 31.4 - 37.1 ppb                | 6              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 37.1 - 45.3 ppb                | 5              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 45.3 - 58.3 ppb                | 4              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 58.3 - 81.6 ppb                | 3              | General "High Risk" Populations |  |
|       | Fish and Shellfish | PFOS / PFOA | > 81.6 - 136.0 ppb               | 2              | General "High Risk" Populations |  |

| State | Media              | PFAS        | Guideline Level (unit specified) | Frequency | Target Populations               | Resources & Notes |
|-------|--------------------|-------------|----------------------------------|-----------|----------------------------------|-------------------|
| MD    | Fish and Shellfish | PFOS / PFOA | > 136.0 - 408.0 ppb              | 1         | General "High Risk" Populations  |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 408.0 ppb                      | Avoid     | General "High Risk" Populations  |                   |
|       | Fish and Shellfish | PFOS / PFOA | < 21.2 ppb                       | No limit  | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 21.2 - 24.0 ppb                | 8         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 24.0 - 27.7 ppb                | 7         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 27.7 - 32.7 ppb                | 6         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 32.7 - 40.0 ppb                | 5         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 40.0 - 51.4 ppb                | 4         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 51.4 - 71.9 ppb                | 3         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 71.9 - 119.9 ppb               | 2         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 119.9 - 359.7 ppb              | 1         | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 359.7 ppb                      | Avoid     | Women "High Risk" Populations    |                   |
|       | Fish and Shellfish | PFOS / PFOA | < 12.2 ppb                       | No limit  | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 12.2 - 13.8 ppb                | 8         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 13.8 - 16.0 ppb                | 7         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 16.0 - 18.9 ppb                | 6         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 18.9 - 23.1 ppb                | 5         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 23.1 - 29.7 ppb                | 4         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 29.7 - 41.5 ppb                | 3         | Children "High Risk" Populations |                   |
|       | Fish and Shellfish | PFOS / PFOA | > 41.5 - 69.2 ppb                | 2         | Children "High Risk" Populations |                   |



| State | Media              | PFAS        | Guideline Level (unit specified) | Frequency          | Target Populations  | Resources & Notes  |
|-------|--------------------|-------------|----------------------------------|--------------------|---|--|
| MD    | Fish and Shellfish | PFOS / PFOA | > 69.2 - 207.6 ppb               | 1                  | Children "High Risk" Populations  |  |
|       | Fish and Shellfish | PFOS / PFOA | > 207.6 ppb                      | Avoid              | Children "High Risk" Populations  |  |
| ME    | Fish               | PFOS        | 3.5 ppb                          | 1 8-oz meal/week   | General Population  |  |
|       | Fish               | PFOS        | 14 ppb                           | 1 8-oz meal/month  | General Population  |  |
|       | Fish               | PFOS        | 60 ppb                           | 3 8-oz meals/year  | General Population  |  |
|       | Deer, Turkey       | PFOS        | 3.5 ppb                          | 1 8-oz meal/week   | Adults  |  |
|       | Deer, Turkey       | PFOS        | 1.7 ppb                          | 1 3-oz meal/week   | Children  |  |
|       | Deer, Turkey       | PFOS        | 15 ppb                           | 1 8-oz meal/month  | Adults  |  |
|       | Deer, Turkey       | PFOS        | 7.5 ppb                          | 1 3-oz meal/month  | Children  |  |
|       | Milk               | PFOS        | 0.21 ppb                         | 76.7 g/kg/day      | Children, 1-2 years old   |  |
|       | Beef               | PFOS        | 3.4 ppb                          | 4.7 g/kg/day       | Children, 1- 6 years old  |  |
| MI    | Fish               | PFOS        | ≤9 ppb                           | 16 meals per month | All Populations   |  |
|       | Fish               | PFOS        | >9-13 ppb                        | 12 meals per month | All Populations   |  |
|       | Fish               | PFOS        | >13-19 ppb                       | 8 meals per month  | All Populations   |  |
|       | Fish               | PFOS        | >19-38 ppb                       | 4 meals per month  | All Populations   |  |
|       | Fish               | PFOS        | >38-75                           | 2 meals per month  | All Populations   |  |
|       | Fish               | PFOS        | >75-150                          | 1 meal per month   | All Populations   |  |
|       | Fish               | PFOS        | >150-300                         | 6 meals per year   | All Populations   |  |
|       | Fish               | PFOS        | >300 ppb                         | Do Not Eat         | All Populations   |  |
|       | Deer               | PFOS        | >300 ppb                         | Do Not Eat         | All Populations   |  |
| MN    | Fish               | PFOS        | <10 ppb                          | 4 meals per week   | Men, Boys Age 15 and Over, and Women Not Planning to Become Pregnant* (*there is already more stringent advice in place for Pregnant Women, Women Who Could Become Pregnant, and Children Under Age 15 due to statewide mercury concentrations) | Statewide guidance for some species based on PFOS; others are 1 meal per week based on mercury or PCB levels, see Fish Consumption Guidance - MN Dept. of Health ( <a href="https://www.health.state.mn.us/communities/environment/fish/index.html">https://www.health.state.mn.us/communities/environment/fish/index.html</a> )   |
|       | Fish               | PFOS        | >10-20 ppb                       | 2 meals per week   | Men, Boys Age 15 and Over, and Women Not Planning to Become Pregnant* (*there is already more stringent advice in place for Pregnant Women, Women Who Could Become Pregnant, and Children Under Age 15 due to statewide mercury concentrations) | Be+A1:G23st Practice for Perfluorooctane Sulfonate (PFOS) Guidelines ( <a href="https://www.health.state.mn.us/communities/environment/fish/docs/consortium/bestpracticepfos.pdf">https://www.health.state.mn.us/communities/environment/fish/docs/consortium/bestpracticepfos.pdf</a> )<br><br>Fish Consumption Guidance - MN Dept. of Health ( <a href="https://www.health.state.mn.us/communities/environment/fish/index.html">https://www.health.state.mn.us/communities/environment/fish/index.html</a> ) |

| State | Media | PFAS | Guideline Level (unit specified) | Frequency                  | Target Populations                | Resources & Notes  |
|-------|-------|------|----------------------------------|----------------------------|-----------------------------------|--|
| MN    | Fish  | PFOS | >20-50 ppb                       | 1 meal per week            | All Populations                   |  |
|       | FISH  | PFOS | >50-200ppb                       | 1 meal per month           | all populations                   | MDH has recommended more stringent guidance for people that are or may become pregnant, people that are breastfeeding or may breastfeed, and children under age 15, when concentrations of PFAS exceed 50 ppb and/or there are greater number or concentrations of other PFAS in fish fillets than found on average. |
|       | Fish  | PFOS | >200 ppb                         | Do Not Eat                 | All Populations                   |  |
| NJ    | Fish  | PFOS | 0.56 ng/g; ppb                   | Unlimited (based on daily) | General and High Risk Populations |  |
|       | Fish  | PFOS | 3.9 ng/g; ppb                    | 1 meal per week            | General and High Risk Populations |  |
|       | Fish  | PFOS | 17 ng/g; ppb                     | 1 meal per month           | General and High Risk Populations |  |
|       | Fish  | PFOS | >17 ng/g; ppb                    | Do Not Eat                 | High Risk Population              |  |
|       | Fish  | PFOS | 51 ng/g; ppb                     | 1 meal every 3 months      | General Population                |  |
|       | Fish  | PFOS | 204 ng/g; ppb                    | 1 meal per year            | General Population                |  |
|       | Fish  | PFOS | >204 ng/g; ppb                   | Do Not Eat                 | General Population                |  |
|       | Fish  | PFNA | 0.23 ng/g; ppb                   | Unlimited (based on daily) | General and High Risk Populations |  |
|       | Fish  | PFNA | 1.6 ng/g; ppb                    | 1 meal per week            | General and High Risk Populations |  |
|       | Fish  | PFNA | 6.9 ng/g; ppb                    | 1 meal per month           | General and High Risk Populations |  |
|       | Fish  | PFNA | >6.9 ng/g; ppb                   | Do Not Eat                 | High Risk Population              |  |
|       | Fish  | PFNA | 21 ng/g; ppb                     | 1 meal every 3 months      | General Population                |  |
|       | Fish  | PFNA | 84 ng/g; ppb                     | 1 meal per year            | General Population                |  |
|       | Fish  | PFNA | >84 ng/g; ppb                    | Do Not Eat                 | General Population                |  |
|       | Fish  | PFOA | 0.62 ng/g; ppb                   | Unlimited (based on daily) | General and High Risk Populations |  |
|       | Fish  | PFOA | 4.3 ng/g; ppb                    | 1 meal per week            | General and High Risk Populations |  |
|       | Fish  | PFOA | 19 ng/g; ppb                     | 1 meal per month           | General and High Risk Populations |  |
|       | Fish  | PFOA | >19 ng/g; ppb                    | Do Not Eat                 | High Risk Population              |  |
|       | Fish  | PFOA | 57 ng/g; ppb                     | 1 meal every 3 months      | General Population                |  |
|       | Fish  | PFOA | 226 ng/g; ppb                    | 1 meal per year            | General Population                |  |
|       | Fish  | PFOA | >226 ng/g; ppb                   | Do Not Eat                 | General Population                |  |

| State | Media | PFAS   | Guideline Level (unit specified) | Frequency                  | Target Populations   | Resources & Notes   |
|-------|-------|--------|----------------------------------|----------------------------|--|---|
| NJ    | Fish  | PFUnDA | 0.40 ng/g; ppb                   | Unlimited (based on daily) | General and High Risk Populations                              | <a href="https://dep.nj.gov/wp-content/uploads/dsr/pfunda-fish-consumption-trigger.pdf">https://dep.nj.gov/wp-content/uploads/dsr/pfunda-fish-consumption-trigger.pdf</a> |
|       | Fish  | PFUnDA | 2.8 ng/g; ppb                    | 1 meal per week            | General and High Risk Populations                              |   |
|       | Fish  | PFUnDA | 12.0 ng/g; ppb                   | 1 meal per month           | General and High Risk Populations                              |   |
|       | Fish  | PFUnDA | >12.0 ng/g; ppb                  | Do Not Eat                 | High Risk Population   |   |
|       | Fish  | PFUnDA | 36.6 ng/g; ppb                   | 1 meal every 3 months      | General Population   |   |
|       | Fish  | PFUnDA | 146 ng/g; ppb                    | 1 meal per year            | General Population   |   |
|       | Fish  | PFUnDA | >146 ng/g; ppb                   |                            | General Population   |   |
|       | Fish  | PFUnDA |                                  |                            |  |   |
| NY    | Fish  | PFOS   | <50 ppb                          | 4 meals per month          | General Population   |   |
|       | Fish  | PFOS   | >50-200 ppb                      | 1 meal per month           | General Population   |   |
|       | Fish  | PFOS   | >50 ppb                          | Do Not Eat                 | Sensitive Population   |   |
|       | Fish  | PFOS   | >200 ppb                         | Do Not Eat                 | General Population   |   |
| TX    | Fish  | PFOS   | 11.338 ng/g                      | 4-13 meals per month       | Subsistence Fishers  | <a href="#">Lower Leon Creek Risk Characterization Addendum 2022.pdf (texas.gov)</a>  |
|       | Fish  | PFOS   | 23 ng/g                          | 2-3 meals per month        | Women of Childbearing Age and Children Less than Six Years Old | <a href="#">Lower Leon Creek Risk Characterization Addendum 2022.pdf (texas.gov)</a>  |
| WA    | Fish  | PFOS   | <1.8 ng/g                        | No Advisory                | General Population   |   |
|       | Fish  | PFOS   | 1.8-2.3 ng/g                     | 8 meals per month          | General Population   |   |

| State | Media    | PFAS | Guideline Level (unit specified) | Frequency         | Target Populations | Resources & Notes |
|-------|----------|------|----------------------------------|-------------------|--------------------|-------------------|
| WA    | Fish     | PFOS | 2.4-4.7 ng/g                     | 4 meals per month | General Population |                   |
|       | Fish     | PFOS | 4.8-9.4 ng/g                     | 2 meals per month | General Population |                   |
|       | Fish     | PFOS | 9.5-28.2 ng/g                    | 1 meal per month  | General Population |                   |
|       | Fish     | PFOS | <28.2 ng/g                       | Do Not Eat        | General Population |                   |
| WI    | Fish     | PFOS | 10-50 ppb                        | 1 meal per week   | All Populations    |                   |
|       | Fish     | PFOS | 50-200 ppb                       | 1 meal per month  | All Populations    |                   |
|       | Fish     | PFOS | >200 ppb                         | Do Not Eat        | All Populations    |                   |
|       | Wildlife | PFOS | 10-50 ppb                        | 1 meal per week   | All Populations    |                   |
|       | Wildlife | PFOS | 50-200 ppb                       | 1 meal per month  | All Populations    |                   |
|       | Wildlife | PFOS | >200 ppb                         | Do Not Eat        | All Populations    |                   |